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Abstract 
 
Background: Radiotherapy is a mainstay of sarcoma treatment, but can cause fibrosis, 
characterized by production of extra-cellular matrix proteins such as collagen by 
cancer-associated fibroblasts (CAFs) in the cancer stroma and surrounding normal 
tissues, which makes tumours more aggressive and resistant to further treatment.  
Mesenchymal stem cells (MSCs) can be recruited to irradiated tumours and can 
differentiate into CAF-like cells but the mechanisms of these effects remain unclear.                                    
Aim: Determine the mechanisms of radiation effects on the recruitment of MSCs to 
tumours and their differentiation into CAF-like cells.                                                        
Methods: Mouse MSCs were irradiated directly or exposed to irradiated mouse 
fibrosarcoma cells (FS120 or FS188) or their conditioned media (CM) and/or irradiated 
endothelial cells. Expression of CAF/fibrosis markers (collagen, fibronectin, PDGF 
receptor-β and α-SMA) by MSCs was assessed 3-4 days’ post radiation. Trans-well 
migration assays were also performed. Candidate proteins were investigated for their 
ability to stimulate migration and maturation of MSCs to CAF-like cells and for the 
ability of radiation to stimulate their production in fibrosarcoma cells. Irradiated FS120 
and FS188 solid tumours were analysed for collagen, using Masson’s trichrome 
staining, and α-SMA using IHC and immunofluorescence.                                                
Results: Direct irradiation of MSCs had limited effects on their expression of CAF 
markers and migration, but exposure to irradiated tumour cells or CM and/or 
endothelial cells increased these effects. Candidate proteins TGF-β1, MCP-1, and SDF-
1α all significantly enhanced the migration of MSCs, and radiation increased their 
production in fibrosarcoma cells. FS188 cells produced more MCP-1 than FS120 cells 
and FS188 and FS120 cells and their CM increased MSC migration in a radiation-
dependent manner. Migration could be at least partially blocked by an MCP-1 blocking 
antibody. MSC expression of the MCP-1 receptor, CCR2, was increased after exposure 
to irradiated FS188 cells or their CM. In vivo, irradiated fibrosarcomas showed 
significant increases in collagen content, with more collagen in FS188 than in FS120 
tumours.             
Conclusion: Results support the notion that MSCs play an important role in radiation-
induced CAF activity and fibrosis in sarcoma. MCP-1 was identified as an important 
mediator of these effects. Moreover, endothelial cells were shown to play an important 
role in the recruitment of MSCs in response to radiation. In vitro results identifying 
FS188 cells as being more pro-fibrotic than FS120 cells were consistent with in vivo 
results. Further work to understand these processes should help to develop novel 
treatment strategies for combination with radiotherapy.  
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1. Introduction 
1.1 Clinical aspects of soft tissue sarcoma (STS) 
 
Soft tissue sarcomas (STSs) are a group of rare malignant tumours that arise from 
mesenchymal cells. Although STSs are relatively rare, they constitute a higher 
proportion of cancer morbidity and mortality in paediatric and adolescent practice than 
in adults (Gronchi and Casali, 2013). STSs account for 0.5-1% of all adult cancers 
(Lahat et al., 2008) and 6-7% in children and young adults which are relatively more 
common than most other types of solid malignancies (Grimer et al., 2010, Sultan et al., 
2010). The most common locations of STS are the extremities (50%), trunk (15%), 
retroperitoneum (15%) and the abdominal cavity (15%) (Clark et al., 2005, Gronchi 
and Casali, 2013). According to the World Health Organization (WHO) tumour 
classification, there are more than 50 subtypes of STS that can present in any age group 
and any location in the body (Fletcher, 2014, Fletcher et al., 2002). The diversity in 
sarcoma subtypes and their rarity make sarcomas very difficult to study.  
There is a link between the histopathological subtype and the age of the patient; the 
most common types in adults are liposarcoma and leiomyosarcoma (Fletcher, 2014), 
while in the elderly, the most common type is undifferentiated pleomorphic sarcoma 
which was previously known as malignant fibrous histiocytoma (MFH) (Sharon and 
Weiss, 2008). Out of all STS in children, around 50% are rhabdomyosarcomas (Kapoor 
and Das, 2012) (Figure 1.1). 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. The relation between age and sarcoma incidence (Sharon 
and Weiss, 2008). 
 
 
Figure 1.1. The relation between age and sarcoma incidence (Sharon 
and Weiss, 2008). 
 
Figure 1.1 The relation betwe n age and sarco a inci  
 
Figure 1.2 The relation between age and sarcoma 
incidence. 
 
Figure 1.3 The relation between age and sarcoma 
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1.2 Standard treatment of STS 
1.2.1 Surgery 
 
The standard treatment for localized STS is surgical excision, ideally aiming for a 
radical resection margin and preserving function if possible (Mendenhall et al., 2009). 
Al-Refaie and colleagues showed that for extremity tumors > 3 cm in largest diameter 
patients should also be treated with adjuvant radiotherapy (Al-Refaie et al., 2010), 
while, for larger tumours or small tumours with marginal or involved resection margins, 
combinations of surgery followed by radiotherapy are preferred (Mendenhall et al., 
2009). Surgical treatment of STS entails a fine balance between preserving function 
and minimizing the risk of local tumour recurrence (Grimer et al., 2010). The type of 
surgical resection is determine by the tumour size and depth, the anatomical location of 
the tumour, the performance status of the patient, and the involvement of nearby 
structures. 10–20% of tumours recur locally, despite improvements in local control but 
in most cases, can still be controlled.  
 
1.2.2 Radiotherapy 
 
Although various studies have shown a relation between radiotherapy (RT) treatment 
and an increase in the risk of angiosarcoma and bone sarcoma (Lagrange et al., 2000, 
Virtanen et al., 2006), RT is still one of the standard effective treatment for intermediate 
and high grade STS (Grimer et al., 2010). 
RT can be given either pre or postoperatively. Some selected patients who have widely 
negative margins may not require radiation (Pisters et al., 2007b). Advances in RT 
technology, such as intensity-modulated radiation therapy (IMRT), brachytherapy and 
intraoperative radiation therapy (IORT), have led to improved treatment outcomes in 
patients with STS (DeLaney et al., 2005).  It has been demonstrated that post-operative 
or adjuvant RT achieves local control and survival similar to radical resection (Yang et 
al., 1998). Various studies have shown that neo-adjuvant RT has better long-term 
functional effects and decreases the risk of joint stiffness (O'Sullivan et al., 2002, Davis 
et al., 2005, Zagars et al., 2003). However, despite these benefits, Cannon et al and 
O'Sullivan et al have showed a high wound complication rate (34%-35%) in patients 
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treated with neo-adjuvant RT compared with patients treated with adjuvant RT (16%-
17%) (Cannon et al., 2006, O'Sullivan and Levin, 2003, O'Sullivan et al., 2002).  
Furthermore, a recent study by Folkert and colleagues has demonstrated that treatment 
by IMRT caused less skin toxicity than using conventional RT (Folkert et al., 2014). 
Despite the effectiveness of RT in the treatment of STS, RT has acute and chronic 
toxicities (El-Bared et al., 2015). Acute toxicities occur within 120 days and include 
skin toxcicity and problems with wound healing. Whereas chronic RT toxicities occur 
after 120 days and include problems such as joint stiffness, oedema and fibrosis (El-
Bared et al., 2015). Recently, a novel study by Alqathami and colleagues called 
SMART (Sensitivity Modulated Advanced Radiotherapy) involving multi-
compartment phantom radio-chromic dosimetry, showed that it may be possible to 
reduce the complications caused by radiotherapy (Alqathami et al., 2012). 
Generally, the recommended neo-adjuvant RT dose is 50 Gy with daily 1.8-2 Gy 
fractions, while for adjuvant RT the dose should be 60-66 Gy in two Gy fractions 
(Kepka et al., 2005, Zagars and Ballo, 2003). 
1.2.3 Chemotherapy 
 
Distant metastases from STSs remain a significant problem with a high mortality 
(Torres et al., 2007). The importance of systemic chemotherapy for most histological 
subtypes in adult STS patients remains controversial, except for some rare, 
predominantly paediatric and young adult types such as rhabdomyosarcoma, 
osteosarcoma, and Ewing`s sarcoma. Chemotherapy is given either as neo-adjuvant 
(preoperative) and/or adjuvant (postoperative) for patients with tumours (Grimer et al., 
2010) belonging to these sub-types.  For other subtypes in the non-metastatic setting, 
the use of chemotherapy is controversial.  One important study was conducted by 
Penella Woll and colleagues in 2012 (Woll et al., 2012). This study represents the 
second largest trial for sarcoma adjuvant therapy after the first EORTC (European 
Organisation for Research and Treatment of Cancer) trial by (Bramwell et al., 1994). 
The Woll et al study consisted of 351 patients followed up for a long time and divided 
into control and patients treated by ifosfomide plus high dose doxorubicin after tumour 
resection (Woll et al., 2012). Radiotherapy given to both groups if the resection margin 
was positive. The results were in agreement with previous studies in which unselected 
patients with sarcoma showed no benefit from doxorubicin and ifosfomide (Petrioli et 
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al., 2002). However, this study has some weakness such as including some patients 
(24%) with small tumours (<5 cm), which are usually treated by surgery and 
radiotherapy alone without chemotherapy. Furthermore, the dose of ifosfomide used in 
the Woll study is lower than that were used in the previous trial by (Frustaci et al., 2001) 
who used a conventional chemotherapy dose. 
Doxorubicin and ifosfomide are the most active chemotherapy agents in the treatment 
of STSs (Elias et al., 1989). A previous study by Frustaci and colleagues has shown an 
increase in disease-free survival for sarcoma patients treated by epirubicin and 
ifosfomide (Frustaci et al., 2001). While other studies have shown improvement in local 
control and disease free survival but no improvement in overall survival (Bramwell et 
al., 1994, Petrioli et al., 2002). Different STS histopathological sub-types have shown 
variation in their chemo-sensitivity. The most chemo-sensitive sarcomas are synovial 
sarcoma, myxoid/ round cell liposarcoma, extra-skeletal Ewing`s tumour and childhood 
rhabdomyosarcoma (Grimer et al., 2010), while the most chemo-resistant sarcoma are 
alveolar soft part sarcoma, dedifferentiated liposarcoma, GIST (gastrointestinal stromal 
tumours), low grade liposarcoma and clear cell sarcoma (Grimer et al., 2010). Pisters 
and colleagues showed that there is no need for routine chemotherapy for low-grade 
resectable tumours or small size high-grade STS (Pisters et al., 2007a). The benefits of 
preoperative chemo-radiotherapy include early treatment of subclinical tumour spread 
and assessment of response, but its importance on survival in STS patients remains 
unknown. For metastatic STS, chemotherapy is used with palliative intent but response 
rates are generally poor (Clark et al., 2005). 
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1.3 Angiogenesis and vascular targeted therapies in STS 
 
Angiogenesis can be defined as the growth of new blood vessels from existing vessels 
(Carmeliet, 2000). It is a physiological and pathological event which occurs in normal 
development and reproduction in early life (as in organogenesis), or in adulthood (as in 
wound healing and menstruation) in which vascular endothelial growth factor (VEGF) 
and its receptors play a central role (Fox et al., 2001). Formation of these new blood 
vessels is important for most solid tumours (Folkman, 1986), as it provides tumour cells 
with nutrition and oxygen which help cells to survive and they represent the primary 
route for metastatic spread. 
Moreover, the tumour microenvironment is affected by these new blood vessels, and 
hence the response of the tumour to the therapy is also affected (Vaupel, 2004). 
Angiogenesis is an important target in sarcoma because it is responsible for tumour 
growth and metastasis. Many studies have been focused on anti-angiogenic treatment 
in sarcoma. Angiogenesis occurs when tumours switch to an angiogenic state during 
tumour development (Bergers and Benjamin, 2003). Many studies have shown that the 
level of pro angiogenic factors is high in malignant tumours, and this leads to growth 
and metastases of tumours (Grunstein et al., 1999, Holash et al., 1999). Using vascular 
targeting agents (VTAs) for cancer treatment was described by Juliana Denekamp 
through her work on mouse blood vessels obstruction (Denekamp, 1982, Denekamp, 
1993, Denekamp, 1999). There are two types of VTAs; those called antiangiogenic 
agents (AAs), or angiogenesis-inhibiting agents (AIAs), which inhibit new blood 
vessels formation, and those that act against already existing tumour vasculature, called 
vascular-disrupting agents (VDAs).  
1.3.1 Anti-angiogenic agents  
 
The action of antiangiogenic agents (AAs) is through the inhibition of new blood vessel 
formation by affecting the various stages involved in angiogenesis. It had been 
documented that tumour cells secrete angiogenic factors that are up regulated by 
different factors like hypoxia, activation of oncogenes, or loss of tumour suppressor 
gene function (Holash et al., 1999, Denekamp and Hill, 1991). These angiogenic factors 
were shown to play an important role in neovascularization and are the chief targets for 
AAs (Ferrara et al., 2003). The most specific and potent angiogenic factor is VEGF, 
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which stimulates the proliferation and migration of endothelial cells and leads to an 
increase in vascular permeability (Ferrara et al., 2003, Pugh and Ratcliffe, 2003, 
Dvorak, 2000). When VEGF ligands bind to their tyrosine kinases receptors (VEGFR1, 
VEGFR2 and VEGFR3), this leads to activation of downstream signalling. 
Bevacizumab (Avastin) is the first AA (anti-VEGF) agent approved for clinical uses. It 
is a humanized anti-VEGF monoclonal antibody that produces angiogenesis inhibition 
through preventing VEGF from binding to its receptors (Wong et al., 2014). Clinical 
trials by Hurwitz and his colleagues for patients with metastatic colorectal cancer 
showed that using bevacizumab combined with fluorouracil chemotherapy 
significantly improved overall survival when compared with chemotherapy alone 
(Hurwitz et al., 2004).  
This improvement in overall survival after combination therapies was also shown in 
patients with non-small lung cancer (NSCLC), renal cell carcinoma and metastatic 
breast cancer (Miller et al., 2007, Sandler et al., 2006). Anti-angiogenic agents are also 
being tested or used in the treatment of STS. In a prospective study done by (Agulnik 
et al., 2013) for patients with angiosarcoma (unresectable or metastatic), showed there 
were responses to bevacizumab as a single agent (Agulnik et al., 2013). In addition, a 
combination of both bevacizumab with doxorubicin was used in the treatment of 17 
patients with metastatic STS as phase II trial by (D'Adamo et al., 2005). However, the 
response rate was 12% in comparison with doxorubicin alone but the overall survival 
was promising (16 months) (D'Adamo et al., 2005). 
Tyrosine kinase inhibitors (TKIs) are another type of AAs that inhibit the tyrosine 
kinase activity of VEGF receptors. The approval of using Imatinib mesylate (IM) in the 
treatment of GISTs in 2002 was the base for using TKIs in the treatment of cancer 
(Demetri et al., 2002). IM is an oral tyrosine kinase inhibitor (TKI) acts in patients with 
positive cKit tumours by inhibition of cKit (CD117). Imatinib also used in the treatment 
of dermatofibrosarcoma protuberance because it also inhibits platelet-derived growth 
factor receptor beta (PDGFR-β). Some GIST patients who cannot tolerate IM, are 
treated with another TKI called sunitinib malate (SM) which inhibits VEGF-R2, cKit 
and PDGFR-β (Demetri et al., 2006).  
It was also shown that SM had activity in liposarcomas and leiomyosarcomas according 
to phase II study was done by Mahmood et al (Mahmood et al., 2011). Interestingly SM 
also showed anti-tumour effects in advanced alveolar soft part sarcoma (Stacchiotti et 
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al., 2011). Sorafenib is another TKI which inhibits VEGF-R2, VEGF-R3, PDGFR and 
cKit, and has effects on advanced angiosarcomas according to a phase II trial (Maki et 
al., 2009). Pazopanib, an oral AA drug that inhibits multiple tyrosine kinases, was 
approved for treatment of STS by the FDA (Food and Drug Administration) and EMA 
(European Medicines Agency). A randomized phase III trial called PALETTE had 
shown the significant improvement in progression free survival of STS patients 
excluding liposarcoma (van der Graaf et al., 2012). Moreover, it has been shown that 
Pazopanib plus bevacizumab and sunitinib was more effective in the treatment of 
metastatic alveolar soft part sarcoma than bevacizumab and sunitinib alone (Read and 
Williams, 2016). 
1.3.2 Vascular-disrupting agents  
 
Vascular-disrupting agents (VDAs) selectively target already established tumour 
vasculature leading to the death of cancer cells secondary to an extensive and rapid 
decrease in tumour blood perfusion. There are two types of VDAs, ligand-directed 
(biological) VDAs and small molecule VDAs. The work of ligand-directed VDAs is 
through using peptides, antibodies, or growth factors which bind to tumour endothelium, 
and death of these endothelial cells by targeting toxins like ricin or pro-coagulants to 
the tumour endothelium (Thorpe, 2004). Small molecule VDAs include flavonoids and 
tubulin binding agents (Siemann et al., 2005). 
On flavonoid derivative is 5, 6-dimethyl-xanthenone-4-acetic acid (DMXAA). It’s 
action is through the production of vasoactive factors and cytokines like tumour 
necrosis factor alpha (TNF-α) which causes damage and necrosis of endothelial cells 
of the tumour vasculature (Baguley, 2003).  The combination of DMXAA with 
radiation had been studied in preclinical mouse models by Murata et al (2001) using 
the C3H mammary carcinoma and the KHT sarcoma. Although this study showed some 
improvement of tumour response compared to radiation alone, this was highly 
dependent on the dose of both DMXAA and radiation gave, and the time interval 
between the drug and radiation (Murata et al., 2001). 
Tubulin-binding agents include colchicine; vinblastine and vincristine, and the newer 
agent combretastatin A-4 disodium phosphate (CA4P). The active component of CA4P, 
CA4, binds to the colchicine binding site on tubulin and works by disrupting tumour 
endothelial cells causing a decrease in blood flow and tumour necrosis (Tozer et al., 
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2001). Tozer and her colleagues (2008) tested CA4P in a mouse fibrosarcoma model. 
They found that mouse fibrosarcomas expressing only the VEGF120 isoform of VEGF 
(FS120 tumours) responded well to CA4P, whereas those expressing VEGF188 
isoform (FS188 tumours) responded less well (Tozer et al., 2008). This was thought to 
be because FS188 tumours have more stable blood vessels than FS120 tumours (Tozer 
et al., 2008). Another combretastatin derivative, ombrabulin, is a pro-drug, which 
showed a synergistic activity with cisplatin through the rapid destruction of tumour 
blood vessels and subsequent necrosis when tested in animal models (Morinaga et al., 
2003). In 2015, a big phase III randomized trial compared ombrabulin plus cisplatin 
against placebo plus cisplatin in patients having advanced soft-tissue sarcomas who 
failed to respond to ifosfomide and anthracycline chemotherapy (Blay et al., 2015). The 
results of this study showed a significant improvement in progression-free survival in 
patients treated with ombrabulin and cisplatin compared to patients treated with 
cisplatin alone. However, this drug failed to show meaningful clinical benefit for 
patients with advanced STS, to support its routine uses in the clinic. 
In a subcutaneous Ewing’s sarcoma mouse model, it has been shown that treatment of 
mice with OXi4503/CA1P (second generation tubulin binding agent) caused a 
shutdown of vasculature completely within 24 hours, and haemorrhage with necrosis 
after 48 hours (Dalal and Burchill, 2009). Furthermore, the effects of OXi4503/CA1P 
were enhanced when doxorubicin was used concurrently and tumour growth delay was 
observed. These studies demonstrate that VDAs have potential therapeutic agents for 
cancer treatment. Eribulin mesylate (Halaven), a synthetic drug derived from marine 
sponge Halichondria okadai, was approved by the FDA in 2016 for treatment of 
liposarcoma. Eribulin works via disrupting the microtubule irreversibly by prevent the 
formation of the mitotic spindle and subsequently cell cycle arrest that cause apoptosis 
(Smith et al., 2010). In a randomised open-label phase 3 trial, Schffoeffski and his 
colleagues showed a significant improvement in overall survival (from 8.4 months to 
15.6 months) for patients with advanced liposarcoma treated by eribulin versus 
dacarbazine (Schffoeffski et al., 2016). 
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1.4 Tumour microenvironment  
 
Stephen Paget’s theory in 1889 was to propose the concept of the tumour 
microenvironment (TME). It suggests that metastases need a suitable tissue 
environment (soil) to help tumour cells (seeds) to grow (Paget, 1989). Thus the TME 
is currently considered as a network of tumour cells as seeds, and the stromal tissue 
(fibroblasts, immune cells, cytokines and vascular tissue) and the extracellular matrix 
(ECM) as the soil (Balkwill et al., 2012). The TME is produced as a result of the 
communication between cancer cells and non-malignant cells, the latter having tumour 
promoting function at all stages of carcinogenesis (Hanahan and Coussens, 2012). The 
communications between cells are determined by many chemokines and cytokines, 
inflammatory enzymes, growth factors, and matrix remodeling enzymes. Multiple 
studies have indicated the similarities between the process of wound healing with the 
cells of TME in their structure, activities and development (Grivennikov et al., 2010, 
Hanahan and Weinberg, 2011). 
1.4.1 Tumour cells 
 
Tumour cells promote their own survival, proliferation and spread through many 
mechanisms, including suppression of apoptosis, evasion of the host immune response, 
deregulated proliferation, induction of neovascularization and mobility (Hanahan and 
Weinberg, 2000). Cancer cells in the TME suffer from genetic and epigenetic instability 
making them more aggressive and out of control. Hypoxia and hypoxia/reoxygenation 
caused by rapid tumour cell proliferation and vascular abnormalities are major drivers 
of genomic instability (Pires et al., 2010, Harding et al., 2011). Reactive oxygen species 
(ROS) that are formed due to the hypoxic environment within the TME cause damage 
to the DNA such as single or double strand breaks, DNA aberrations, and point 
mutations, and so on. Moreover, hypoxia by itself impairs DNA damage repair (Chang 
et al., 2002) which contributes to genetic instability. 
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1.4.2 Stromal tissue 
 
Stroma is the connective and supportive tissue. Balkwill and colleagues (Balkwill et 
al., 2012) described TME stromal cells as fibroblasts, myofibroblasts, immune cells, 
pericytes, and vascular endothelial cells. The main cells within cancer stroma are 
fibroblasts. They are spindle shaped and metabolically active cells that are responsible 
for the production and turnover of ECM. These cells cause fibrosis through their 
differentiation into myofibroblasts during tissue injury (Li and Wang, 2011). 
Fibroblasts within cancer stroma are called cancer-associated fibroblasts (CAFs), 
activated myofibroblasts, or tumour-associated fibroblasts (Li et al., 2007, Kalluri, 
2016). CAFs express α-smooth muscle actin (α-SMA), fibroblast specific protein 
(FSP)-1, and platelet-derived growth factor receptors-β (PDGFR-β) (Sugimoto et al., 
2006, Anderberg et al., 2009). CAFs are a source of matrix metalloproteases (MMPs), 
plasminogen activators, and cathepsins, which all have protease activity and induce 
invasiveness (Roy et al., 2009, Boire et al., 2005, Xing et al., 2010). MMPs were shown 
to be essential in the growth of tumours, angiogenesis and metastasis (Stetlerstevenson 
et al., 1993, Boire et al., 2005), as MMPs release growth factors such as angiogenic 
factors and chemokines that bind to the matrix which then stimulate tumour cells to 
grow and endothelial cells to form new blood vessels (Rundhaug, 2003, Bergers et al., 
2000, Iozzo et al., 2009, Ebrahem et al., 2010). Despite the fact that CAFs are thought 
to be tumour promoting, a study conducted by Oezdemir and his colleagues have shown 
the opposite. They showed that depletion of CAFs from pancreatic cancer in mice leads 
to increase tumour invasiveness and hypoxia with a decrease in the immunity and 
survival (Oezdemir et al., 2014). More information about CAFs will be discussed in 
detail later in this chapter.  
Another important stromal cell in the TME (Figure 1.2) is the vascular endothelial cell. 
During cancer growth certain chemokines and growth factors like VEGFs, fibroblast 
growth factors (FGFs) and PDGFs stimulate endothelial cells and pericytes to drive the 
process of neovascularization (Carmeliet and Jain, 2011). Pericytes are another 
important stromal cells which have stem cell-like properties and may constitute a source 
of myofibroblasts progenitors in addition to their functions such as induction of 
angiogenesis, sustaining tumour growth, metastasis and immune-suppression (Armulik 
et al., 2011). Pericytes are found surrounding blood vessels and express markers like 
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PDGF receptor-β, NG2 and desmin, and recruitment and differentiation of pericytes 
depend on signaling pathways of PDGF, transforming growth factor beta (TGF-β) and 
angiopoietin (Gaengel et al., 2009). Pericytes limit tumour metastasis through their 
desensitization effects on the endothelium to VEGF and making blood vessels more 
stable; consequently, tumour cells find it more difficult to get through them to 
metastasis (Gerhardt and Semb, 2008, Armulik et al., 2011). 
Tumour-associated macrophages (TAMs) are important innate immune cells within the 
TME. Different cytokines, chemokines, and growth factors play a role in the 
recruitment of macrophages/monocytes cells into the TME such as monocyte 
chemoattractant protein-1 (MCP-1) (Qian et al., 2011), VEGF (Valkovic et al., 2002), 
PDGF (Solinas et al., 2009) and plasminogen (Phipps et al., 2011). These recruited 
monocytes differentiate into M1 macrophages (pro-inflammatory) and M2 
macrophages (pro-tumorigenic). In the TME, macrophages that related to tumour 
development have an M2-like phenotype (Sica and Mantovani, 2012, Mantovani and 
Locati, 2013). Presence of TAMs in the tumour stroma causes the resistance of a tumour 
to treatment with anti-angiogenic agents. Firstly, as hypoxia is a major feature of the 
TME, TAMs secrete multiple pro-angiogenic factors (in response to hypoxia) that 
activate endothelial cells and enhance angiogenesis (Murdoch et al., 2008, Schmidt and 
Carmeliet, 2010, Mantovani et al., 2013). Moreover, treatment of tumours with anti-
VEGF therapy can cause tumour hypoxia, potentially resulting in recruitment of TAMs 
to the a tumour, leading to the supply of pro-angiogenic factors to re-start angiogenesis 
(Tripathi et al., 2014).  
TAMs also aid in the degradation of ECM via secretion of different MMPs, which can 
contribute to metastasis (Huang et al., 2002, Murdoch and Lewis, 2005). The important 
role of immune system to control or prevent cancer has been studied since years. 
Nevertheless, cancer immunotherapy has become a reality only within the last two 
decades. For cancer immunotherapy, two approaches are currently in progress: direct 
targeting of the tumour and indirect targeting the tumour (via activation of immune 
cells) (Sathyanarayanan and Neelapu, 2015). The response to immunotherapy depends 
on the interactions between cancer cells and the immunomodulators within the TME. 
This means that the key role in the activation or reduction of the immune responses is 
the TME (Tang et al., 2016). 
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Understanding the communications between the TME and immunotherapy is critical to 
provide new methods in improving the effectiveness of current immunotherapies.  
 
1.4.3 Extracellular matrix  
 
ECM is a non-cellular element of tissue that provides physical support and regulates 
the function and homeostasis of all eukaryotic cells (Lu et al., 2011). The main 
components of the tumour ECM are elastin, collagen, proteoglycans and other essential 
proteins, which are synthesized mainly by CAFs. Cell surface receptors called integrins 
bind components of the ECM and promote cancer angiogenesis, growth and metastasis 
(Alphonso and Alahari, 2009). The spread and progression of cancers depend mainly 
on the ECM, as the adhesion of a cell to the ECM is a key to the movement of cancer 
cells out of and into the TME.   
Because of increased ECM deposition and remodeling as a consequence of altered gene 
expression of CAFs, tumours are stiffer than the surrounding normal tissues. It has been 
shown that the lysyl oxidase (LOX) enzyme causes cross-linking of collagen fibers and 
contribute to stiffening of the matrix (Levental et al., 2009). The cells adhere to the 
matrix through integrins and produce enzymes that can degrade matrix and therefore 
allow them to move/migrate through it which is an important step in tumour metastasis 
(Taddei et al., 2013). 
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Figure 1.2 Tumor Microenvironment cell : TME consist of the parenchymal cells 
(malignant cells, and cancer stem cells) which are responsible of tumor recurrence 
and metastases, and the stromal cells like endothelial cells, mesenchymal stem cells, 
cancer cells, pericytes, immune cells, inflammatory cells, and fibroblasts. When 
fibroblasts activated and accumulated in tumor area, they called Cancer-Associated 
Fibroblasts (CAFs), which cause fibrosis. This Figure based on figure from 
(Hanahan and Weinberg, 2000). 
 
 
Figure 1.2 Tumor Microenvironment cell : TME consist of the parenchymal cells 
(malignant cells, and cancer stem cells) which are responsible of tumor recurrence 
and metastases, and the stromal cells like endothelial cells, mesenchymal stem cells, 
cancer cells, pericytes, immune cells, inflammatory cells, and fibroblasts. When 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mesenchymal stem cell 
Cancer-associated fibroblast (CAF) 
Cancer cell 
Pericyte 
Cancer stem cell 
Adipocyte 
Endothelial cell 
Immune cell 
Dendritic cell 
 
 
Figure 1.9 Tumor Microenvironment cellsMesenchymal stem cell 
Cancer-associated fibroblast (CAF) 
Cancer cell 
Pericyte 
Cancer stem cell 
Adipocyte 
Endothelial cell 
Immune cell 
Dendritic cell 
 
 
Figure 1.2 Tumor Microenvironment cel s: 
 
Figure 1.2 Tumor Microenvironment 
cellFigur  1.21 Tumor Microenvironment 
cells: 
 
Figure 1.2 Tumor Microenvironment cell : 
TME consist of the parenchymal cells 
(malignant cells, and cancer stem cells) which 
are responsible of tumor recurrence and 
metastases, and the stromal cells like 
endothelial ll , mesenchymal st m cells, 
c cer cell , pericytes, immune c lls, 
inflammatory c lls, and fibroblasts. When 
                                                                                              
 
15 
 
1.4.4 Hypoxia and TME 
 
Hypoxia is a very common feature in solid tumours and, as mentioned above, it occurs 
because tumour cells proliferate avidly, with alteration of tumour metabolism and 
development of abnormal tumour blood vessels that cause a decrease in oxygen and 
nutrients (Vaupel and Harrison, 2004). Studying tumour hypoxia is very important 
because is strongly related to many factors that support tumour growth as well as 
radioresistance in malignant tumours, recurrence of a tumour after radiotherapy and 
even in determining the prognosis of cancer patients after RT (Brown and William, 
2004, Aebersold et al., 2001).  
Hypoxia in tumours is classified into two types; acute perfusion-limited hypoxia and 
chronic diffusion-limited hypoxia, this division was according to the duration of 
exposure to hypoxia and the causative factors (Brown and William, 2004). In chronic 
hypoxia, there is a gradient of oxygenation that surrounds the perfused vessels; this 
means that within this oxygen gradient, there are cells with different oxygen 
concentrations (normoxic cells near the vessels and cells anoxic in distal areas). In acute 
perfusion limited hypoxia, the instability in blood flow inside the vessels may cause 
rapid fluctuations in oxygenation levels in a tumour (Lanzen et al., 2006).  
It was establish that cancer cells become more invasive, aggressive and metastasize in 
hypoxic conditions. For example, culturing of multiple myeloma cells in hypoxic 
conditions in vitro and then injecting them into mice allowed these cells to metastasise 
into other bone marrow (BM) compared to the same cells cultured within normal 
oxygen condition (Azab et al., 2012, Muz et al., 2015). Moreover, in vivo studies by 
Cairns et al. showed that mouse sarcoma tumours exposed to acute hypoxia enhanced 
their metastasis to the lungs (Cairns et al., 2001).  
Hypoxia leads to the formation of the transcription factor, hypoxia-inducible factor 1 
(HIF-1), which is positively related to the degree of hypoxia inside a tumour (Semenza, 
2000). There are three types of HIF with their oxygen-sensitive α subunit, HIF-1-α, 
HIF-2-α and HIF-3-α (Wang et al., 1995), which are stabilised under hypoxia. It has 
been shown that HIF-1 plays a role in the regulation of paracrine signalling molecules, 
such as TGF-β, PDGF-β and basic fibroblast growth factor (bFGF), secreted by hypoxic 
tumour cells (Caniggia et al., 2000, Moeller et al., 2004, Schito et al., 2012). These 
paracrine signalling molecules enhance changes of progenitor cells into CAFs (Gilkes 
et al., 2014).  
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Moreover, hypoxia was shown to enhance the expression of CXCL12, stromal derived 
factor 1 alpha (SDF1-α) receptor in many cells (Schioppa et al., 2003), and SDF1-α has 
been shown to promote the growth of cancer (Orimo et al., 2005).  
Regarding effects of hypoxia on ECM, it has been shown that HIF-1 enhanced fibrosis 
in the liver, kidney and adipose tissue via its remodelling effects on ECM (Moon et al., 
2009, Halberg et al., 2009, Higgins et al., 2007). Moreover, HIF-1 and HIF-2 have been 
shown to enhance breast cancer metastasis through the transcription of integrin subunits 
α5 and β1 (Ju et al., 2017). In addition to integrins, the synthesis of ECM proteins such 
as collagen and fibronectin can regulate by hypoxia. It has been shown that secretion 
of collagen can be regulated by HIF at different stages (Bentovim et al., 2013, Eisinger-
Mathason et al., 2013). Beside these effects, hypoxia causes ECM degradation through 
the activity of MMP2, MMP9 and MMP15 via HIF-1 (Krishnamachary et al., 2003, 
Choi et al., 2011). 
It is well known that endothelial cells, which are crucial for the structure of blood 
vessels, play a key role in the migration of tumour cells (Franses et al., 2011). It was 
shown that using endothelial cells depleted of HIF-1α caused decreased migration of 
cancer cells via endothelial cells. These results were opposite if using HIF-2 α depletion, 
in which the migration of cancer cells was enhanced. This differences between HIF-1α 
and HIF-2α could be due to their abilities to differentially regulate nitric oxide, that 
regulates endothelial cell function (Branco-Price et al., 2012). Many studies showed the 
involvement of HIF-1α and HIF-2α at all stages of blood vessels formation (Semenza 
and Wang, 1992, Conway et al., 2001, Carmeliet, 2005).  
HIFs are also involved in the recruitment of endothelial progenitor cells from BM into 
tumour tissue and cause their differentiation into endothelial cells via VEGF, 
stimulation of VEGF-R2, and PDGF (Conway et al., 2001, de la Puente et al., 2013). 
Hypoxia also enhances tumour metastasis via epithelial-mesenchymal transition (EMT) 
(Thiery and Sleeman, 2006). EMT in hypoxia is associated with a decrease of 
epithelial-associated gene expression (β-catenin and E-cad) and increase in 
mesenchymal-like gene expression (SMA, vimentin, N-cad, and CXCR4) (Kim et al., 
2002, Hsu et al., 2000, Manotham et al., 2004, Muz et al., 2015). Furthermore, hypoxia 
increased TGF-β that regulates EMT (Azab et al., 2012).  
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It was demonstrated that inhibition of the hypoxia-inducible enzyme, carbonic 
anhydrase IX (CAIX), caused decreased growth and metastasis of tumours (Lou et al., 
2011).  
Although severe hypoxia is ultimately toxic for cells, many tumour cells are adapted 
for a hypoxic environment, for instance by upregulation of enzymes involved in 
glycolysis, and hypoxia is even involved in tumour cells becoming resistant to 
treatment with RT and chemotherapy (Rohwer and Cramer, 2011). The mechanisms of 
hypoxia-induced resistance of tumour cells to treatment include cell cycle arrest, 
reduced apoptosis and senescence and, control p53, autophagy and mitochondrial 
activity (Das et al., 2008, Rohwer and Cramer, 2011). Moreover, hypoxia affects the 
delivery of drugs and cellular uptake of the chemotherapy via drug efflux pump 
expression like permeability glycoprotein (P-gp) (Abraham et al., 2015). 
 
1.5 Cancer-Associated Fibroblasts (CAFs) 
 
1.5.1 Characteristics and activation of CAFs 
 
CAFs are large heterogenous spindle-shape cells that represent major components of 
stromal cells within the TME. The most common origin of CAFs are resident fibroblasts, 
but it is thought that they can also originate from pericytes, adipocytes, epithelial cells, 
endothelial cells, and mesenchymal stem cells MSCs (Anderberg and Pietras, 2009). 
Early studies did not show any effects of CAFs on tumour progression, but later studies 
have shown that CAFs are important cells in cancer development and progression (Cirri 
and Chiarugi, 2012, Franco et al., 2010).  It has been shown that cancer proliferation 
and survival in the TME depends on CAFs that maintain the microenvironment (Cirri 
and Chiarugi, 2012, Marsh et al., 2013). Some studies showed that targeting cancer 
cells therapeutically using anti-cancer therapies is not enough without targeting CAFs 
that maintain the TME (Sun, 2015). Although activated CAFs generally express 
fibroblast activation protein α (FAP-α), PDGF receptor α and β, and vimentin, α-SMA 
is the most common markers used to recognise CAFs (Sugimoto et al., 2006, Park et 
al., 1999, Kim et al., 2015).  
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1.5.2 Role of CAFs in cancer  
1.5.2.1 CAFs and tumour growth 
 
It has been shown that CAFs enhance tumour growth and survival, migration, and 
invasiveness of tumours by secreting paracrine and/or autocrine cytokines, chemokines 
and growth factors like hepatocyte growth factor (HGF), epidermal growth factor 
(EGF), insulin-like growth factor (IGF 1 & 2), and the receptor integrin α11 (Oestman 
and Augsten, 2009). These cytokines and chemokines secreted by CAFs contribute to 
the recruitment of BM-derived MSCs and immune cells into the TME (Servais and Erez, 
2013). It has been shown that CCL5, CCL14, and CCL12 or SDF-1α play roles as pro-
metastatic factors (Luker et al., 2012, Augsten et al., 2014, Mi et al., 2011). These 
factors (especially SDF-1α) and TGF-β cause recruitment of BM-derived CAFs into 
tumour stroma (Quante et al., 2011).  
Mi et al, 2011 showed in oral cancer that chemokine, MCP-1, expression were up 
regulated in CAFs (Li et al., 2014). This increase in MCP-1 level promoted the 
secretion of ROS in the cancer cells which later cause proliferation, migration, and 
invasion of the tumour cells (Li et al., 2014). 
CAFs also cause ECM degradation through secretion of MMPs such as MMP3 which 
enhances tumour invasiveness (Lochter et al., 1997). MMP3 enhanced cleavage of E-
cadherin protein of epithelial cells (mammary), which then undergo an epithelial-to-
mesenchymal transition that enhances cancer invasiveness. 
1.5.2.2 CAFs and tumour angiogenesis 
 
VEGF has been shown to play a crucial role in angiogenesis and lymphangiogenesis 
and subsequent cancer progression and metastasis (Shibuya and Claesson-Welsh, 2006). 
In addition to tumour cells, a primary source of VEGF in the TME is CAFs which 
increase their expression of VEGF due to cancer-stromal cell signalling interactions 
(Gomes et al., 2013). It has been shown that production of VEGF within TME depends 
on PDGF derived from CAFs. PDGF activates VEGF via its receptor (PDGFR) that 
plays an important role in angiogenesis through recruitment of resident fibroblasts and 
BM stromal cells (Gomes et al., 2013, Ferrara, 2010). BM stromal cells can differentiate 
into smooth muscle cells and endothelial cells that proliferate and migrate in response 
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to PDGF (Ferrara, 2010). Endothelial cells produce PDGF-BB that cause recruitment 
of pericytes to the vessel wall and subsequent angiogenesis (Zhang and Liu, 2013, 
Bergers and Song, 2005). Another study suggested that colon cancer cells stimulate 
fibroblasts to secrete IL-6 that then causes angiogenesis (Nagasaki et al., 2014). 
Moreover, when IL-6 receptor was blocked using a neutralizing antibody, angiogenesis 
was inhibited.  
1.5.2.3 CAFs and tumour metastasis 
 
Many studies showed the role of CAFs in tumour metastasis (Karagiannis et al., 2012, 
Pavlides et al., 2012). Some studies have suggested that the CAFs have mesenchymal-
like phenotype that might cause enhancement of cancer metastasis (Dumont et al., 
2013). A recent study by Wang et al, 2017 showed that conditioned media (CM) from 
CAFs that were isolated from lung cancer increased the migration of lung cancer cells 
in vitro (Wang et al., 2017). Moreover, in this study, CAFs caused EMT (increase 
vimentin level and decreased E-cadherin level) that promoted lung cancer cells 
metastasis. 
It has been shown in gastric cancer that the expression of SRF (serum response factor) 
was high in fibroblasts causing cancer cell metastasis via increasing SDF-1α/CXCR4 
signalling (Qiao et al., 2016). CAFs secrete SDF-1α that might cause EMT as shown in 
breast cancer studies and oral squamous cell carcinoma (Soon et al., 2013, Onoue et al., 
2006). 
In addition, CAFs may cause metastasis by enhancing angiogenesis within the stroma 
of tumours. A study by Guo et al, 2008, in a gastric cancer mouse model, showed that 
after activation of cancer cells, the stromal fibroblasts secrete VEGF-A which enhances 
angiogenesis (Guo et al., 2008). These studies suggest the important role of CAFs in 
the mediation of cancer metastasis. 
1.5.2.4 CAFs and cancer therapy 
 
In cancer cells, resistance to treatment not only depends on genetic or epigenetic 
modifications but also on the TME. Although CAFs are more stable genetically than 
cancer cells, many studies suggested that CAFs make cancer cells more resistant to 
therapies (Correia and Bissell, 2012, Kerbel, 1997, Li et al., 2015, Kharaishvili et al., 
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2014). Some studies showed that the cancer stroma contains cytokines or chemokines 
that play a role in tumour drug-resistance.  
CAFs modulate ECM-cancer cell interaction pathways and chemokines and/or cytokine 
signaling that cause anti-cancer drug resistance (Paraiso and Smalley, 2013). In BRAF-
mutant melanoma cells, a study by Hirata et al., 2015 showed that CAFs play an 
important role in increasing resistance to BRAF inhibitors (PlLX4720). BRAF is a 
human gene encoding a protein B-Raf involved in cell growth. Melanoma-associated 
fibroblasts generate a fibronectin-rich TME, which can sustain cancer cells via 
fibronectin-activating β1-integrin-FAK-ERK signaling (Hirata et al., 2015). Moreover, 
culturing melanoma cell lines with CM from tumour fibroblasts caused resistance to 
treatment.  In head and neck cancer, it has been shown that CAFs enhanced anti EGFR 
drug resistance (Cetuximab) via secretion of MMP-1 (Johansson et al., 2012). In 
prostatic cancer, Kharaziha and colleagues have shown that culturing of primary CAFs 
with prostatic cancer cells protected cancer cells from sorafenib cytotoxic effect via 
over-expression of Bcl-xL (anti-apoptotic protein) (Kharaziha et al., 2012). In ovarian 
cancer, it has been shown that the level of MCP-1 expression in paclitaxel-resistant 
ovarian cancer cell lines was increased. Moreover, blocking of MCP-1 caused 
enhancement of carboplatin and paclitaxel drugs in ovarian cancer (Moisan et al., 2014). 
MCP-1 was induced by CAFs via activation and phosphorylation of transcription 3 
(STAT3). This CAF-derived MCP-1 regulated cancer stem cells via activation of 
NOTCH signalling and in turn, enhanced cancer progression (Tsuyada et al., 2012). 
NOTCH signalling regulates apoptosis and cell proliferation and differentiation 
(Artavanis-Tsakonas et al., 1999). 
In the cancer stroma, CAFs are the common source of SDF-1α (CXCL12). It has been 
shown that SDF-1α and its receptor (CXCR4) signalling activate Akt, ERK, and 
adhesion kinase signalling pathways that caused resistance to cancer therapies in 
pancreatic cancer (Weekes et al., 2012, Singh et al., 2010). Moreover, any disruption 
of SDF-1α/ CXCR4 signalling pathways caused sensitisation of prostate, lung, and 
colon cancer cells to chemotherapy (Domanska et al., 2012, Burger et al., 2011, 
Heckmann et al., 2013). In conclusion, as CAFs play a key role in cancer growth, 
metastasis, invasiveness, and angiogenesis, it is very important to find new anti-cancer 
therapies that target them. 
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1.6 Role of mesenchymal stem cells in cancer 
 
Friedenstein and colleagues in 1970 described a group of BM originating cells that have 
fibroblast features, the ability to differentiate and showed clonal growth (Friedenstein 
et al., 1970). They called these cells “colony-forming cells”. Caplan used the name 
“mesenchymal stem cells” later for the population of BM-derived cells that were able 
to differentiate into cartilage and bone (Caplan, 1991). MSCs are multipotent (can 
produce multiple types of specialized cells) being able to differentiate into muscle, 
cartilage, bone and connective tissues (Prockop, 1997, Pittenger et al., 2000). MSCs 
have an important characteristic, namely being able to migrate to sites of tissue injury 
like heart, kidney and skin, primarily due to inflammatory mediators which are 
produced locally as a result of tissue damage and remodelling (Wu et al., 2003, Morigi 
et al., 2004, Li et al., 2006). They express surface markers like CD90, CD105, and 
CD73 with the absence of hematopoietic markers (Lama et al., 2007).  
In wound healing, MSCs recruited to the wound helps in homeostasis, tissue repair, and 
immune modulation. In cancer, tumour cells that proliferate permanently and 
invasively produce an inflammatory microenvironment (a wound that never heals) 
(Karnoub et al., 2007). Once in the TME, MSCs play important roles through their 
special cellular interactions by either promoting or inhibiting tumour cell growth 
(Klopp et al., 2011). As inhibitors for tumour growth, MSCs block Akt and Wnt 
signalling, suppress angiogenesis, and apoptosis through cell cycle arrest (Hass and 
Otte, 2012, Rhee et al., 2015). Suppression of tumour development has been shown in 
different cancer types such as colon cancer, lymphoma, and melanoma (Nakamizo et 
al., 2005, Loebinger et al., 2009, Grisendi et al., 2010). As tumour promoters, MSCs 
can be recruited to a tumour and activated by TGF-β to form CAFs that play a key role 
in tumour growth, as described above (Barcellos-de-Souza et al., 2016). Moreover, 
Karnoub et al and Shinagawa et al showed that MSCs caused immune modulation and 
stimulation of tumour development (Karnoub et al., 2007, Shinagawa et al., 2010). 
Local MSCs can secrete bioactive molecules that play an important role in tissue injury 
by stimulation of angiogenesis and can have immune modulatory effects to maintained 
homeostasis (Lazennec and Jorgensen, 2008, Uccelli et al., 2008). It has been shown 
that MSCs enhanced angiogenesis and tumour growth through their abilities to 
differentiate into pericyte-like, and endothelial cell-like cells (Oswald et al., 2004, Ball 
et al., 2004, Suzuki et al., 2011). Moreover, co-culture of adipose-derived MSCs with 
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prostate cancer was shown to cause differentiation of MSC into endothelial-like cells 
and increased tumour vascularity and enhancement of the tumour growth (Lin et al., 
2010, Prantl et al., 2010). Many studies have shown that MSCs enhanced cancer 
progression via promoting the metastatic ability of cancer cells together with their role 
in EMT (Karnoub et al., 2007, Kabashima-Niibe et al., 2013). By contrast, other studies 
have shown that MSCs caused suppressive effects on the tumour growth. Ho and his 
colleagues have shown that the human glioma tumour volume and vascularity were 
reduced after administered human BM-derived MSCs with glioma cells (Ho et al., 
2013). In Ho et al study, MSCs caused suppression of a tumour through modification 
of Akt signalling and inhibition of angiogenesis. Furthermore, a study by Otsu et al. 
showed that MSCs were potentially cytotoxic (anti-angiogenic) by generating ROS that 
inhibited tumour growth (Otsu et al., 2009).  
These opposing results may be because experiments were done under different 
conditions like differences in the sources of MSCs used; some used BM-derived and 
other used adipose-derived MSC. In addition, each study used different timing 
schedules and different cell administration methods. Moreover, culture media for in 
vitro experiments do not have all the active factors that are present in the real stem cell 
niche (Watt and Hogan, 2000). In murine gastric cancer due to chronic inflammation, 
it has been reported that 20% of CAFs originated from resident BM-derived MSCs 
(Quante et al., 2011). These MSC-derived CAFs were recruited to a tumour in response 
to TGF-β and SDF-1α. These results suggested that epithelial dysplasia due to chronic 
inflammation leads to relocation of the BM-niche to a tumour and consequent increases 
in MSC numbers promote cancer progression. 
1.6.1 Direct communication of MSC with tumour cells 
 
One of the important ways in which MSCs interact with tumour cells is NOTCH 
signalling that regulates immune cell functions, cell proliferation, differentiation and 
tissue repair (Kopan and Ilagan, 2009). It has been shown that the addition of MSCs 
enhanced breast cancer cells growth both in vivo and in vitro via NOTCH pathway 
signalling (Mandel et al., 2013). Moreover, blocking of NOTCH signalling caused 
decreased CD90 expression by MSCs and inhibited the growth of tumour cells (Mandel 
et al., 2013, Geling et al., 2002). CD90 (Thy-1) is a cell surface protein expressed by 
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MSCs, hematopoietic cells, endothelial cells, fibroblasts, and myofibroblasts (Haeryfar 
and Hoskin, 2004, Craig et al., 1993, Saalbach et al., 1999). CD90 helps to regulate 
cancer cell proliferation, migration, angiogenesis, apoptosis, metastasis and fibrosis 
(Rege and Hagood, 2006, Saalbach et al., 1999, Saalbach et al., 1996).  
MSCs can also communicate with tumour cells by gap junctions that connect 
neighbouring cells through gap junctional intercellular communication (GJIC). GJIC 
maintain tissue homeostasis, and control cell growth and differentiation (Kandouz and 
Batist, 2010). It has been shown that breast cancer cells can gain CD90 via GJIC 
signalling when co-cultured with MSC. The expression of CD90 by breast cancer cells 
was decreased when gap junction inhibitors were used such as carbenoxolone (Mandel 
et al., 2013). 
Another way of communication between MSCs and tumour cells is through nanotubes, 
which enable neighbouring cells to exchange molecules, organelles, and glycoproteins 
(Gurke et al., 2008). Breast cancer cells have been reported to use nanotubes to obtain 
mitochondria from BM-derived MSCs resulting in increased tumour cells proliferation 
and invasiveness (Caicedo et al., 2015). Formation of fusion between MSC and cancer 
cells is also a way of communication that is rare and its molecular mechanisms are still 
poorly understood. 
1.6.2 Indirect communication of MSC with tumour cells 
 
This occurs through secretory mediators from tumour cells such as growth factors, 
chemokines and cytokines that trigger intra-cellular signalling pathways via attaching 
to receptors of neighbouring MSCs. MSCs activate and secrete different bioactive 
compounds that regulate adjacent cells such as tumour cells (Melzer et al., 2016). It has 
been shown that MSCs secrete CC-chemokine ligand 5 (CCL5) or RANTES that 
interact with receptors (chemotactic cytokine) like CCR5, CCR3, CCR1 (Karnoub et 
al., 2007). In breast cancer, the G-protein coupled receptor (GPR75) is activated via 
MSC-derived CCL2 in a paracrine manner, which resulted in enhancement of 
migration, invasiveness and metastatic ability of breast cancer cells (Karnoub et al., 
2007). 
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Another way of the indirect interplay of MSC with tumour cells is via metabolites. 
Many metabolites like indoleamine2, 3-dioxygenase or prostaglandins secreted into the 
tumour stroma motivate other cells in the TME in a paracrine way (Li et al., 2012, Yuan 
et al., 2013). These metabolites affect tumour growth and lead to an alteration in cancer 
cell properties such as invasion, self-renewal and survival. 
Studies by Bonuccelli et al. (2004) on osteosarcoma cells suggested that human adipose 
MSC increased production of lactate in response to oxidative stress induced by cancer 
cells. Subsequently, the lactate efflux receptor expression was increased by 
osteosarcoma cells that increased their ATP production which enhanced the migratory 
ability of the tumour cells (Bonuccelli et al., 2014). 
MSCs can also interact with tumour cells via microparticles such as microvesicles (50-
100 nm in diameter, plasma membrane origin) and exosomes (40-100 nm in diameter, 
endocytic origin) (Lee et al., 2012). The cellular interaction between cancer cells and 
MSCs in the TME occurred through microvesicles and exosomes proteins, micro-
RNAs, and functional mRNAs (Yang et al., 2015a). It has been shown that MSC-
derived exosomes produce MMP-2 and ecto-5’-nucleotidase that modify tumour cell 
function in TME (Yang et al., 2015a, Friedl and Alexander, 2011). Moreover, in 
prostatic cancer, differentiation of BM-derived MSC into CAFs was enhanced by 
cancer cells-derived exosomes and subsequent tumour growth (Chowdhury et al., 
2015). 
Regarding anti-tumour effects of microvesicles, Wu and his colleagues showed, both 
in vitro and in vivo that the growth of bladder cancer cells (T24) was inhibited in 
response to microvesicles derived from MSCs from human umbilical cords. These 
cause tumour cell cycle arrest and apoptosis (Wu et al., 2013). 
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1.7 Tumour microenvironment and radiation 
 
Ionizing radiation is an important modality of curative and palliative cancer treatment. 
More than half of cancer patients need treatment by radiation therapy (Owen et al., 
1992, Delaney et al., 2006). DNA is the main target of radiation leading to cytotoxicity. 
Radiation effects are either directly through DNA damage, or indirectly by forming free 
radicals inside cells from interactions with tissue water. These are highly reactive and 
themselves damaging to DNA. The direct and indirect effects of radiation depend on 
the linear energy transfer (LET), which is the energy transferred per unit length of track 
(Eric and Hall, 2006). Moreover, tumour hypoxic cells during RT treatment are about 
three times more radiation-resistant than normoxic cells (Brown and William, 2004). 
Apart from the tumour cells themselves, tumour endothelial cells are relatively 
radiosensitive, at least partly due to their rapid proliferation (Barker et al., 2015). 
Tumour blood vessels differ from those in normal tissues, for instance in that, they are 
tortuous and more permeable (due to structural abnormalities of the basement 
membrane, a relative paucity of pericytes and stretching of endothelial cells). These 
features may make them particularly susceptible to radiation damage (Fajardo, 2005, 
Jain, 2003). The radiation effects on the tumour vasculature depend on many factors 
such as radiation dose, fractionation, site and size of the tumour, and tumour types (Park 
et al., 2012, Karam and Bhatia, 2015).  
In fact, low dose radiation (<5 Gy) can enhance tumour growth via increased VEGF 
secretion promoting angiogenesis (Heissig et al., 2005, Vala et al., 2010). Moreover, 
Lerman and his colleagues showed that low-dose radiation (5 Gy) causes stimulation 
of HIF-1α in endothelial cells that upregulate SDF-1α and endothelial cell migration 
(Lerman et al., 2010). In contrast, high dose radiation has been shown to cause severe 
vascular damage and disruption of the TME (Song et al., 2015, Maeda et al., 2017). 
Solesvik et al. showed that within a week of irradiation of melanoma xenografts (human) 
with single doses of 10-15 Gy there was damage to nearly half of all the tumour blood 
vessels (Solesvik et al., 1984). Another study showed that vascular density of human 
ovarian cancer xenograft was decreased to a half of control after irradiation with 20 Gy 
(5 Gy/ fraction) (Dings et al., 2005). 
Vascular damage caused by radiation can lead to tumour hypoxia and release of HIF-
1α (Figure 1.3). As discussed in section 1.4.4, HIF-1α enhances secretion of cytokines 
and chemokines to recruit immune cells like BM-derived cells. These BM-derived cells 
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can differentiate into endothelial cells by VEGF and PDGF (Ahn and Brown, 2009, 
Maeda et al., 2017, Conway et al., 2001). Multiple studies have indicated the activation 
of several genes by HIF-1 during hypoxia, such as erythropoietin, glucose transporters, 
glycolytic enzymes and VEGF (Sutherland, 1998, Blouin et al., 2004, Williams et al., 
2005). 
These activated genes make tumour cells more aggressive, radioresistant and able to 
survive in adverse conditions. RT can cause angiogenesis and radio-resistance 
(Koukourakis et al., 2001), because radiation makes endothelial cells produce many 
cytokines that work as proangiogenic factors like PDGF, TGF-β, TNF-α, b FGF, IFN-
γ and VEGF (Wachsberger and Burd, 2004, McBride et al., 2004). Moreover, radiation 
causes sprouting of endothelial cells (the first step in angiogenesis) through stimulation 
of nitric oxide pathways inside these cells (Sonveaux et al., 2003) (Figure 1.3). Gorski 
and colleagues reported VEGF up-regulation after radiation in several cancer cell lines 
(Gorski et al., 1999). 
Radiation can also affect CAFs. As mentioned earlier (see section 1.5), CAFs represent 
the most common cells within the TME that play a role in cancer growth, metastasis, 
and angiogenesis. CAFs have the ability to recruit endothelial cells via secretion of 
SDF-1; in addition, CAFs enhance secretion of ECM-degrading enzymes (MMPs). It 
has been found that CAFs and normal fibroblasts are radioresistant (Hawsawi et al., 
2008, Papadopoulou and Kletsas, 2011, Tachiiri et al., 2006). However, most of these 
studies were on fibroblasts rather than CAFs. Irradiation can cause senescence in 
fibroblasts and release of cytokines, proteolytic enzymes, growth factors and ROS, 
which all enhance tumour formation (Rodier et al., 2009, Papadopoulou and Kletsas, 
2011, Velarde et al., 2013, Liu and Hornsby, 2007). Interestingly, senescence occurs 
more clearly after single dose radiation of lung CAFs rather than fractionated irradiation 
with the same dose (Hellevik et al., 2012). 
Radiation causes inflammation in the TME and subsequent recruitment of fibroblasts 
to the site of injury. Fibroblasts differentiate into CAFs via TGF-β that is released in 
response to inflammation. CAFs secrete ECM proteins like collagen, fibronectin and 
laminin which cause fibrosis in the long term (Yarnold and Brotons, 2010). 
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 Figure 1.3 The effect of hypoxia on tumour gro      : During tumour growth 
or after radiation, tumour hypoxia increases and this leads to initiation of 
Hypoxia Inducible Factor 1 (HIF-1), which then cause vascularisation in 
hypoxic areas through VEGF upregulation, and angiogenesis formation. 
 
 
Figure 1.28 The effect of hypoxia on tumour growth : Figure 1.3 The effect of 
hypoxia on tumour gro      : During tumour growth or after radiation, tumour 
hypoxia increases and this leads to initiation of Hypoxia Inducible Factor 1 
(HIF-1), which then cause vascularisation in hypoxic areas through VEGF 
upregulation, and angiogenesis formation. 
 
 
Figure 1.29 The effect of hypoxia on tumour growth : 
 
Figure 1.30 Origin of Myofibroblasts (CAFs) in cancerFigure 1.31 The effect of 
.   ff t f i  o  t o r growth: 
 
Figure 1.46 Origin of Myofibroblasts (CAFs) in 
cancerFigure 1.47 The effect of hypoxia o  tumour 
growth : 
 
Figure 1.48 Origin of Myofibroblasts (CAFs) in 
canc r 
 
Figure 1.4 Origin of Myofibroblasts (CAFs) in 
cancerFigure 1.49 Origin of Myofibroblasts (CAFs) 
in cancerFigure 1.50 The effect of hypoxia on 
tumour growth : 
 
Figure 1.51 Origin of Myofibroblasts (CAFs) in 
cancerFigure 1.52 The effect of hypoxia on tumour 
growth : 
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1.8 Radiation effect on MSC biology and subsequent fibrosis 
 
Although radiation therapy is an essential component of cancer therapy, side effects are 
inevitable. Radiation side effects are either acute, like skin erythema and desquamation, 
mucositis, nausea and diarrhoea or chronic (long term) affecting patient’s quality of life 
such as radiation fibrosis, and vascular damage (Bentzen, 2006). The severity of 
radiation long-term effects depends on radiation-dose, treatment volume, and fraction 
size. One of the important and life-threatening radiation late effects is radiation-induced 
fibrosis (RIF). The development of RIF is a complicated process that involves different 
growth factors, cytokines, inflammation, fibroblast differentiation, and remodelling of 
the ECM (Wynn, 2008). 
In regards to the response of MSCs to irradiation in human and mouse, it has been 
shown in vitro that MSC survival after high dose irradiation was higher than for other 
stem cells derived from the BM (Chen et al., 2006, Nicolay et al., 2014). A study by 
Islam et al. showed that adult human MSCs were more radioresistant than embryonic 
stem cells (Islam et al., 2015). Fractionated or hyperfractionated radiotherapy of 0.5-2 
Gy has been shown to cause radioresistance in MSCs (Tomuleasa et al., 2010, Clavin 
et al., 2008). 
In hypoxic conditions, Sugrue et al. showed that hypoxia increased radioresistance of 
mouse MSCs in vitro by increasing their proliferation, DNA damage repair, and long-
term survival after irradiation (Sugrue et al., 2014). Moreover, another study confirmed 
these results in vivo and showed that after irradiation of porcine mandibular bone with 
single doses of up to 18 Gy, MSCs that survived maintained their proliferation and 
differentiation abilities (Singh et al., 2012). 
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1.8.1 Radiation and fibrosis  
 
Fibrosis and tissue repair are strongly related to myofibroblasts, which commonly 
originate from local fibroblasts. Within normal connective tissue, fibroblasts are 
considered the most common cell type responsible for the synthesis, remodelling, and 
degradation of ECM in disease and health (Evans et al., 2003). Fibroblasts differentiate 
into myofibroblasts (in cancer called CAFs) as a consequence of fibrogenic cytokines 
secreted by inflammatory cells and other cells (Hinz et al., 2007). This differentiation 
is called activation and at this stage, α-SMA appears associated with coarse fibres 
responsible for the contractile properties of myofibroblasts (Hinz et al., 2007). 
Myofibroblasts are responsible for the production of collagens type I, III, IV and V, 
fibronectins and other matrix proteins (Sime and O'Reilly, 2001, Wynn, 2008). 
Myofibroblasts compared to fibroblasts secrete large amounts of collagen and they 
represent the main source of collagen in tissues (Ramos et al., 2001). Moreover, 
myofibroblasts represent the main sources of pro-fibrotic cytokines such as TGF-β and 
MCP-1 in idiopathic pulmonary fibrosis (Goodwin and Jenkins, 2009, Phan, 2002). 
Presence of myofibroblasts within fibrotic lesions in animal models and in human 
fibrotic diseases proved them as key cells in the pathogenesis of fibrosis (Zhang et al., 
1994). Myofibroblasts play a key role in wound healing through regulation of tissue 
repair. However, if their extra cellular matrix secretion becomes uncontrolled, it can 
cause severe impairment of organ function (Hinz et al., 2007, Yarnold and Brotons, 
2010). Normally, fibroblasts (that express little or no α-SMA) produce low ECM, while 
after tissue injury; fibroblasts become activated through cytokines released from 
epithelial cells in response to the injury. The activated fibroblasts (myofibroblasts) 
migrate to damaged tissue to synthesise and deposit ECM. To prevent excessive ECM 
deposition and tissue restoration, apoptosis is activated (Wynn, 2008). It has been 
shown that myofibroblasts are resistant to apoptosis, which causes excessive ECM 
production and scar formation (Ramos et al., 2001). 
RIF is one of the commonest long-term side effects of radiotherapy treatment that 
develops by complex molecular processes involving different growth factors, cytokines, 
chemokines, inflammation, and ECM degradation. The molecular mechanisms of RIF 
are similar to other fibrotic diseases (Yarnold and Brotons, 2010, Cheresh et al., 2013). 
The first step in fibrosis is the remodelling of ECM in connective tissue and production 
of myofibroblasts from different cell-types via fibroblast activation, or EMT (Zvaifler, 
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2006, Krenning et al., 2010). In healthy tissue, the injury response and wound healing 
depend on activation of fibroblasts and remodelling of ECM (Bielefeld et al., 2013). In 
fibrotic diseases, the activity of myofibroblasts remains even after damage repair 
(Wynn, 2008). Moreover, different types of cells are involved in regulation of tissue 
such as epithelial and endothelial cells in addition to immune cells (Krenning et al., 
2010, Milliat et al., 2006, Xiao et al., 2012). Several growth factors, hormones, and 
mediators drive or suppress the fibrotic process. TGF-β, connective tissue growth factor 
(CTGF), and interleukin-6 (IL6) act as radiation fibrosis inducers (Kruse et al., 2009, 
Haydont et al., 2008, Gaugler et al., 2005), whereas fibrosis suppressors include gamma 
interferon, hepatocyte growth factor, and thrombomodulin (Hu et al., 2009, Gottlober 
et al., 2001, Yarnold and Brotons, 2010). A cascade of active cytokines persists after 
irradiation, which is responsible for long-term radiation tissue damage effects (Devalia 
and Mansfield, 2008). The initiation of this cascade is still unclear, but may be radiation 
leads to activation of macrophages and monocytes that secrete cytokines like IL-1, IL-
6, and tumour necrosis factor alpha (TNFα), which attract other macrophages, and 
monocytes. These activated macrophages synthesize cytokines (fibrogenic) such as 
CTGF, TGF-β, and PDGF which are responsible for the synthesis of ECM proteins, 
MMPs and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs) (Haase and 
Rodemann, 2004, Bentzen, 2006). 
RIF is a complex process that is driven by multiple intracellular signalling pathways 
including Smad signalling related to TGF-β, rho/ROCK kinase signalling, integrin 
signalling, DNA damage response (DDR), and stress response signalling (Milliat et al., 
2006, Puthawala et al., 2008, Haydont et al., 2008). Both DDR and stress response are 
important in radiotherapy treatment of cancer as they determine the normal tissue side 
effects from irradiation and the effectiveness of the treatment (Moding et al., 2013). 
Radiation leads to ROS, and different DNA cell-cycle arrest through activation of 
checkpoints and subsequent apoptosis (Cheresh et al., 2013, Moding et al., 2013). 
Long-term radiation response leads to delayed onset genomic instability with loss of 
ability of the tissue to regenerate that caused tissue dystrophy and radiation fibrosis 
(Koturbash et al., 2006, Sperk et al., 2012, Westbury and Yarnold, 2012). Radiation 
causes damage to the DNA of the cells within the irradiated areas but cells also secrete 
factors that cause DNA damage of distant cells through a bystander effect (Koturbash 
et al., 2006, Dickey et al., 2009). Many studies suggest that long-term radiation effects 
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rely on loss of stem cells, persistent DNA damage, changes in cellular signalling, and 
genetic/epigenetic deviations (Koturbash et al., 2006, Dickey et al., 2009, Coppes et al., 
2009, Kuhmann et al., 2011, Yarnold and Brotons, 2010). In summary, inflammation 
plays a key role in the development of RIF.  
1.8.2 Origin of myofibroblasts (CAFs) in cancer 
 
There are different types of cells from which CAFs can originate in cancer (Figure 1.4). 
The main source of CAFs is from resident fibroblasts that become 
activated/differentiated by TGF-β (Postlethwaite et al., 2004). As described previously, 
in response to the tissue injury, epithelial cells secrete TGF-β that induces 
differentiation of fibroblasts to CAFs. However, evidence from research have 
suggested alternative sources that CAFs may originate from. It was shown that 
epithelial cells, macrophages and pericytes undergo phenotypic differentiation to form 
CAFs (Flier et al., 2010, Lamouille et al., 2014, Zeisberg et al., 2007b). Epithelial cells 
can differentiate into CAFs through EMT in the presence of TGF-β. Moreover, it has 
been suggested that CAFs can derive from endothelial cells through endothelial-
mesenchymal transition (En-MT) (Kalluri and Neilson, 2003). In the En-MT process, 
endothelial cells gain mesenchymal properties and expresses CAFs differentiation 
markers like α-SMA, collagens and vimentin and decrease endothelial cell markers 
such as vascular endothelial cadherin (VE-cadherin) (Zeisberg et al., 2007a). Jimenez 
et al and Kong et al have shown the involvement of En-MT in the development of 
pulmonary fibrosis (in systemic sclerosis), cardiac fibrosis and intestinal fibrosis in 
humans (Jimenez, 2016, Kong et al., 2014). It is not yet understood why En-MT plays 
a role in the pathogenesis of fibrosis in humans. Understanding of molecular 
mechanisms of En-MT involvement in fibrosis should help in the development of novel 
anti-fibrotic drugs. 
Another source of CAFs is from BM stem cells or tumour MSCs. It has been shown 
that circulating fibroblasts derived from BM can differentiate into CAFs (Bucala et al., 
1994, Ebihara et al., 2006). These mesenchymal stem cell progenitors (fibrocytes) have 
the phenotype of fibroblast/myofibroblasts and they express collagen I, CD34, and 
CD35 (Ebihara et al., 2006, Brittan et al., 2002, Forbes et al., 2004). Although it appears 
that CAFs derive from differentiation of many cellular types, the main source of CAFs 
remains the resident fibroblasts. 
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Figure 1.4 Origin of Myofibroblasts (CAFs) in cancer: CAFs originate from 
different sources such as: resident fibroblasts, circulating bone marrow progenitors 
(fibrocytes), endothelial cells experiencing endothelial-mesenchymal transition (En-
MT), pericytes, macrophages, MSCs and epithelial cells experiencing epithelial-
mesenchymal transition (EMT). 
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1.8.3 Role of TGF- β in RIF  
 
1.8.3.1 TGF-β overview and superfamily 
 
TGF-β is 25-kDa multi-functional polypeptide cytokine that plays an important role in 
fibrosis. It regulates differentiation and proliferation of cells, development and growth 
of organs, immune response, apoptosis, tumour growth and suppression (O'Sullivan 
and Levin, 2003, Bentzen, 2006). TGF-β belongs to a superfamily of more than 60 
proteins (29 of them encoded by the human genome) that regulate homeostasis, 
embryonic development, control of cell cycle, and wound healing in multicellular 
organisms, (Feng and Derynck, 2005, Leask and Abraham, 2004). TGF-β is present as 
three isoforms (TGF-β1-3) that have similar biological activities (Gorelik and Flavell, 
2002). Although in humans all three isoforms are expressed, the TGF-β1 isoform is 
most prevalent and is associated with tissue fibrosis (Wynn, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Pro-fibrotic effects of TGF-β1 
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1.8.3.2 TGF-β signalling 
 
The secretion of the TGF-β from most cells (like CAFs and macrophages) occurs in a 
latent form, which needs to be activated in the extracellular space in order to bind to 
the receptor. TGF-β is stored inside cells as an inactive homodimer form that is bound 
to latency-associated peptide (LAP) that keeps TGF-β inactive. Its activation occurs by 
dissociation of the LAP (Lawrence, 2001). This means that after exposure to triggering 
factors including ionising radiation, the large amount of latent TGF-β in the 
extracellular space can be mobilized. It has been shown that within a few minutes or 
hours after exposure to ionizing radiation with 0.1 Gy, TGF-β becomes activated 
(Ehrhart et al., 1997, Ewan et al., 2002). When TGF-β becomes activated, it can bind 
to its receptors TGF-β R1 and TGF-β R2, which then activate a family of transcription 
factors called Smads. Through Smads, TGF-β signalling transmitted downstream from 
the receptor to the nucleus. In addition, an alternative non-Smad pathway has been 
described including p38, MAPK, m-TOR, RAS, P42/p44 MAPK (Zhang, 2009). 
Smad pathways regulate translation, transcription, microRNA biogenesis, post-
translational modifications and protein synthesis (Hussey et al., 2011, Mu et al., 2012). 
Within the Smad family, there are three sub-types: inhibitory Smads (I-Smads), 
receptors that regulate Smads (R-Smads), and common partner Smads (Co-Smads). 
The phosphorylation of R-Smads, Smad-2 and Smad-3 occur after activation of TGF-
β receptor I kinase. Then, a heteromeric complex is formed from Smad-2 and -3 with 
co-Smad (Smad-4). The resultant complex then imported into the nucleus to regulate 
gene transcription (Attisano and Wrana, 2002, Verrecchia and Mauviel, 2002). Smad-
6 and -7 work as inhibitors for signalling by inhibiting gene induction through 
preventing phosphorylation of R-Smad (Nakao et al., 1997) (Figure 1.6). 
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Figure 1.6 Role of TGF-β in radiation fibrosis:  
TGF-β activated by ionizing radiation that leads to dissociation from the latency-
associated peptide (LAP). Moreover, radiation causes damage to endothelial 
cells, which in turn leads to the secretion of chemokines and pro-fibrotic 
cytokines such as TGF-β. EC-derived chemokines recruit macrophages or 
monocytes, which cause apoptosis and further release of growth factors and 
cytokines like TGF-β. These extracellular actions cause TGF-β signaling 
pathway activation through Smad pathways. The phosphorylation of Smad-2 
and Smad-3 occur after activation of TGF-β receptor I kinase. Then, a 
heteromeric complex formed from Smad-2 and -3 with co-Smad (Smad-4). This 
resultant complex transmitted into the nucleus to regulate gene transcription. 
Smad-7 works as an inhibitor for signalling by inhibiting gene induction through 
preventing phosphorylation of R-Smad and Smad-3. The final result from this 
process is increased ECM proteins like collagens. 
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1.8.3.3 TGF-β and fibrosis 
 
As previously mentioned, TGF-β has strong pro-fibrotic effects on epithelial cells and 
fibroblasts, so it plays an important role in the development of fibrosis. It has been 
shown, both in vitro and in vivo, that TGF-β induces fibroblast differentiation into 
myofibroblasts (Desmouliere et al., 1993, Sime et al., 1997). There are three ways by 
which TGF-β enhances fibrogenesis. Firstly, TGF-β causes remodelling of the ECM 
via suppression of the MMPs, enhancing production of tissue inhibitor of 
metalloproteinases gene (TIMP3), and subsequently inhibits ECM degradation (Martin 
et al., 2000, Eddington et al., 2007).  
Secondly, through Smad signalling, TGF-β leads to the formation of myofibroblasts 
through EMT. During EMT, the epithelial markers like E-cadherin and cytokeratins are 
down-regulated while mesenchymal markers like vimentin and α-SMA are up-
regulated (Xu et al., 2009). Through EMT, epithelial cells gain invasive and migratory 
properties of cancer stem cells that can differentiate into different types of cells (Jain et 
al., 2007, Mani et al., 2008). It has been shown that in adult tissue, both fibrinogenesis 
and wound healing displaying EMT (Kalluri and Neilson, 2003). Thirdly, TGF-β 
enhances production of the matrix via Smad-3 dependent or non-Smad mechanism (Lan, 
2003). It has been shown that the Smad-3 levels increased in many fibrotic models, 
moreover, mice with Smad-3 knockout were protected from lung fibrosis induced by 
bleomycin drug (Liu et al., 2003). A study by (Roberts et al., 2006) showed that 
fibrinogenesis was reduced in mice after deletion of Smad-3 that blocks EMT. 
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1.8.4 Connective tissue growth factor in cancer and fibrosis 
 
Connective tissue growth factor (CTGF) or CNN2 is a matricellular protein that plays 
a role in fibroblast proliferation, and production of matrix and granulation tissue (Leask 
and Abraham, 2004, Yarnold and Brotons, 2010). It is a 36-38 kDa protein and was 
discovered in 1991 as a secreted protein in the CM from HUVEC (Human umbilical 
vascular endothelial cells) (Bradham et al., 1991). Tumour growth and progression is 
related to CTGF expression. For example, CTGF expression in breast cancer increased 
in bone metastasis (Kang et al., 2003) and was associated with bad prognosis in 
oesophageal cancer (Koliopanos et al., 2002), and increased invasiveness in pancreatic 
cancer (Wenger et al., 1999). On the other hand, some studies showed the reverse. 
Shakunaga and his colleagues showed, in chondrosarcoma, that the expression of 
CTGF was negatively related to tumour growth and grade (Shakunaga et al., 2000). 
Moreover, another study showed that over expression of CTGF was related to 
decreased oral squamous cell carcinoma tumour growth (Moritani et al., 2003). Lee and 
his colleagues showed that CTGF was responsible for differentiation of human BM-
MSCs into fibroblasts that expressed increased collagen-I, or into myofibroblasts in the 
presence of TGF-β (Lee et al., 2010). 
It has been shown that, in fibroblasts, CTGF enhanced the mRNA expression of α1 
collagen-I, fibronectin, and α5 integrin (Frazier et al., 1996). CTGF also mediates   
endothelial cell migration, proliferation, differentiation and enhanced angiogenesis 
(Shimo et al., 1999, Babic et al., 1999). 
Regarding the role of CTGF in fibrosis, the fibrotic activity of TGF-β is dependent on 
CTGF activities (Mori et al., 1999, Parada et al., 2013). Moreover, in fibrosis and 
wound healing the CTGF expression is increased alongside that of TGF-β (Barrientos 
et al., 2008). Leask and Abraham suggested that some of TGF-β’s functions, like 
secretion of ECM (collagen and fibronectin) and fibroblast proliferation, are mediated 
by CTGF (Leask and Abraham, 2004). It has been reported that after being secreted 
from cells, CTGF interacts with different growth factors and cytokines like VEGF, 
TGF-β, IGF1, BMP-4 and BMP-7 (Yang et al., 2010, Liu et al., 2007). In human skin 
fibroblasts, previous studies have shown that TGF-β caused a huge increase in the 
expression of CTGF mRNA (Igarashi et al., 1993). Moreover, TGF-β required CTGF 
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to activate Smad1-ERK1/2 signalling (no effects on Smad-3 phosphorylation) 
(Nakerakanti et al., 2011). Through the Smad-3 binding site at the CTGF promotor, 
TGF-β caused fibroblasts to express CTGF (Verrecchia and Mauviel, 2007).  
The up-regulation of CTGF in fibrosis was evident in different studies. A study by 
Nguyen et al. (2008) in diabetic kidney disease showed that CTGF inhibits BMP-7 
signalling that caused altered gene transcription and subsequent reduction in MMP 
activity (Nguyen et al., 2008).  BMP-7 plays a role in neutralizing the pro-fibrotic 
effects of TGF-β (Wahab and Mason, 2006, Mitu and Hirschberg, 2008). Mori and his 
colleagues reported that when a single administration of CTGF or TGF-β was injected 
subcutaneously in new born mice, a transient fibrosis occurred represented by 
granulation tissue formation (Mori et al., 1999). Furthermore, if CTGF was injected 
together with TGF-β, a fibrotic response happened and continued for a week. These 
results suggested that CTGF plays an essential role in the development of fibrosis. 
Although most studies have shown the positive correlation between TGF-β and CTGF, 
other studies showed the reverse. A study by Diziadzio et al. (2005) showed that in 
systemic sclerosis the level of CTGF was increased in the circulation compared to 
normal levels of TGF-β in the serum from both control healthy and diseased patients 
(Dziadzio et al., 2005). However, a study by Okada et al. (2005) showed that animals 
treated by CTGF antisense oligodeoxynucleotide did not affect the levels of TGF-β 
while it inhibited the expression of CTGF and reduced fibrosis (Okada et al., 2005). 
These studies are consistent with other studies suggesting that when the activity or 
synthesis of CTGF was blocked, inhibition of many TGF-β-responding transcriptions 
such as synthesis of collagen, adhesion, proliferation of fibroblasts and differentiation 
of myofibroblasts occurred (Frazier et al., 1996, Duncan et al., 1999, Grotendorst et al., 
2004, Shi-Wen et al., 2006). Ma et al. suggested that CTGF, TGF-β2, and gremlin 
(BMPs antagonist) were involved in EMT of lens epithelial cells to form myofibroblasts 
and synthesis of ECM via Smad pathways (Ma et al., 2014). In summary, CTGF is both 
a mediator and marker for fibrosis in health and disease. A further understanding of the 
cellular mechanisms involved in the influence of CTGF on fibrosis is required. CTGF 
and CTGF-related pathways are also potential targets for the treatment of fibrosis. 
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1.9 MSCs homing toward cancer 
 
How MSCs migrate to sites of tissue injury or into tumours is not fully understood. 
However, various different mediators like growth factors, cytokines, and chemokines 
have been described to be involved in the MSC homing mechanisms to inflammatory 
sites. 
1.9.1 Growth factors involved in ‘homing’ of MSCs 
 
Growth factors are polypeptide molecules that stimulate cell proliferation 
/differentiation, migration, and survival through their extracellular signalling (Vanden 
Berg-Foels, 2014). Growth factors play roles in wound healing and during 
embryogenesis (Cohn et al., 1995, Cross and Mustoe, 2003). One of the critical factors 
that play a role in the migration of MSCs is VEGF. It has been shown that MSC 
migration was enhanced by VEGF secreted by breast cancer cells. Moreover, receptors 
for VEGF are expressed on MSCs, and blocking of VEGF can cause a reduction in 
MSC migration (Ritter et al., 2008). PDGF also plays a role in the homing of MSCs. 
PDGF has been shown to play roles in wound healing and in embryogenesis (Alvarez 
et al., 2006).  It is a polypeptide dimer that has four homo-dimers with their receptors 
such as PDGF-AA, PDGF-BB, PDGF-CC, and PDGF-DD. Each PDGF dimer has two 
receptors,  and . PDGF-AA binds / receptors and PDGF-BB binds /,  /, and 
/ receptors (Fang et al., 2004). It has been shown in vitro that migration and 
recruitment of human MSCs were enhanced by PDGF-AA, and PDGF-BB (strongest 
response) (Fiedler et al., 2004). On the other hand, studies by (Ruster et al., 2005) and 
(Nedeau et al., 2008) have shown that only a minimal number of MSCs migrated in 
response to PDGF-BB. The differences in the effects of PDGF-BB on the recruitment 
of MSCs might be due to using different MSCs and culture conditions.  
Other growth factors that have a role in MSC homing are shown in Table 1.1. 
1.9.2 Chemokines 
 
Chemokines are families of chemotactic cytokines with small molecular size (8-10 
kDa) which induce chemotaxis of leukocyte cells (Baggiolini, 1998). Based on their 
cysteine residues number, chemokines are divided into four groups: C, CC, CXC, and 
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CX3C (Clarklewis et al., 1995). They play key roles in wound healing, tissue 
homeostasis, and immune response through regulation of cell migration. 
1.9.2.1 Stromal cell derived factor 1α  
 
Stromal cell derived factor 1α (SDF-1α) is CXC chemokine 12 (CXCL12) that is 
expressed at injury sites and is involved in wound healing, embryogenesis, and in 
response to hypoxia (Gillitzer and Goebeler, 2001, Rezzoug et al., 2011, Abbott et al., 
2004). SDF-1α is an 8-12 kDa peptide that enhances the progression of cancer and 
promotes angiogenesis by recruitment of endothelial cells to the tumour site (Kryczek 
et al., 2007, Diomedi-Camassei et al., 2008, Meier et al., 2007, Sung et al., 2008). 
CXCR4 is a protein encoded by the CXCR4 gene and acts as a receptor for SDF-1 α. 
SDF-1α works on cancer cells through enhancing proliferation via CXCR4 that is 
expressed on cancer cells.  
It has been shown that SDF-1α induces recruitment of human MSCs in vitro (Schmidt 
et al., 2006, Sordi et al., 2005). Moreover, Kitaori et al showed that, in vivo, SDF-1α 
recruited MSCs to a fracture site in mouse and helped the regeneration of the bone. On 
the other hand, using anti-SDF-1 antibody and anti-CXCR4 caused inhibition of MSC 
recruitment (Kitaori et al., 2009). Some studies have demonstrated, in mouse models, 
that in the presence of tissue injury, the migration of MSCs to the area of injury, where 
SDF-1α was expressed, was increased (Abbott et al., 2004, Ji et al., 2004). It has been 
shown that tumour cells secreted soluble factors that caused MSCs to secrete SDF-1α 
that, in turn, activates their migration (Gao et al., 2009). 
These studies indicate the importance of SDF-1α chemokine in the recruitment of 
MSCs.  
1.9.2.2 Monocyte chemoattractant protein-1  
 
During tissue injury, myofibroblasts, macrophages, and other active cells that are 
recruited to the injury site via chemokines work together with pro-fibrotic cytokines. 
Chemokines allow leukocytes to interact with fibroblasts by recruiting them into tissue 
across endothelial barriers (Hasegawa and Sato, 2008). One of the important chemokine 
signalling pathways that play a role in the recruitment of MSCs and fibrosis is the CC- 
and CXC-chemokine receptor families (Wynn, 2008). (Carulli et al., 2005, Distler et 
al., 2009, Ong et al., 2003) have demonstrated monocyte chemoattractant protein-1 
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(MCP-1) or CCL-2 and MCP-3 (CCL-7) as pro-fibrotic mediators. MCP-1 is 
responsible for recruitment of monocytes to the injury site and its receptor (CCR2) is 
expressed on the MSCs (Ringe et al., 2007, Ponte et al., 2007). In vitro, it has been 
shown that MCP-1 causes direct and indirect expression of collagen through 
endogenous signalling of TGF-β or IL-4 (Distler et al., 2006). Moreover, when MCP-
1 was neutralized using anti-MCP-1 antibodies, a reduction in fibrosis resulted (Lloyd 
et al., 1997, Belperio et al., 2001). Similar results were obtained in mice deficient to 
chemokine receptor 1 and 2 (CCR1, and CCR2) confirming their important roles in 
fibrosis (Tokuda et al., 2000, Anders et al., 2002, Moore et al., 2001). It has been shown 
that the migration of human and mice BM-derived MSCs were enhanced by MCP-1 
chemokine in vivo and in vitro (Boomsma and Geenen, 2012, Dwyer et al., 2007, 
Belema-Bedada et al., 2008). Using anti-CCR2 antibodies caused inhibition of MSC 
migration via blocking of CCR2 downstream signalling (Belema-Bedada et al., 2008). 
Conversely, studies by Ringe et al and Takano et al showed that MCP-1 had no 
significant migratory effect on BM-derived MSCs (Ringe et al., 2007, Takano et al., 
2014). A study by Dwyer et al showed that MCP-1 secreted from breast cancer cells 
enhanced the migration effects of MSCs (Dwyer et al., 2007). Moreover, Klopp et al 
and Baek et al showed that cytokines and growth factors such as TGF-β, PDGF, and 
VEGF that were secreted from tumour cells and enhanced MSCs migration were 
increased post irradiation (Klopp et al., 2007, Baek et al., 2011). 
These variations in the MSC migratory response to MCP-1 chemokine need an 
additional investigation to study the role of MCP-1 in MSCs homing. 
Other chemokines are in Table 1.1. 
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Growth factors 
Ligands Receptors Reference 
VEGF-A VEGFR-1, -2 (Sorrentino et al., 2008) 
PDGF-AA PDGF-α (Ponte et al., 2007) 
PDGF-BB PDGF-β (Sorrentino et al., 2008) 
EGF EGFR (Ponte et al., 2007) 
TGF TGFR (Baek et al., 2011) 
BMP-2, -4 BMPR-1a, -1b, -2 (Lavery et al., 2008) 
HGF HGFR (Neuss et al., 2004) 
IGF-1, -2 IGF-1R (Ponte et al., 2007) 
Ang-1 TIE-2 (Sorrentino et al., 2008) 
FGF-2 FGFR-1, -2, -3, -4 (Walsh et al., 2000) 
Chemokines 
MCP-1 (CCL2) CCR2 (Ringe et al., 2007) 
RANTES (CCL5) CCR5 (Ponte et al., 2007) 
MCP-2, MCP-3, 
MCP-4 
CCR1 (Sordi et al., 2005) 
CCL20 (MIP-3α) CCR6 (CD196) (Ringe et al., 2007) 
CCL25 (TECK) CCR9 (CDw199) (Honczarenko et al., 
2006) 
CCL27 (CTACK), 28 
(MEC) 
CCR10 (Brooke et al., 2008) 
CXCL12 (SDF-1) CXCR4 (CD184) (Ponte et al., 2007) 
CXCL13 (BLC) CXCR5 (CD185) (Ringe et al., 2007) 
Others 
HMGB-1 RAGE; TLR2, (Meng et al., 2008) 
LPA LPA-1 (Edg2) (Song et al., 2010) 
TNF-α TNFR1 (Croitoru-Lamoury et 
al., 2007) 
Lipoproteins, 
peptidoglycans 
TLR1 (CD281) (Tomchuck et al., 2008) 
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Table 1.1 Growth factors, chemokines and other chemoattractant ligands 
and receptors expressed by human bone marrow MSCs.  
Adapted from (Vanden Berg-Foels, 2014). VEGF, vascular endothelial growth 
factor; PDGF, platelet-derived growth factor; EGF, epidermal growth factor; 
TGF, transforming growth factor; BMP, bone morphogenetic protein; HGF, 
hepatocyte growth factor; IGF, insulin-like growth factor; FGF, fibroblast 
growth factor; MCP, monocyte chemoattractant protein; RANTES, regulated on 
activation normal T-cell expressed and secreted; MIP, macrophage 
inflammatory protein; MDC, macrophage-derived chemokine; SLC, secondary 
lymphoid tissue chemokine; IL, interleukin; SDF, stromal cell derived factor; 
TNF, tumour necrosis factor; RAGE, receptor for advanced glycation end 
products; HMGB, high mobility group box; LPA, lysophosphatic acid; S1P, 
sphingosine 1-phosphate; TLR, Toll-like receptor. 
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1.9.3 Radiation and MSCs homing toward cancer 
 
It has been shown that radiation induces the expression of many cytokines like EGF, 
pro-inflammatory cytokines and fibroblast growth factor (Wang et al., 1998). Moreover, 
in tissues exposed to high or low doses of ionizing radiation, there is early and persistent 
activation of TGF-β1 (Anscher et al., 1990, Wang et al., 1998). Klopp et al. studied the 
effects of radiation on the migratory ability of MSC. They showed, both in vitro and in 
vivo, that radiation enhanced MSC migration through inflammation cytokines and 
chemokines that released after tissue injury in response to radiation (Klopp et al., 2007). 
Furthermore, they were able to identify the chemokines and cytokines responsible for 
the recruitment of MSC toward irradiated tumours. They showed that after irradiation 
of the tumour cells, their ability to produce cytokines that recruit MSCs (like VEGF, 
TGF-β1, and PDGF) were increased (Klopp et al., 2007). Also, they found that the level 
of chemokine receptor CCR2 (MCP-1 receptor) was up-regulated in irradiated MSCs. 
Ren et al. demonstrated that blocking of CCR2 in vitro caused decreased MSC 
migration (Ren et al., 2012). These studies indicate that the post inflammation 
mediators were increased in response to irradiation, which enhanced MSCs migration 
toward tumour microenvironment.  
However, there is still more to be studied about the molecular mechanisms behind the 
recruitment of MSCs to the tumour site post-irradiation, and whether MSCs play a key 
role in the fibrotic changes that occur post-irradiation via their differentiation into CAF-
like cells. 
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1.10 Aims of the study 
 
As described earlier, radiotherapy is one of the standard treatments for patients with 
intermediate and high-grade soft tissue sarcoma. Some studies have shown that 
radiation recruits MSCs to tumours (Klopp et al., 2007, Fenton and Paoni, 2007), but 
the mechanism behind this event is still unclear. MSCs can differentiate into CAFs, 
which is responsible for ECM secretion and deposits of collagen and other matrix 
proteins with subsequent fibrosis (Azorin-Vega et al., 2015). CAFs play a key role in 
cancer initiation, invasion and metastasis (Luo et al., 2015) and the exact origin of 
CAFs in irradiated tumours has not been established. In normal tissues, growth factors 
such as PDGF and TGF-β play a key role in the differentiation of myofibroblasts, so 
similar factors may be involved in response to radiation in the tumour. 
The general hypothesis to test in this project is that radiation alters MSC protein 
expression and behaviour, either directly or indirectly via radiation effects on other cell 
types present in solid tumours. These alterations have the potential to play a significant 
role in radiation-induced changes within the TME linked to CAF-induced tumour 
progression.   
The aims of this project were, therefore: 
- Using in vitro models, determine whether radiation induces migration of MSCs and 
differentiation of MSCs into CAF-like cells. 
- Determine the influence of irradiated tumour cells and/or endothelial cells on these 
processes, utilizing mouse fibrosarcoma cells (FS120 and FS188) previously shown to 
have differential effects on the composition of the TME, when propagated in vivo 
(Tozer et al., 2008)*. 
- Investigate the role of specific cytokines/chemokines previously shown to be induced 
by irradiation of tumour cells on the above processes and determine the effect of 
irradiation on expression/secretion of these factors in FS120 and FS188 cells. 
- Identify the differences between FS120 and FS188 tumour cells and solid tumours 
(i.e. in vitro and in vivo) that could potentially influence the recruitment /differentiation 
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of MSCs.  
* FS188 tumour sections showed more positive cellular staining for -SMA than FS120 
tumour sections. A proportion of these -SMA-positive cells were closely associated 
with blood vessels, suggestive of pericytes.   
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CHAPTER TWO: 
Materials and methods 
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2.1 Materials  
Reagents for cell culture Supplier 
Cells 
Balb/c Mouse Mesenchymal Stem Cells  Purchased from Cyagen 
Biosciences Cat. No. 
MUCMX-01001 
C3H/10T1/2, clone 8  Mouse Mesenchymal Stem 
Cells 
Purchased from ATCC® 
(ATCC® CCL-226TM) 
HDMEC (Human Dermal Microvascular 
Endothelial Cells) 
PromoCell® 
H5V mouse cardiac endothelial cell A kind gift from Dr 
Annuciatta Vecchi (Garlanda 
et al, 1994, PNAS, 91) 
Mouse fibrosarcoma cells These cells were developed in 
our laboratory (Tozer et al., 
2008). 
Antibodies 
PDGF Receptor β Rabbit mAb (Cat. 3169) Cell Signalling Technology® 
Monoclonal Anti- β Tubulin mAb (Cat. T4026) SIGMA-ALDRICH®  
Anti-Actin, α-Smooth Muscle mAb (A 2547) SIGMA-ALDRICH® 
GAPDH (14C10) Rabbit mAb (Cat. 2118) Cell Signalling Technology® 
Anti-Mouse Collagen Type I pAb (Cat.AB765P) Millipore® 
Anti-TGF beta antibody pAb (ab 66043) Abcam® 
Anti-Fibronectin antibody pAb (ab 2413) Abcam® 
MCP-1 Antibody pAb (Cat. 2029) Cell Signalling Technology® 
Mouse TGF-β2 Antibody mAb (Cat. MAB73461) R & D systems® 
Purified Rat Anti-Mouse CD31 (Cat. 553370) BD Pharmingen 
TM 
Anti-TGF beta 1 antibody pAb (ab 155264) Abcam® 
Anti-alpha smooth muscle actin antibody mAb (ab 
124964) 
Abcam® 
Anti-CCR2 antibody mAb (ab 203128) Abcam® 
Anti-CTGF antibody pAb (ab 6992) Abcam® 
SDF1 Antibody pAb (Cat. 3740) Cell Signalling Technology® 
Recombinant Murine JE/MCP-1 (CCL2) (Cat. 250-
10) 
Peprotech® 
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Recombinant Murine SDF-1 (CXCL12) (Cat. 250-
20A) 
Peprotech® 
Recombinant Human TGF-β2 (Cat. 100-35B) Peprotech® 
Recombinant Human TGF-β1 PeproTech® 
DuoSet® ELISA kits 
Mouse CCL2/JE/MCP-1 Antibody (Cat. AB-479-
NA) 
R & D systems® 
Normal Goat IgG Control (Cat. AB-108-C) R & D systems® 
Goat Anti-Mouse JE Capture Antibody (Cat. 
DY479-05) 
R & D systems® 
Biotinylated Goat Anti-Mouse JE Detection 
Antibody (Cat. DY479-05) 
R & D systems® 
Recombinant Mouse JE Standard (Cat. DY479-05) R & D systems® 
Wash buffer (Cat. WA126) R & D systems® 
Reagent Diluent (Cat. DY008) R & D systems® 
Streptavidin-HRP (Cat. DY479-05) R & D systems® 
Colour Reagent A & B (Cat. DY999) R & D systems® 
Coating buffer (Cat. DY479-05) R & D systems® 
Stop solution (Cat. DY994) R & D systems® 
Masson's trichrome reagents 
Weigert`s Iron Hematoxylin Set Sigma-Aldrich® 
Ponceau Xylidine Sigma-Aldrich® 
Light Green SF Yellowish Sigma-Aldrich® 
Acid Fuchsin Sigma-Aldrich® 
Phosphotungstic acid solution Sigma-Aldrich® 
Phosphomolybdic acid hydrate  Sigma-Aldrich® 
Western blotting, IHC and IF materials 
Cell Extraction Buffer (Cat.FNN0011) Invitrogen® 
Ultra Pure ProtoGel® National Diagnostics 
ProtoGel® Resolving Buffer National Diagnostics 
ProtoGel® Stacking Buffer National Diagnostics 
Ammonium persulfate  Sigma-Aldrich® 
M.O.M ™ Immunodetection kit Vector® 
Nitrocellulose membrane Hybond® ECL™  
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PVDF membrane Immobilon®-P Polyvinylidene 
difluoride membranes 
Thick blotting paper Invitrogen™  
Laemmli Sample Buffer (4X) Bio-Rad 
NuPAGE™ Sample Reducing Agent (10X) Fisher Scientific 
Centrifugal filter tube amicon Ultra-4 ultracel 3KD Millipore® 
Bovine serum albumin  Sigma-Aldrich® 
Immun-Blot® PVDF Membranes for Protein Blotting Bio-Rad 
Nitrocellulose Membranes, 0.2 µm Bio-Rad 
Dimethyl sulfoxide Sigma-Aldrich® 
Texas Red® Streptavidin (Cat. SA-5006) Vector® 
Goat Anti-Rat IgG H&L (FITC) (ab 97056) Abcam® 
Precision Plus ProteinTM Standards Bio-Rad® 
TEMED Sigma-Aldrich® 
Tween 20 Bio-Rad 
Isopropanol Fisher Scientific 
Ethanol 96% vol Fisher Scientific 
Methanol Fisher Scientific 
Triton X-100  Fisher Scientific 
Bovine serum albumin  Sigma-Aldrich® 
Glycerol  Fisher Scientific 
DAB                                       Vector Laboratories 
Avidin–biotinylated enzyme complex (ABC) Vector Laboratories 
Cell culture reagent 
Dulbecco’s Phosphate Buffered Saline BioWhittaker® 
Cell culture insert 8.0 µm Falcon® 
Multiwell 24 well Falcon® 
Cell Scraper Fisherbrand® 
DMEM BioWhittaker® 
HDMEC growth media (Endothelial cell medium 
MV Catalogue No. C-39220) 
PromoCell® 
Minimum essential medium eagle  Sigma-Aldrich® 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Cell lines 
 
All cells were cultured and subcultured using pre-warmed (37°C) growth media, PBS 
and trypsin. A biosafety cabinet was used to perform all cell culture work.  
A) C3H/10T1/2 Clone 8 (ATCC® CCL-226™) cell line 
 
C3H/10T1/2 cells subsequently referred to as C3H10 cells, are a multipotent 
mesenchymal stem cell line derived from C3H mouse embryos (Reznikof.Ca et al., 
1973), often used in research as a model of differentiation in vitro. The morphology of 
these cell lines is fibroblast-like; they are flat and polygonal with long cytoplasmic 
processes (Figure 2.1). These cells grown in the following medium: Eagle's Minimum 
Essential Medium (EMEM) that is modified to contain Earle's Balanced Salt Solution, 
non-essential amino acids and 1500 mg/L sodium bicarbonate (Sigma M5650). 500 ml 
of Sigma M5650 MEM was supplemented with 2mM L-glutamine (5 ml glutamine 
aliquot), 5 ml Penicillin/Streptomycin, 1mM sodium pyruvate (5 ml of 100 mM 
solution Sigma S8636), and 50 ml FCS (final concentration of 10%). It is important to 
trypsinise and subculture C3H10 cells before they become confluent otherwise they can 
start differentiation. 
B) OriCell TM Strain Balb/c Mouse Mesenchymal Stem Cells 
 
Subsequently referred to as Balb/c MSCs, these cells are multipotent mesenchymal 
stem cells that derived from Balb/c mouse BM. They have the ability to differentiate 
into different types of cells such as chondrocytes, osteocytes, and adipocytes (Prockop, 
1997) (Figure 2.2). Moreover, these cells have abilities to migrate to the injury-site of 
tissue like skin, heart and kidney (Li et al., 2006, Wu et al., 2003, Morigi et al., 2004) 
For regular use, Balb/c MSCs were cultured in Eagle’s Minimum Essential Medium 
(Sigma, M8042), 20% foetal bovine serum supplemented with the penicillin-
streptomycin mixture, and L-glutamine (Klopp et al., 2007). 
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Figure 2.1 Early passage C3H/10T1/2 Clone 8 in their 
media.    
They are flat and polygonal with long cytoplasmic 
processes. Also they have fibroblasts-like morphology.  
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Figure 2.2 Early passage C3H/10T1/2 Clone 8 in their 
media. 
 They are flat and polygonal with long cytoplasmic 
processes. Also they have fibroblasts-like morphology. 
Figure 2.2 Balb/c Mouse Mesenchymal Stem cells,      
BM- derived cells passage 9 
 
 
Figure 2.3 Balb/c Mouse Mesenchymal Stem cells,      
BM- derived cells passage 9 
 
 
Figure 2.4 Balb/c Mouse Mesenchymal Stem cells,      
BM- derived cells passage 9 
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C) Mouse fibrosarcoma cells 
 
Mouse fibrosarcoma (FS) cells that express single isoforms of VEGF, either VEGF 188 
or VEGF 120 were used. These cells were developed in our laboratory through 
separation of primary mouse embryo fibroblasts that express a single isoform of VEGF 
(VEGF 120, or VEGF 188) from mouse embryos. These fibroblasts were genotyped, 
immortalised, and transformed to cancer cells using retroviral transduction with Simian 
Virus 40 HRAS. The tumour cell lines (fibrosarcoma) which resulted were sustained in 
a medium made of DMEM (high glucose), L-glutamine, FCS, and the antibiotics 
puromycin, and G-418 (Tozer et al., 2008). 
In vivo, fibrosarcomas that express VEGF 188 have been shown to recruit more 
pericytes and CAFs than fibrosarcoma cells which express VEGF 120 (Tozer et al., 
2008). Moreover, Kanthou et al have shown that tumour cell expression of VEGF 188 
is linked to increasing apoptosis levels and slower proliferation rate compared with 
tumour cells expressing VEGF 120, proliferate rapidly and have increased survival 
(Kanthou et al., 2014).  
Kanthou and colleagues also showed that FS188 cells display typical mesenchymal 
features (spindle-shaped cells with extended processes and ruffles) compared to FS120 
cells, which display less mesenchymal features (a mixture of rounded-elongated cells 
with less extended processes)  (Kanthou et al., 2014). Recently, English et al. (2017) 
showed (in mouse) that tumour cells expressing VEGF 120 (FS120) metastasised to the 
lungs and produced lung colonies more than tumour cells expressing VEGF 188 
(FS188). Likewise,  these FS120 tumour cells that metastasised to the mice lungs 
showed more sensitivity to anti-VEGFA therapy than that FS188 (English et al., 2017). 
These features made these cells good models to study the indirect response of MSCs to 
radiation, as each line potentially provides a different array of growth factors affecting 
the differentiation of MSCs to CAF-like cells.  
The culture media for these cells was DMEM (high glucose), supplemented with Foetal 
calf serum (FCS) final concentration 10%, 5 ml Glutamine (stock 200 mM; final 
concentration 2mM), 3ml G-418 (stock 100 mg/ml; final concentration 600 μg/ml), and 
1 ml puromycin (stock 1mg/ml; final concentration 2 μg/ml). 
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D) H5V (mouse cardiac endothelial cells) 
 
H5V are immortalized transformed endothelial cells which were derived from hearts of 
C57BL/6 mouse and were a kind gift from Dr Annuciatta Vecchi (Garlanda et al., 1994). 
They were grown in DMEM (Dulbecco’s Modified Eagle’s Medium) with L-glutamine 
(2mM), 10 % FCS, Streptomycin (100µg/ml), and penicillin (100U/ml) (Figure 2.3). 
 
 
 
 
 
 
 
 
 
 
E) Human Dermal Microvascular Endothelial Cells (HDMEC) 
  
HDMEC are primary microvascular endothelial cells of the blood and lymphatic origin 
derived from human adult skin (PromoCell Catalogue number C-12210). They express 
vascular endothelial growth factor (VEGF), which plays an important role in 
angiogenesis, cell migration and vasculogenesis (Nor et al., 1999, Bernatchez et al., 
1999) (Figure 2.4). 
HDMEC were used up to passage 10 and were grown in their media (Endothelial cell 
medium MV Catalogue No. C-39220). The MV growth medium supplemented with 
10 %FCS-DMEM: (Dulbecco’s Modified Eagle’s Medium) supplemented with 10 % 
FCS, 2mM L-glutamine, 100 U/ml penicillin and 100 μg/ml Streptomycin. 
 
 
 
 
 
  
 
Figure 2.3 Mouse cardiac endothelial cells (H5V) 
 
Figure 2.10 Mouse cardiac endothelial cells 
(H5V)Figure 2.3 Mouse cardiac endothelial cells 
(H5V) 
 
Figure 2.11 Mouse cardiac endothelial cells 
(H5V) 
 
 
Figure 2.12 Mouse cardiac endothelial cells 
(H5V)Figure 2.3 Mouse cardiac endothelial cells 
(H5V) 
 
Figure 2.13 Mouse cardiac endothelial cells 
(H5V)Figure 2.3 Mouse cardiac endothelial cells 
(H5V) 
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Figure 2.18 Mouse cardiac endothelial cells (H5V) 
 
 
Figure 2.19 Mouse cardiac endothelial cells (H5V) 
 
 
Figure 2.20 Mouse cardiac endothelial cells (H5V) 
 
 
Figure 2.3 Mouse cardiac endothelial cells (H5V) 
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Figure 2.22 Mouse cardiac endothelial cells (H5V) 
 
 
Figure 2.23 Mouse cardiac endothelial cells (H5V) 
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2.2.1.2 Freezing cells in liquid nitrogen 
 
For additional experiments, early passage and healthy cells were frozen using liquid 
nitrogen. Before freezing cells, their media were changed the day before, in order to 
ensure that the cells would be healthy.  
First, the freezing solution (10% DMSO) was prepared by adding 1ml of DMSO to 9 
ml of the full fresh medium. Then, the freezing solution was mixed and filtered by 0.22-
μm filters, before placing on ice. The early passaged cells (75-80% confluent) were 
washed with PBS, trypsinsed and centrifuged. The pellet was suspended in a suitable 
volume of ice-cold freezing medium (106 cells/ml). Thereafter, cells were aliquoted in 
1ml aliquots and placed in pre-labelled cryovials. The vials were labelled with cell type, 
a number of passage, and date. After that, the cryovials were placed immediately into a 
freezing container (Mr Frosty™, Thermo Fisher Scientific™) which was transferred to 
-80°C freezer overnight. The cryovials were then stored in liquid nitrogen. 
 
 
 
 
 
 
 
 
Figure 2.4 Human Dermal Microvascualar 
Endothelial Cells (HDMEC) passage 5 
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Figure 2.4 Human Dermal Microvascualar 
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Human Dermal Microvascualar Endothelial Cells 
(HDMEC) passage 5 
 
Figure 2.4 Dermal Microvascu lar 
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Human Dermal Microvascualar Endothelial Cells 
(HDMEC) passage 5 
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Figure 2.4 Human Dermal Microvascualar 
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2.2.1.3 Thawing cells 
 
Cryovials were removed from liquid nitrogen and thawed quickly in a 37°C water bath. 
After complete thawing of the cells, the outside of the cryovial was disinfected using 
70% ethanol. The cells were then transferred to a T-75 flask that contains a cell-growing 
medium. The flask was incubated at 37°C in a 5% CO2 humidified incubator. To 
remove the effects of DMSO, the medium was changed with fresh, pre-warmed 
medium the next day. After the confluence of the cells reached 80-90%, they were 
trypsinised, aliquoted (1 x 106 cells/mL) and stored in liquid nitrogen (1x 106 cells/ml) 
for long-term use. 
2.2.1.4 Cell counting 
 
Cell counting is a critical step to determine the number of cells within a given volume 
of a sample. A haemocytometer was used as an accurate tool to calculate cell number. 
Trypan blue was used to colour the dead cells since live cells have intact cell membranes 
and exclude the dye. 1:1 ratio was used (one volume cell suspension to one volume 
Trypan Blue) to be loaded into the haemocytometer chamber. Subsequently, the cells 
were counted inside four outer squares plus the central striped square using a Nikon 
phase contrast microscope (Figure 2.5). 
In order to calculate the total number of cells/ml: 
Total number of viable cells counted/square X                         X 104 
 
Number of squares  
Figure 2.5 The Counting chamber 
of haeocytometer (grid The cells 
were counted in 1, 2, 3, 4 and 5 
squares. Cells touching the outer 
lines on two sides of each square 
were excluded from counting. 
(Adapted from The 
Hemocytometer, 2010). 
 
Figure 2.51 The AGO X-Ray machine 
and its chamberFigure 2.5 The 
Counting chamber of 
haeocytometer (grid The cells were 
Dilution Factor (2) 
 
Figure 2.31 The 
Counting 
chamber 
of 
haeocyto
meter 
(grid 
layout).Di
lution 
Factor (2) 
 
Figure 2.32 The 
Counting 
chamber of 
haeocyto eter 
(grid layout). 
Figure .  ounting chamber 
of haeocytometer (grid layout). 
 
Figure 2.5 The Counting chamber of 
haeocytometer (grid Figure 2.39 The 
Counting chamber of 
haeocytometer (grid layout). 
 
Figure 2.5 The Counting chamber 
of haeocytometer (grid The cells 
were counted in 1, 2, 3, 4 and 5 
squares. Cells touching the outer lines 
on two sides of each square were 
                                                                                              
 
58 
 
2.2.1.5 Sub-culturing of the cells 
 
In order to prevent overgrowth of cells, the cells were subcultured every 3 days. Cell 
flasks were maintained in the incubator with routine daily observation to evaluate the 
density of the cells. When the cells reached ~80% confluence, they were subcultured. 
For routine sub-culturing of the cells, their media were changed by discarding the old 
medium and washing the monolayer with PBS twice. In order to dislodge cells from 
the flask surface, a pre-warmed trypsin solution was added to the cells before incubating 
the cells for 3-4 minutes. Next, when the cells were dislodged completely from the flask, 
they were collected in a 5 ml tube that contained a pre-warmed full medium. The cells 
were syringed to make them a single-cell suspension before they were counted by either 
haemocytometer (see above), or by a ViCell cell counter machine (Bio-Rad TC20™ 
Automated Cell Counter). Then, cells were subcultured to a new T25 flask by adding 
25x 104 cells to 5 ml pre-warmed fresh medium and placed in the incubator. 
2.2.1.6 In vitro irradiation of the cells 
 
All cells were irradiated using an AGO 250 kV X-ray machine (Model No. CP160/1, 
Gulmay LTD) (Figure 2.6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 The AGO X-Ray machine and its 
chamber 
 
Figure 2.59 Schematic representatives of 
concentration of CM.Figure 2.6 The AGO X-Ray 
machine and its chamber 
 
Figure 2.60 Schematic representatives of 
Figure 2.6 The AGO X-Ray machine nd its chamber 
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Each sample of cells in the T25 flask was positioned at 40 cm distance from the 
radiation source. Cells were irradiated at a dose rate of 537.6 mGy per minute (200kV 
and 12.8 mA). Different radiation doses were used that ranged from 0.5 to 4 Gy (Table 
2.1).  
 
 
 
 
 
 
 
 
 
 
 
2.2.1.7 Collection and concentration of conditioned media (CM) 
 
Tumour cells (FS120 cells and FS188 cells) were plated in T75 flasks (5 x 105 /ml) and 
when they reached 80% confluence the cells were washed carefully with PBS twice 
(2X) and with pre-warmed serum-free medium three times (3X).  
Then the cells were incubated with serum-free medium for 2-3 hours in the incubator 
before irradiation. After irradiation of the cells with 0, 0.5 Gy, or 4 Gy, they were 
incubated as above. 3-4 days’ post-irradiation, the conditioned media were collected 
and cells were counted (as described above). In order to eliminate any debris or dead 
cells, the CM was centrifuged at 2000 r.p.m. for 5 minutes and the supernatant stored 
at -80 oC. The CM was normalised according to the counted cells as follow: 
lowest cell number value
cell number value
 X CM amount in μl 
 
Table 2.1 The radiation dose used by AGO X-ray machine 
Kv mA Dose (Gy) Time (minutes) 
200 12.8 0.5 0.7 
200 12.8 1 1.5 
200 12.8 4 6 
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Therefore, if we decided to use 200 μl as a total volume, the amount of CM needed will 
be 130 μl, see an example below: 
 
To concentrate the CM, 4 ml of CM sample were added to an Amicon Ultra-4 ultracel 
centrifugal filter tube (3 KD, Millipore®). The device was spun at 4000 r.p.m. for 30 
minutes. The concentrated solute (1 ml) collected in the filter was extracted and stored 
at -80 oC (Figure 2.7). 
 
 
 
 
 
 
 
 
 
Total amount Laemmli buffer (4X) Reducing agent (10X) CM amount 
200 μl 50 μl 20 μl 130 μl 
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Figure 2.7 Schematic representatives of concentration of CM. First, tumour 
cells were plated in T75 flask. When the cells reach 80 % confluence, they were 
washed with PBS (2X), and pre-warmed serum-free medium (3X). 3 hours later, 
the cells were irradiated and incubated for 4 days in serum-free medium. 
Subsequently, CM was collected and centrifuged at 2000 r.p.m. for 5 minutes and 
stored at -80 oC.  Later, 4 ml of CM sample were added to Amicon Ultra-4 ultracel 
centrifugal filter tube (3 KD). The device was spun at 4000 r.p.m. for 30 minutes. 
The concentrated solute (1 ml) collected from the filter was extracted and stored at 
-80 oC. 
 
Table 2.8 Cells number per radiation dose used for clonogenic assayFigure 2.7 
Schematic representatives of concentration of CM. First, tumour cells were 
plated in T75 flask. When the cells reach 80 % confluence, they were washed with 
PBS (2X), and pre-warmed serum-free medium (3X). 3 hours later, the cells were 
Sche atic representatives of concentration of CM. 
 
Figure 2.7 Schematic representatives of concentration of 
CMFigure 2.67 Schematic represent ives f concentration of 
CM. 
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80 % confluence, they were washed with PBS (2X), and pre-
warmed serum-free medium (3X). 3 hours later, the cells were 
irradiated and incubated for 4 days in serum-free medium. 
Subsequently, CM was collected and centrifuged at 2000 r.p.m. for 
5 minutes and stored at -80 oC.  Later, 4 ml of CM sample were 
added to Amicon Ultra-4 ultracel centrifugal filter tube (3 KD). 
The device was spun at 4000 r.p.m. for 30 minutes. The 
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2.2.2 Clonogenic assay 
 
The aim of doing this in vitro biological technique is to study the radiation effects on 
the proliferation and survival of tumour cells (fibrosarcoma), and MSCs (Balb/c & 
C3H10 cells). First, cells were plated in several T-25 flasks at a density of 250,000 cells 
per flask. When the cells became almost confluent (80%), their media were removed 
and changed with a pre-warmed medium to 37°C in a water bath. Then, the cells were 
incubated for one hour before irradiation with 0, 0.2, 0.5,1, 2 and 4 Gy. Afterwards, the 
cells were returned to the cell culture incubator until ready to start the clonogenic assay 
(about one hour). Cells were trypsinised using 1ml trypsin and re-suspended in 4 ml of 
full serum-containing medium. The cell suspension was then syringed using 21 gauge 
needles to achieve a single-cell suspension. Viable cells per ml were counted using a 
haemocytometer (as described earlier).  
Because there were differences in the smallest number of cells required to form colonies 
and to survive after irradiation between each cell line, different cell numbers were used 
for each radiation dose (Table 2.2). The cells were plated in 6-well plates, then the 
plates were left in the incubator at 37°C without moving them for 10-14 days. One 6-
well plate was used for each radiation dose per experiment (triplicate for each group). 
 
 
 
 0 Gy 0.2 Gy 0.5 Gy 1 Gy 2 Gy 4 Gy 
FS120 cells 
& FS188 
cells 
50/100  50/100 100/150 150/200 200/400 
C3H10 
MSCs 
50/100 100/150 100/150 150/200 150/200 300/400 
Balb/c 
MSCs 
50/100 100/150 100/150 150/200 150/200 300/400 
Table 2.2 Cells number per radiation dose used for clonogenic assay. 
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Table 2.2 Cells number per radiation dose used for clonogenic assay 
 
Table 2.16 Cells number per radiation dose used for clonogenic assay 
 
Table 2.17 Cells number per radiation dose used for clonogenic assay 
 
Table 2.18 Cells number per radiation dose used for clonogenic assay 
 
Table 2.2 Cells number per radiation dose used for clonogenic assay 
 
Table 2.19 Cells number per radiation dose used for clonogenic assay 
 
Table 2.20 Cells number per radiation dose used for clonogenic assay 
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It is important not to do any movement of the plates during these 10-14 days, as any 
movement may disturb colony formation through dislodging them.  
After 10-14 days, and when the colonies were formed, the plates were taken out from 
the incubator and their media were removed. The colonies were fixed in 100% iced 
cold methanol in a freezer for 15 minutes. Subsequently, the methanol was removed 
and the cells were stained with 0.25% crystal violet in 25% methanol. The stain was 
left for 10 minutes before it was washed off in tap water, and the plates were left to dry 
at room temperature to be ready for counting the next day manually (Figure 2.8). 
Lastly, all colonies (a colony is a group of approximately 50 cells or more) in all plates 
were counted manually. Plating efficiency (PE) with survival fraction (SF) was 
calculated using the following equations: 
PE =
Number of colonies formed
Number of cells seeded
 X 100 
 
                                                    SF =
PE  after irradiation
PE of control (0Gy)
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Figure 2.73 Diagram of clonogenic assay steps: 
 
Figure 2.74 Diagram of clonogenic assay steps: 
 
Figure 2.8 Diagram of clonogenic assay steFigure 2.75 Diagram of clonogenic 
assay steps: 
 
Figure 2.76 Diagram of clonogenic assay steps: 
 
Figure 2.8 Diagram of clonogenic assay steps: 
 
Figure 2.77 Diagram of clonogenic assay steps: 
 
Figure 2.78 Diagram of clonogenic assay steps: 
 
Figure 2.8 Diagram of clonogenic assay steFigure 2.79 Diagram of clonogenic 
assay steps: 
 
Figure 2.80 Diagram of clonogenic assay steps: 
 
 
 
 
 
 
 
 
Figure 2.8 Diagram of clonogenic assay ste A-The confluent cells (~80%) inside 
T-25 flasks were irradiated (except for 0 Gy as a control) with different radiation 
doses. B- After irr diation, the cells were trypsinised, and different cells number 
were seeded in each well of the 6-well plates. The plates were incubated for 10-14 
days (without movement or changing media). C- After 10-14 days, and when the 
colonies were formed, the colonies were fixed in 100% iced cold methanol in a 
freezer for 15 minutes. Subsequently, methanol was removed and the cells were 
stained with 0.25% crystal violet in 25% methanol. The stain was left for 10 
minutes then washed off in tap water, and the plates were left to dry at room 
temperature. A colony is described as 50 cells or more. 
  
 
Figure 2.93 Schematic demonstrative of cell extraction buffer preparation.Figure 2.8 
Diagram of clonogenic assay ste A-The confluent cells (~80%) inside T-25 flasks 
were irradiated (except for 0 Gy as a control) with different radiation doses. B- 
After irradiation, the cells were trypsinised, and different cells number were seeded 
in each well of the 6-well plates. The plates were incubated for 10-14 days (without 
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media). C- After 10-14 days, and when the 
colonies were formed, the colonies were fixed in 
100% iced cold methanol in a freezer for 15 
minutes. Subsequently, methanol was removed 
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2.2.3 Growth Curve assay 
 
The viability and proliferation of the cells can be determined through counting of the 
cells. In order to measure the growth rates of cells, Balb/c MSCs and C3H10 MSCs 
were plated individually at a density of 3x 104 cells/well in triplicate at 6-well plate (4 
plates were used). Three wells of each plate were treated with TGF-β1 (human TGF-β 
1, Cat. No.100-21). The viability of the cells was evaluated on a daily basis. Each day, 
one plate was rinsed twice with PBS after removal of the medium. Then, the cells were 
trypsinised, and collected in a tube, centrifuged for 5 minutes at 1000 rpm. Next, media 
from the pellet were removed and the full medium was added to the pellet, mixed well 
and cells were counted. 
2.2.4 Radiation effects on MSC differentiation  
 
2.2.4.1 Irradiation of cells 
 
Cells were plated in two wells of 6 well-plates. The cells were left in the incubator for 
3 days to become ~80% confluent. One hour before radiation, the medium was changed 
to a pre-warmed medium. After that, the plates were irradiated (as described above, 
2.2.1.5) with different radiation doses (0-4 Gy). The plates were placed in the incubator 
3-4 days’ post-irradiation.  
2.2.4.2 Collection of cell extracts and sample preparation for western blotting 
 
Protease inhibitors and working on the ice were used to minimise protein degradation. 
To extract proteins from cells, the monolayer of the cells was washed twice with ice-
cold PBS. The cold PBS was pipetted to the side of the well without detaching the cells. 
After that, tilting the plate and aspirating any traces of PBS from the corner. The cells 
in each well were lysed with an appropriate volume of ice-cold cell extraction buffer 
(Cat. No. FNN0011, Invitrogen®) that contained 10 mM Tris, 100 mM NaCl, 1 mM 
EDTA, 1 mM NaF, 20 mM NaPO, 2 mM NaVO, 1% Triton X-100, 10% glycerol, 0.1% 
SDS, 0.5% deoxycholate. I supplemented this cell extraction buffer with protease 
inhibitor and 1 mM PMSF before use. 
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The volume of lysis buffer used to lyse the cells depending on the size of the plate used 
and how dense the cells were. 250 µl was used for each well of a six-well plate. To 
prepare the lysis buffer, a complete protease inhibitor tablet (Roche) was dissolved in 
200 µl of PBS. Then, 100 µl of the dissolved complete tablet was added to 5 ml of 
lysing buffer that was inside a tube in the ice. The rest of the dissolved tablet stored at 
-20 oC to be used later.  
PMSF (Phenyl Methyl Sulfonyl Fluoride) stock was a 0.3 M solution in DMSO and is 
an irreversible inhibitor of serine proteinases. For every 5 ml of the total, 17 µl was 
added to lysing buffer tube (final concentration ~1 mM). This ice-cold cell extraction 
buffer was kept on the ice and used within 30 minutes of preparation to lyse the cells 
(Figure 2.9). The cell monolayer was scraped using a cell scraper and the lysates were 
collected in pre-cooled Eppendorf tubes. Tubes were then centrifuged for 10 minutes 
at 10,000 rpm in a micro-centrifuge after it was cooled down to 4oC. Supernatants were 
aliquoted for each sample into three Eppendorf tubes and immediately stored in -80oC 
freezer.  
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Figure 2.9 The Schematic demonstrative of cell extraction buffer preparation. First, 
5 ml lysis buffer was added to the tube on the ice (total volume of the buffer 
depends on the size of plate was used and how dense the cells were). After that, a 
Complete Mini Protease Inhibitor Tablet was dissolved in 200 µl PBS (each tablet 
is enough for 10 ml = 200 µl 10 ml), and 100 µl was taken and added to the tube. 
Finally, 17 µl from PMSF stock was added to the mixture and put on ice. 
 
Table 2.28 BCA standard preparationsFigure 2.9 The Schematic demonstrative of cell 
extraction buffer preparation. First, 5 ml lysis buffer was added to the tube on the 
ice (total volume of the buffer depends on the size of plate was used and how dense 
the cells were). After that, a Complete Mini Protease Inhibitor Tablet was dissolved 
in 200 µl PBS (each tablet is enough for 10 ml = 200 µl 10 ml), and 100 µl was 
taken and added to the tube. Finally, 17 µl from PMSF stock was added to the 
mixture and put on ice. 
 
Table 2.29 BCA standard preparations 
Fig  Schematic demonstrative of cell extraction eparation. 
 
Figure 2.9 The Schematic demonstrative of cell extraction buffer 
preparationFigure 2.101 Sc ematic demonstrative of cell extraction buffer 
preparation. 
 
Figure 2.9 The Schematic demonstrative of cell extraction buffer preparation. First, 5 
ml lysis buffer was added to the tube on the ice (total volume of the buffer depends 
on the size of plate was used and how dense the cells were). After that, a Complete 
Mini Protease Inhibitor Tablet was dissolved in 200 µl PBS (each tablet is enough 
for 10 ml = 200 µl 10 ml), and 100 µl was taken and added to the tube. Finally, 
17 µl from PMSF stock was added to the mixture and put on ice. 
 
Table 2.22 BCA standard preparationsFigure 2.9 The Schematic demonstrative 
of cell extraction buffer preparationFigure 2.102 Schematic demonstrative of 
cell extraction buffer preparation. 
 
                                                                                              
 
68 
 
2.2.4.3 Pierce Micro BCA™ Protein Assay 
 
The Thermo Scientific™ Micro BCA Protein Assay Kit (Product No. 23225) is a 
detergent-compatible bicinchoninic acid (BCA) formulation for the colourimetric 
detection and quantitation of total protein. The principle of this assay is the detection 
of cuprous ion (Cu+1) through BCA reagent to form a purple-coloured solution. Cu+1 is 
formed by reduction of cupric ion (Cu+2) by protein in an alkaline environment (Smith 
et al., 1985). This water-soluble complex exhibits a strong absorbance at 562 nm that 
is linear with increasing protein concentrations. From the provided stock solution of 
standard BSA that is 2 mg/ml, a 1:10 dilution in dH2O was done to obtain a stock of 
0.2 mg/ml (or 200 g /ml) (100 l stock plus 900 l dH2O). 
Further standards of 20, 15, 10, 7.5, 5, 2.5 and 0 g/ml were set up (Table 2.3). 
The unknown samples were prepared by diluting into 1 ml of dH2O 
 10 l sample + 990 dH2O (1:100) 
 5 l sample + 995 dH2O  (1:200)    
Further dilutions were prepared if the readings were not on the standard curve. 150 l 
of standards and diluted samples were put into wells of a 96 well plate. Triplicates of 
each were used.  150 l of working reagent, prepared following the manufacturer’s 
instructions, was added to each well and mixed. The 96 well-plates was covered with 
the lid and incubated at 37oC for 2 hours. The absorbance was measured at 562 nm 
using a spectrophotometer. Linear regression analysis was done using GraphPad Prism 
software to interpolate concentrations of protein samples from BSA standards. 
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2.2.4.4 SDS-PAGE and western blotting  
 
Western blotting, also known as immunoblotting or protein blotting, is an important 
technique in cell and molecular biology. It is used to detect the presence of a specific 
protein in a complex mixture extracted from cells. 
In order to analyse equal amounts of protein by western blotting, the samples that were 
already quantified by BCA protein assay were kept on ice and prepared in sample buffer 
as described below. So the aim is to make each sample contain the same amount of total 
protein in a similar volume and a final concentration of 1X sample buffer. The stock 
Laemmli sample buffer was 4X (Laemmli Sample buffer, Biorad, USA, catalogue 
#161-0747). The reducing agent (NuPAGE® Sample reducing agent 10X, Cat. No. 
NP0005) was added and the remaining volume was made up with dH20.  
Single-use cassettes (Invitrogen™) and Handcasting Systems (Bio-Rad) were used for 
casting gels. Each cassette takes approximately 10 ml of gel volume. For large 
molecular weight proteins (>100 kDa), a low percentage acrylamide gel (8%) with large 
pores was used. While for smaller proteins (< 20 kDa), a higher percentage gel (12%) 
was used. The reagents used are shown in (Table 2.4).  
Standard 
(g/ml) 
l of 200 g 
/ml stock 
l dH2O 
0 0 1000 
2.5 12.5 987.5 
5.0 25 975 
7.5 37.5 962.5 
10 50 950 
15 75 925 
20 100 900 
Table 2.3 BCA standard preparations 
 
Table 2.3 BCA standard preparations 
 
Table 2.3 BCA standard preparations 
 
Table 2.3 BCA standard preparations 
 
Table 2.3 BCA standard preparations 
 
Table 2.3 BCA standard preparations 
 
Table 2.3 BCA standard preparations 
 
Table 2.3 BCA standard preparations 
able 2.3  standard preparations 
 
able 2.36 BCA standard preparations 
 
Table 2.37 BCA standard preparations 
 
Table 2.38 BCA standard preparations 
 
Table 2.3 BCA standard preparations 
 
Table 2.39 BCA standard preparations 
 
Table 2.40 BCA standard preparations 
 
Table 2.41 BCA standard preparations 
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A gel cassette was placed upright on a rack and the gel solution was prepared by adding 
the ingredients in the order given in Table 2.5. The APS was added first and the 
TEMED was the last and immediately the solution was mixed gently then poured 
carefully into the cassette leaving enough space for the stack. 
The stacking gel was then prepared according to the recipe in Table 2.5 and poured. 
Immediately the comb was put in the slot to form wells and left for 30 minutes at room 
temperature to polymerize.  
 
 
 
 
 
 
ProtoGel 30% (acrylamide with bis-
acrylamide) 
National Diagnostics, Geneflow, 
UK 
10% glycerol solution Made by measuring out 10 ml of 
glycerol using a graduated cylinder 
and adding 90 ml of dH20                  
Resolving buffer 4X concentrate, National 
Diagnostics, Geneflow 
Stacking gel buffer 4X concentrate, National 
Diagnostics, Geneflow 
10% Ammonium persulphate APS SIGMA-ALDRICH® 
TEMED (Tetramethylethylenediamine) SIGMA-ALDRICH® 
Isopropanol SIGMA-ALDRICH®, UK 
Table 2.4 Reagents used for casting gels in western blotting 
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The reagents used for loading the gels were as in Table 2.6. 
 
 
 
 
Table 2.42 Different gel and ingredients concentrations used in 
experiments for a total 10 ml gel (single gel) 
Table 2.5 iff t l  i i t  i   i  
i ts f   t t l  l l (si l  l) 
 8% 10% 15% Stack 
Protogel 2.7 ml 3.3 ml 5 ml 1.3 ml 
dH2O 4.7 ml 4.1 ml 2.4 µl 6.1 ml 
10% glycerol 100 µl 100 µl 100 µl 50 µl 
Resolving buffer 2.5 ml 2.5 ml 2.5 ml  
Stacking buffer    2.5 ml 
10% APS 50 µl 50 µl 50 µl 50 µl 
TEMED 5 µl 5 µl 5 µl 10 µl 
Total volume 10 ml 10 ml 10 ml 10 ml 
Table 2.43 Reagents used for loading the gels in western blotting Table 2.6 Reagents used for loading the gels in western blotting 
Tris/Glycine/SDS 
PAGE Buffer 
10 X, National Diagnostics, Geneflow, UK 
Sample buffer 4X Laemmli Sample buffer, Biorad, USA, catalog 
#161-0747 
Reducing agent NuPAGE® Sample Reducing Agent (10X), Cat. No. 
NP0005 
Protein molecular 
weight markers 
Precision Plus Protein™ Prestained Standards 
BioRad, USA, Cat. #161-0374  
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The gel cassette was assembled in the tank and 600 ml 1X Tris-Glycine-SDS running 
buffer was added to the outer chamber (prepared from a 10X stock by diluting 1:10, ie 
100 ml buffer plus 900 ml dH2O).  20 g of protein samples were loaded into each well 
and a similar volume (30 l) of 1X Laemmli reducing sample buffer was also loaded 
in the unused wells. 6 l of Precision plus protein™ standards (Bio-Rad) was mixed 
with 24 l of 1X Laemmli LDS reducing sample buffer and this was loaded in the last 
well.  
The gel was run at 150 V (constant voltage). The running time was around 60 minutes 
until the bromophenol blue dye has reached the bottom of the gel. After running, 
proteins on the gel were transferred to a PVDF or nitrocellulose membrane using Bio-
Rad transfer machine (Trans-Blot® Turbo™ Transfer System). The transfer was done 
according to the manufacturer`s instructions.  
One time transfer buffer was prepared by adding 100 ml Tris Glycine 10X transfer 
buffer to 700 ml dH20 and 200 ml methanol to make up to 1 Litre. The flat gel placed 
in a dish containing 10-20 ml of cold 1X transfer buffer. PVDF membrane needs to be 
soaked in methanol first for 3-5 minutes. 
Electro-blotting was for 30 minutes at 150 volts. After the transfer of proteins was 
finished, the membrane placed (protein side up) in TBS containing 0.1% Tween-20 
(TBS-T) buffer. 
The membrane incubated with PBS-T or TBS-T buffer containing blocking agent, 
which was 5% dried milk and was prepared by dissolved 2.5 g dry-powdered milk in 
50 ml of TBS-T. This was used as a blocking solution and an antibody-binding buffer 
(5% milk solution).  
The membrane was blocked for one hour at room temperature on a shaker. The blocking 
agent removed and the antibody was added. The antibodies concentrations were used 
as in Table 2.7. 
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Table 2.7 Primary antibodies used in western blotting 
Primary 
antibody 
Molecular 
Weight  
Dilution Catalogue 
No. 
Secondary 
antibody 
Gel 
concentration 
Anti-
Fibronectin 
285 kDa (1:2000) in 5% 
non-fat milk in 
TBS-Tween 
(ab2413) Anti-rabbit 8% 
Anti-
Mouse 
Collagen 
Type I 
140-210 
kDa 
(1:1000) in 5% 
non-fat milk in 
TBS-Tween 
(Cat.ABP) Anti-rabbit 8% 
α-SMA 42 kDa (1:3000) in 5% 
non-fat milk in 
TBS-Tween 
(ab12496) Anti-rabbit 10% 
Anti-TGF 
beta 
antibody 
13 kDa (1:1000) in 5% 
non-fat milk in 
TBS-Tween 
(ab6604) Anti-rabbit 15% 
PDGFR-β 190 kDa (1:1000) in 5% 
non-fat milk in 
TBS-Tween 
(Cat.316) Anti-rabbit 8 % 
Monoclon
al Anti-β 
Tubulin 
55 kDa (1:2000) in 5% 
non-fat milk in 
TBS-Tween 
(Cat.T42) Anti-mouse 10 % 
MCP-1 
Antibody 
13 kDa (1:1000) in 5% 
non-fat milk in 
TBS-Tween 
(Cat.2029) Anti-rabbit 15% 
Mouse 
TGF-β2 
Antibody 
25 kDa (1:1000) in 5% 
non-fat milk in 
TBS-Tween 
(Cat.MAB7
3461) 
Anti-rat 15% 
Anti-CCR2 
antibody 
43 kDa (1:1000) in 5% 
non-fat milk in 
TBS-Tween 
(ab20312) Anti-Rabbit 15% 
Anti-CTGF 
antibody 
36 kDa (1:1000) in 5% 
non-fat milk in 
TBS-Tween 
(ab 6992) Anti-Rabbit 15% 
SDF1 
Antibody 
9 kDa (1:1000) in 5% 
non-fat milk in 
TBS-Tween 
(Cat.3740) Anti-Rabbit 15% 
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Antibody incubations were performed on a shaker at 4oC overnight. After that, the 
antibody was removed and the membrane rinsed with TBS-T buffer 4 x 5 minutes’ 
washes. The secondary HRP-coupled antibody was prepared in buffer containing the 
same blocking agent used for blocking primary antibody. DAKO HRP coupled 
antibodies was used at 1:2000 dilution and incubated for one hour at room temperature 
on the shaker.   
Then, the membrane rinsed 4 x 5 minutes. The membrane was left in the buffer to be 
used for ECL detection. The work was done in the darkroom to detect the proteins 
through chemiluminescence (ECL). The ECL reagent was left on the membrane for 
three minutes and exposed to ECL film for 1-5 minutes. The membrane was developed 
and fixed by Kodak X-ray developer and fixer reagents. The developed film then rinsed 
in water and dried. To analyse western blotting results through densitometric 
quantification, the x-ray films were scanned using a scanner (HP Scanjet 4850).  
Then, the scanned picture where uploaded to Fiji image j software where the density of 
peak area of the band was quantified. The percentage value of the target protein was 
divided by the value of the loading control to get a relative intensity. In order to re-
probe the membrane with another antibody, the membrane was stripped for 15 minutes 
on the shaker at RT with 20 ml of Pierce stripping buffer (Thermo Scientific, Cat.no. 
21059). Subsequently, the membrane was washed with TBS-T and then incubates with 
the antibody as above. 
2.2.5 Radiation effects on the migration of MSCs  
2.2.5.1 Trans-well migration assay 
 
The aim of this assay is to see whether the secreted factor(s) from irradiated tumour 
cells mediate MSCs migration. This assay is sometimes named the Boyden chamber 
assay, as Boyden originally introduced it (Boyden, 1962). In this assay, media in two 
chambers (upper and lower) are separated by a filter membrane through which cells can 
migrate.  For the migration assay, C3H10 MSCs, and Balb/c MSCs were cultured 
separately on trans-well plates (Falcon® 8.0 μm pore size), while the chemo-attractant 
was in the lower compartment.  
Thus, vertical cell migration was expected toward the attractant. Different laboratory 
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techniques and radiation doses were used (Figure 2.10). After the incubation period (8-
16 hours), the MSCs located in the upper compartment (Falcon® 8.0 μm pore size filter) 
were fixed by ice-cold methanol for 10 minutes. Then, the filters were washed with 
PBS and stained with haematoxylin staining for 20 minutes. Next, the filters were 
washed with PBS and left to dry at room temperature. The cells from the topside of the 
inserts were wiped off using a damp cotton bud. The filters were removed from the 
filter cup using a sharp razor blade and mounted on a glass slide using DPX. The cells, 
which were migrated to the bottom of the filter, were counted using the microscope 
(40X objectives). All migration experiments were done in duplicates, and cells were 
counted in 10 random views per filter at 40 X objective lens. 
- Direct irradiation: MSCs were cultured on trans-well plates and irradiated directly 
using an Ago x-ray machine (see above) with 0, 0.5 Gy, and 4 Gy. The migration of 
MSCs was calculated after fixation and staining of the migrated cells. 
- Incubation with conditioned media (neat or concentrated) from irradiated 
tumour cells: MSCs were cultured on trans-well plates. A CM obtained from irradiated 
tumour cells (FS120 cells or FS188 cells) was moved to the lower compartment. 
Migration of cells was assessed as above. 
- Co-culture of MSCs with irradiated tumour cells: Tumour cells (FS120 cells or 
FS188 cells) were plated in the lower chamber. When they became ~80% confluent, 
they were irradiated with different radiation doses. 24 hours later, MSCs were seeded 
into the insert and their migration was assessed. 
- Co-culture of MSCs with irradiated mouse endothelial cells (H5V): Mouse 
endothelial cells were seeded in the lower chamber and irradiated after they became 
confluent. After 24 hours, MSCs were seeded into the insert and their migration was 
evaluated as above. 
- Co-culture of MSCs with irradiated human endothelial cells (HDMEC): The 
method was the same as for H5V, except the incubation time was different. 
- Co-culture of MSCs with irradiated HDMEC+ FS: Both tumour cells (FS120 cells 
or FS188 cells) and human endothelial cells (HDMEC) were plated together (with 
HDMEC medium) at the lower chamber. As the tumour cells were growing faster than 
HDMEC, a 1:4 ratios were used to seed them together. Two days later, the media were 
changed to MSCs media and irradiated. 24 hours post radiation the MSCs were seeded 
into the insert and their migration was assessed as described above. 
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- Effects of TGF-β1, MCP-1, and SDF1 on the migration assay: MSCs were 
stimulated with TGF-β1, MCP-1 and SDF-1α.  
 
 
 
 
 
 
 
Figure 2.10 Schematic representatives of different C3H10 MSCs, and Balb/c 
MSCs migration assay procedures.  
A- Direct irradiation of MSCs B- Incubation of MSCs with conditioned media (neat 
and concentrated) from irradiated FS 120 cells, and FS188. C- Co-culture of MSCs 
with irradiated FS120 cells, and FS188 cells. D- Co-culture of MSCs with irradiated 
moues endothelial cells (H5V). E- Co-culture of MSCs with irradiated HDMEC. F- 
Co-culture of MSCs with irradiated FS120 cells, FS188 cells and HDMEC. The 
radiation doses used was 0, 0.5 Gy, and 4 Gy. The time under each scheme, represent 
incubation period after seeding of MSCs.  
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Figure 2.122 Preparation of ELISA standards by serial dilution.D 
 
Figure 2.123 Preparation of ELISA standards by serial dilution.D 
E 
 
E 
 
E 
 
E 
 
E 
 
E 
 
E 
 
E 
F 
 
F
i
g
u
r
e 
2
.
1
0
7 
S
c
h
e
m
a
t
i
c 
r
e
p
r
e
s
e
n
t
a
t
i
.  Sche atic representatives of different C3H10 MSCs and Balb/c 
 
Figure 2.10 Schematic representatives of different C3H10 MSCs, and Balb/c MSCs 
migration assay proceduresFigure 2.115 Schematic representatives of different 
C3H10 MSCs and Balb/c MSCs migration assay procedures. 
 
Figure 2.10 Schematic representatives of different C3H10 MSCs, and Balb/c 
MSCs migration assay procedures.  
A- Direct irradiation of MSCs B- Incubation of MSCs with conditioned media (neat 
and concentrated) from irradiated FS 120 cells, and FS188. C- Co-culture of MSCs 
with irradiated FS120 cells, and FS188 cells. D- Co-culture of MSCs with irradiated 
moues endothelial cells (H5V). E- Co-culture of MSCs with irradiated HDMEC. F- 
Co-culture of MSCs with irradiated FS120 cells, FS188 cells and HDMEC. The 
radiation doses used was 0, 0.5 Gy, and 4 Gy. The time under each scheme, represent 
incubation period after seeding of MSCs.  
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2.2.5.2 Trans-well migration assay using neutralizing antibodies to MCP-1 
 
Neutralizing antibody was used to block the activity of MCP-1 in certain experiments. 
A fresh CM extracted from irradiated tumour cells (FS120 cells or FS188 cells) was 
concentrated first (as in section 2.2.1.7). Then, the concentrated CM was tested using 
western blotting to check that the MCP-1 protein is present. Before starting the assay, 
the concentrated CM was incubated with the non-immune IgG or antibodies in 
polypropylene tubes for 2 hours on a roller at room temperature. Using a 24-well plate, 
the migration assay was performed. Therefore, 3x 104 Balb/c MSCs in 200-μl medium 
were cultured on trans-well plates (Falcon® 8.0 μm pore size) and then incubated for 
16 hours in the incubator. Fixation, staining, and counting of the migrated cells were 
done as previously explained. 
2.2.6 Measuring MCP-1 release from irradiated tumour cells via enzyme-linked 
immunosorbent assay (ELISA) 
Sandwich ELISA was done to detect and quantify mouse MCP-1 chemokine in the CM. 
The DuoSet® development system was used to detect mouse MCP-1 in the CM from 
irradiated fibrosarcoma tumours. Firstly, a 96-well plate was coated with the capture 
antibody (goat anti-mouse) that was diluted to the working concentration (Table 2.8). 
100 μl per well of the diluted capture antibody was used, and then the plate was sealed 
and incubated at room temperature overnight. 
 
Table 2.8 Working concentration and preparation of reagents for ELISA 
Reagent Amount 
per vial 
Working 
concentration 
Preparation 
Capture antibody 50 μg 200 ng/ml Reconstitute in 0.5 ml PBS 
Detection 
antibody 
3 μg 50 ng/ml Reconstitute in 1 ml Reagent diluent 
Standard 45 ng 3.91-250 pg/ml Reconstitute in 0.5 ml Reagent 
diluent 
Streptavidin-HRP N/A 40-fold Dilute in Reagent diluent 
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Next day, the wells were washed 3 times with 400 μl washing buffer after removal of 
the capture antibody and put to dry on a paper towel. Then, the wells were blocked for 
one hour with 300-μl reagent diluent at room temperature before washing with 400 μl 
washing buffer as earlier explained. 
Standards were prepared as described in (Figure 2.11), while CM samples were diluted 
1:10, 1:50, 1:100, 1:150 and 1:200 with the reagent diluent. Each sample 100 μl was 
tested in duplicate and incubated for 2 hours at room temperature followed by three 
washings with 400 μl washing buffer. 100 μl of the detection antibody (biotinylated 
goat anti-mouse JE) diluted in reagent diluent was added to each well and left for 2 
hours at room temperature prior to washing 3 times with washing buffer (as above).  
 
 
 
Figure 2.11 Preparation of ELISA standards by serial dilution. Initially, the 
recombinant mouse JE Standard was reconstituted with 0.5 mL of reagent diluent. 
According to manual instructions, a standard curve as prepared starting from 250 
pg/mL to 3.9 pg/mL. 2.77 μl of standard was added to 1 mL of diluent reagent (first 
tube), and was mixed well. Next, 500 μl was taken from the first tube and added to 
the second tube (which already contained 500 μl of reagent diluent) followed by the 
same for the next tubes. One tube was without standard, and was used as a negative 
control for the curve (only reagent diluent). 
i  2.11 Preparation of ELISA standards by serial dilution. 
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Subsequently, 100 μl of Streptavidin-HRP diluted to 40-fold with reagent diluent was 
added to the wells and incubated for 20 minutes at room temperature away from light. 
Washing with washing buffer was repeated as above and 100 μl of substrate solution 
(1:1 mixture of colour reagent A and colour reagent B) was added to each well and 
incubated for 20 minutes at room temperature (in the dark). When enough yellow colour 
was detected in each well, the reaction was stopped by adding 50 μl of stop solution to 
each well and the plate was tapped smoothly to ensure full mixing. 
Using a plate reader, the optical density of each well was determined immediately at 
450 nm with background correction at 570 nm. To remove the background, the 
absorbance at 450 nm was subtracted from the absorbance at 570 nm. GraphPad Prism 
(Linear regression test) was used to determine the concentrations of the unknown 
protein samples from the standard curve. 
2.2.7 Staining procedures for tumour sections from an in vivo experiment 
 
All tumour sections (paraffin and frozen) that were used to analyse fibrosis and CAFs 
in vivo were provided by Mr Matthew Fisher, Senior Technician, Department of 
Oncology and Metabolism. These sections were taken from an experiment done by Dr 
Debayan Mukherjee who injected the fibrosarcoma cells (FS120 cells or FS188 cells) 
subcutaneously in CD1 nude mice.  
After tumours had grown to ~100 mm3 in volume, they were irradiated in situ with 20 
Gy over 4 days (8 x 2.5 Gy fractions) starting from day 1. When they reached ~1000-
1200 mm3, they were excised, embedded in paraffin and sectioned by a microtome. Mrs 
Maggie Glover, Histology Technician, Department of Oncology and Metabolism did 
tumours sectioning and embedding in paraffin. While, Mr Matthew Fisher, Senior 
Technician prepared tumours frozen sections. 
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2.2.7.1 Immunohistochemical staining of formalin-fixed, paraffin-embedded 
fibrosarcoma tumour sections 
 
IHC is a method for demonstrating the presence and location of proteins in tissue 
sections. It analyses and identifies cell types based on the binding of antibodies to 
specific components of the cell.  Before starting with the staining protocol, the slides 
were deparaffinised and rehydrated, as incomplete removal of paraffin can lead to poor 
staining of the section.  
The IHC protocol was given to me by Mr Matthew Fisher, which I then optimised. The 
sections were dewaxed by placing the slides in a rack, and performed the following 
washes: 
 
 Xylene 2 X 10 minutes. 
 100% ethanol 2 X 5 minutes. 
 95% ethanol for 5 minutes. 
 70% ethanol for 5 minutes. 
 Distilled water for one minute. 
 Rinse slides in PBS for 2 minutes. 
 
The next step was antigen retrieval, which is important due to the formation of 
methylene bridges during fixation, which cross-links proteins and therefore masks 
antigenic sites. Heat-mediated retrieval by pressure cooker was used with target 
retrieval solution (DAKO® Target Retrieval Solution, 10X concentrate, Code No. S 
1699) which was diluted at 1:10 in dH2O.  
700 ml of dH2O were added inside the pressure cooker while the slides were put in the 
target retrieval solution. Heating with pressure cocker was for 2 hours, then, the slides 
were removed and rinsed once in PBS. Sections were circled by wax pen and left for 
10 minutes to dry at room temperature before rinsing with PBS. 
In order to block endogenous peroxidase activity, the slides were blocked with 3% 
H2O2/PBS for 20 minutes (dilution was 1:10 dilution from 30% H2O2 stock solution). 
Subsequently, the slides were rinsed with PBS and blocked with the mouse on mouse 
(M.O.M. ™) IgG for 60 minutes at room temperature (Vector®M.O.M ™ 
Immunodetection kit, Cat. No. BMK-2202) to prevent non-specific antibody binding 
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to tissue. The primary antibody (α-SMA 2 mg/ml anti-mouse, made in mouse) was 
diluted 1: 10,000 in PBS plus M.O.M. ™ diluent. The blocking solution was removed 
and the primary antibody was added on the slides and incubated at 4 oC overnight. 
Next day, the primary antibody was removed and slides were rinsed three times in PBS. 
The secondary antibody (biotinylated anti-mouse IgG reagent 1:250) was put over the 
sections and incubated for 10 minutes. The slides were rinsed twice in PBS and then 
incubated with avidin-biotin complex (ABC) for 60 minutes and washed three times 
with PBS. Incubation with DAB (3, 3'-diaminobenzidine) from 1-10 minutes 
(visualised under a microscope) was the next step.  
The slides then washed with tap water and counterstained with Mayer`s haematoxylin 
stain for 30 seconds to visualize the nuclei, and then washed in tap water for 5 minutes. 
The slides finally dehydrated with 70% ethanol for 5 minutes, 95% ethanol for 5 
minutes, 100% ethanol 2 X 5 minutes, and Xylene 2 X 5 minutes. The slides were then 
mounted with DPX (distyrene, plasticizer, and xylene) and cover slipped then left to 
dry at room temperature. 
2.2.7.2 Collagen staining (Masson’s trichrome staining) of paraffin-embedded 
fibrosarcoma tumour sections 
 
Masson’s trichrome consists of three-colour staining; dark brown-black for cell nuclei, 
orange-red for cytoplasm and green-blue for collagen. Samuel F Harding, Research 
Technician at the Diabetes, Endocrinology & Metabolism Unit, Department of 
Oncology and Metabolism, provided me with a basic protocol which I then optimised. 
Fibrosarcoma tumour sections were dewaxed in xylene for 10 minutes (X2), followed 
by ethanol 100%, 95%, 75%, and water for 2 minutes each.  Then, the slides were 
incubated for 10 minutes in Weigert’s iron haematoxylin staining, followed by one-
minute washing in tap water, and one minute blue in Scott’s tap water. The slides were 
then placed in Ponceau stain (Fucshin 2:1 0.5% Ponceau 2R in 1% Acetic acid, 0.5% 
Acid fucshin in 1% Acetic acid) for 10 minutes, followed by washing in tap water. 
Phosphomolybdic acid-phosphotungstic acid (2.5%) was used for 2 minutes and the 
slides were transferred quickly to tap water to remove the acid. After that, the sections 
were stained with 2% light green in 2% acetic acid for 4 minutes, rinsed in tap water 
(one dip only).  
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Dehydration of the samples was through ethanol 75%, 95%, and 100% (very quickly) 
followed by xylene for 5 minutes (X2). Finally, the slides were mounted using DPX. 
To prepare solutions: 
- Ponceau:Fucshin 2:1 (0.5% Ponceau 2R in 1% Acetic acid, 0.5% Acid fucshin in1% 
Acetic acid) 
 1% Acetic acid: 10 ml of glacial acetic acid was added to 1000 ml of distilled 
water. 
 2.5 g of Fuschin was weighted and added to 500 ml of 1% acetic acid. 
 2.5 g of Ponceau 2R was weighted and added to 500 ml of 1% acetic acid. 
 Fuscin and Ponceau red solutions were mixed at a ratio of 2:1 (200 ml Fuschin 
and 100 ml Ponceau). 
- 5% Phosphomolybdic acid: (5% Phosphotungstenic acid in 2% Acetic acid) 
 2% Acetic acid solution was prepared by adding 20 ml of glacial acetic acid to 
1000 ml of dH2O. 
 100 ml of the 10% Phosphomolybdic acid was mixed with 100 ml of the 10% 
Phosphotungstenic acid and then 200 ml of 2% acetic acid was added. 
- 2% light green in 2% acetic acid  
 10 g of light green powder was weighed and dissolved in 500 ml of 2% acetic 
acid. 
To analyse images from Masson’s trichrome staining: 
Two ways were used, the first method was via Aperio ImageScope software (version 
12.2), in which eight images were taken from each stained tumour section (16 tumour 
sections were used, 4 for FS120 CTR, 4 FS120 irradiated, 4 FS188 CTR and 4 FS180 
irradiated) using a 10X objective and a Nikon microscope (Nikon Optiphot-2). First, 
the image to be analysed was uploaded to the Aperio ImageScope software by clicking 
the “File” menu and selecting “Open Image”. In order to analyse the image on a 
spectrum, an algorithm was created. The parameters were adjusted (Hue value, Hue 
width, colour saturation threshold, Iwp, and Isp) of the algorithm and saved the setting 
to apply for all subsequent images. To do that, from the “View” menu “Analyse” was 
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chosen and “Select Algorithm”, another window opened with three choices. “Positive 
Pixel count V9 Parameters” was selected followed by “Run”.  
The parameters were adjusted according to what wanted to analyse (analyse the green-
blue collagen area) by clicking it in the list and selecting the parameter. These 
parameters were set as the default parameters and were used for all slides images. After 
achieving the analysis, from the ImageScope “View” menu, “Annotations” was 
selected. Next to each parameter, the number of positive pixels for the chosen colour 
for that analysed section result appeared. Results were exported to an Excel spreadsheet 
for further analysis. A schematic representation of images analysis via Aperio 
ImageScope is shown in Figure 2.12. The results from the analysis were divided into 
either positive areas (presence of collagen), or negative areas (no collagen). In the 
positive areas, there were three areas, weakly positive, positive or strongly positive. 
The positivity was calculated by summation of all the positive areas (weak positive + 
positive + strong positive) then divided by the total area (all positive areas + negative 
areas). The percentage of positivity was estimated by multiplying positivity by 100 
(Figure 2.12). 
The positivity was calculated by summation of all the positive areas (weak positive + 
positive + strong positive) then divided by the total area (all positive areas + negative 
areas). The percentage of positivity was estimated by multiplying positivity by 100 
(Figure 2.12). 
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Figure 2.12 Schematic representative of analysing Masson’s trichrome staining 
analysis of paraffin embedded fibrosarcoma tumour sections using Aperio 
ImageScope software version 12.2.  
Aperio ImageScope version 12.2 software was used for the analysis. After the image 
has been uploaded, from “View” menu “Analyse” and “Select Algorithm” were 
chosen (A & B). “Positive Pixel count V9 Parameters” was selected followed by 
Run (C). The parameters were adjusted according to what we wanted to analyse (we 
wanted to analyse the green-blue collagen area) by clicking it in the list and select 
the parameter. These parameters were used as default parameters for all other 
images later. After finishing the analysis, from ImageScope “View” menu, 
“Annotations” was selected (D). Next to each parameter, the colour for that analysed 
section result will appear (E). To save the results, “Export Grid to Excel 
Spreadsheet” was chosen. The results from the analysis were divided into either 
positive area (presence of collagen), or negative area (no collagen). Within the 
positive areas, there were three areas, weak positive, or positive, or strong positive. 
The positivity was calculated by summation of whole positive areas (weak positive 
+ positive + strong positive) then divided by the total number (all positive areas + 
negative areas). The percentage of the positivity was estimated by multiplying 
positivity by 100 (F). 
 
Figure .  i  l i  ss ’s trichro e staining 
analysis f   secti s using Aperio 
I ageScope soft are version 12.2. 
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The second method used to analyse Masson’s trichrome staining in paraffin sections 
was by scanning sections with the TissueGnostics Confocal Slide scanner (TISSUE 
FAX 200, Tissue Gnostics Vienna, Austria) (Figure 2.13) and using HistoQuest 
software analysis system V4.0. Using this more sensitive method of analysis allows us 
to analyse more tumour sections in less time. The system is a multi-colour high-
resolution slide scanner with 5 μm confocal sectioning, and up to 50 μm optical slice 
in sample thickness. Dr Maya Boudiffa, a post-doctoral research associate, Bone 
Biology Unit, Department of Oncology and Metabolism, scanned the sections using the 
Slide Scanner and provided training in data analysis using the HistoQuest software.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13 TissueGnostics Confocal Slide Scanner with the TissueFAXS 200 
autoloader. 
i re .  iss e stics f c l li e c er it  t e iss e   
t l er. 
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The high-resolution images from the scanned slides were sent to the computer-assisted 
analysis HistoQuest software system (TissueGnostics GmbH). All images were 
analysed using specific protocol in the software. 
As shown in Figure (2.14 C), for each tissue sections the total area was first measured 
followed by necrotic and non-necrotic (viable) area measurements. Each area was 
measured as mm2. The green area (collagen) was measured within the total tissue area, 
necrotic area, and non-necrotic (viable) areas. The percentage of the green areas 
(collagen) in each tissue section was calculated as follows: 
Green area (mm2)
Total tissue area (mm2)
 X 100 
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Figure 2.14 Analysis collagen content of the Masson’s trichrome stained 
paraffin sections using HistoQuest software.  
The stained slides were scanned via TissueGnostics Confocal Slide Scanner 
(TISSUEFAXS 200). Then the high-resolution images were analysed by HistoQuest 
software V 4.0. Multiple shades segmentation was applied to the images and area 
measurements were performed (A). The viable or necrotic areas within the section 
were outlined (B). The results of the analysis measured the total tissue area, and the 
green area (collagen) in mm2 (C). For each sample the whole tissue area, the necrotic 
areas and viable areas were analysed. The green area (collagen) was measured 
within the total tissue area, necrotic area, and non-necrotic (viable) areas. The % of 
the green areas (collagen) in each tissue section was calculated:     
𝐆𝐫𝐞𝐞𝐧 𝐚𝐫𝐞𝐚 (𝐦𝐦𝟐)
𝐓𝐨𝐭𝐚𝐥 𝐭𝐢𝐬𝐬𝐮𝐞 𝐚𝐫𝐞𝐚 (𝐦𝐦𝟐)
 X 100. 
 
Figure 2.14 l sis   t i  stai e  
paraffin sections using isto uest soft are. 
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2.2.7.3 Immunofluorescence staining of frozen fibrosarcoma tumour sections 
 
Tumour sections (frozen) were left to dry at room temperature for 15 minutes. Then, 
they were circled with a wax pen and allowed to dry for 10 minutes at room temperature. 
The sections were fixed in ice-cold acetone for 10 minutes before they were washed 
twice with PBS. 
Blocking was with MOM IgG (Vector®M.O.M ™ Immunodetection kit, Cat. No. BMK-
2202) for one hour at room temperature. Thereafter, incubation with the antibody (α-
SMA 2 mg/ml anti-mouse, made in mouse) was done overnight at 4°C and was diluted 
1: 10,000 in PBS plus M.O.M. ™ diluent. Next day, the slides were washed with PBS 
X3 and incubated with the secondary antibody (1:250 biotinylated anti-mouse IgG 
reagent) for 10 minutes at room temperature. The slides then were incubated with Texas 
Red® Streptavidin (diluted 1:200 in 1% BSA/PBS) for one hour at room temperature, 
after washing the slides with PBS X3. 
Blocking the slides with 10% goat serum in 1% BSA/PBS for one hour was done at 
room temperature followed by incubation with the CD31 antibody (diluted 1:200 in 1% 
BSA/PBS) overnight at 4°C. 
Washing the slides with PBS X3 was done next day, and then the slides were incubated 
for one hour with goat anti-rat IgG H&L (FITC) diluted 1:200 in 1% BSA/PBS. After 
washing the slides with PBS X3, they were mounted with Vector shield hard set with 
DAPI (4', 6-diamidino-2-phenylindole). 
 
2.3 Statistical analyses 
 
Statistical analyses were achieved using GraphPad Prism 7.0 Software. To compare 
between two groups, unpaired two-tailed t-test was used. While one-way analysis of 
variance (ANOVA) was used to see whether there are any significant differences 
(statistically) between the means of two or more independent groups. 
For clonogenic assay, the linear-quadratic model was used to analyse data. This was 
done in GraphPad Prism via changing in the Format Axis dialog.  
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CHAPTER THREE: 
The effects of radiation on the differentiation of 
MSCs into cells with CAF-like characteristics 
and its consequences on MSC 
migration/recruitment 
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3.1 Introduction & aims 
 
Radiotherapy is one of the standard effective treatments for intermediate and high-soft 
tissue sarcoma. Around 60% of patients with cancer will receive radiotherapy as a part 
of their treatment (Robbins et al., 2012). More importantly, as discussed formerly, 
radiotherapy can cause fibrosis, which is characterised by deposits of collagen and other 
matrix proteins and presence of activated fibroblasts known as CAFs, which are major 
producers of collagen in tumours (Azorin-Vega et al., 2015). CAF play a key role in 
cancer initiation, invasion and metastasis (Luo et al., 2015). The underlying cellular 
mechanisms of radiation fibrosis in tumours are not fully understood. MSCs can 
differentiate into CAF-like cells (Mishra et al., 2008), but the exact origin of CAFs in 
irradiated tumours has not been established. In normal tissues, growth factors such as 
PDGF and TGF-β1 play a key role in the differentiation of MSCs to CAFs, therefore, 
similar factors may be involved in response to radiation in a tumour. Moreover, Klopp 
et al and Fenton and Paoni showed that irradiation induced recruitment of MSCs to 
tumours (Klopp et al., 2007, Fenton and Paoni, 2007). The mechanisms that rule 
migration of MSCs into the sites of injury have not been fully explained (Karp and 
Teol, 2009). Some studies have shown that chemotaxis is a mode of recruitment for 
MSCs in response to chemoattractants like chemokines or growth factors (Vanden 
Berg-Foels, 2014). Presence of the MSCs in the tumour microenvironment will 
promote tumour angiogenesis, suppress the immune response, enhance the stemness of 
tumour cells, induce chemotherapy resistance and endorse EMT (Sun et al., 2014). 
The aims of this chapter are: 
- To determine whether radiation induces the differentiation of MSCs into cells with 
CAF-like characteristics using sarcoma cells in vitro to model the tumour 
microenvironment. 
- Use in vitro models, to investigate the role of post-radiation injury cytokines and 
chemokines in radiation-enhanced MSC recruitment to tumours.  
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3.2 Results 
3.2.1 Effects of radiation on tumour cells and MSC colony formation  
 
It has long been established that radiation causes DNA damage and cell death (Nikjoo 
et al., 2001, Warters and Hofer, 1977). In order to choose appropriate radiation doses 
for later experiments, the radio-sensitivities of tumour cells and MSCs were tested. The 
clonogenic assay was used as a cellular response technique to test the effectiveness of 
radiation on the proliferation and survival of cells. A colony means a group of at least 
50 cells.  
Cells were irradiated with different radiation doses (0-4 Gy), plus a non-irradiated 
group, which was used as a control. Next, the cells were trypsinised and counted by 
haemocytometer, before being sub-cultured into 6-well plates and incubated for 12 days. 
Table 2.2 shows cell numbers plated for each radiation dose condition. Fixation and 
staining of the cells with crystal violet was done followed by manual counting of the 
colonies. The plating efficiency (PE) with survival fraction (SF) was calculated as 
described in chapter two (section 2.2.2). 
Cell survival curves were fitted with Linear Quadratic modelling and plotted as a 
logarithm of the surviving fraction versus radiation dose in Gray (Gy) (Figure 3.1). 
The survival fraction for all cells was decreased in a dose-dependent manner. At 4 Gy, 
both Balb/c and C3H10 MSCs were more radio-resistant than fibrosarcoma cells (P = 
0.014 for Balb/c, and 0.020 for C3H10 cells, using Linear regression test). In addition, 
at 4 Gy FS120 cells were more radioresistant than FS188 cells (P = 0.0123, Linear 
regression test). The results were averages of 5 independent experiments each plated in 
triplicate (Figure 3.1). The survival fraction at 4 Gy were 40.0%, 25.6%, 3.1%, and 
0.98% for Balb/c MSCs, C3H10 MSCs, FS120 cells, and FS188 cells respectively.  
Although 4 Gy was lethal-sublethal for tumour cells and there was moderate cell killing 
for MSCs, it was chosen for subsequent experiments as the upper limit dose to mimic 
the radiation dose used in the clinic. The data presented in Figure 3.1.  
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Figure 3.1 Radiation effects on survival of FS 120 cells, FS 188 cells, C3H10 
MSCs, and Balb/c MSCs cells.   
Representative images of colonies from FS 120 cells (A), and FS 188 cells (B). 
Cells were seeded after irradiation with 0, 0.5, 1, 2 and 4 Gy (0 represent control 
un-irradiated cells). Colonies were fixed, stained and counted 12 days after 
radiation. 50 cells or more were representing a colony. The survival fraction (SF) 
was calculated and plotted for each cell line as a logarithm of the survival fraction 
versus radiation dose in Gray using Linear Quadratic model. At 4 Gy, both Balb/c 
(P = 0.014) and C3H10 MSCs (P = 0.020) were more radio-resistant than 
fibrosarcoma cells. In addition, at 4 Gy FS120 cells were more radioresistant than 
FS188 cells (P = 0.0123). The data points are the averages of 5 independent 
experiments each plated in triplicate. The dose-response curves were fitted by linear 
regression analysis, the mean ± SEM is presented *P < 0.05. The survival fraction 
for all cells was decreased in a dose-dependent manner. The survival fractions at 4 
Gy were 40.0%, 25.6%, 3.1%, and 0.98% for Balb/c MSCs, C3H10 MSCs, FS120 
cells, and FS188 cells respectively.  
 
Figure 3.2 Radiation effects on survival of FS 120 cells, FS 188 cells, C3H10 
MSCs, and Balb/c MSCs cells.   
Representative images of colonies from FS 120 cells (A), and FS 188 cells (B). 
Cells were seeded after irradiation with 0, 0.5, 1, 2 and 4 Gy (0 represent control 
un-irradiated cells). Colonies were fixed, stained and counted 12 days after 
radiation. 50 cells or more were representing a colony. The survival fraction (SF) 
was calculated and plotted for each cell line as a logarithm of the survival fraction 
versus radiation dose in Gray (Gy). At 4 Gy, both Balb/c (P = 0.014) and C3H10 
MSCs (P = 0.020) were more radio-resistant than fibrosarcoma cells. In addition, at 
4 Gy FS120 cells were more radioresistant than FS188 cells (P = 0.0123). The data 
points are the averages of 5 independent experiments each plated in triplicate. The 
Figure .  i ti  effects  s rvival of FS 120 cells, S 188 cells, 10 
S s,  l /c S s cells. 
 
Figure 3.5 Radiation effects on survival of FS 120 cells, FS 188 cells, C3H10 MSCs, 
and Balb/c MSCs cells.   
Representative images of colonies from FS 120 cells (A), and FS 188 cells (B). 
Cells were seeded after irradiation with 0, 0.5, 1, 2 and 4 Gy (0 represent control 
un-irradiated cells). Colonies were fixed, stained and counted 12 days after 
radiation. 50 cells or more were representing a colony. The survival fraction 
(SF) was calculated and plotted for each cell line as a logarithm of the survival 
fraction versus radiation dose in Gray (Gy). At 4 Gy, both Balb/c (P = 0.014) 
and C3H10 MSCs (P = 0.020) were more radio-resistant than fibrosarcoma 
cells. In addition, at 4 Gy FS120 cells were more radioresistant than FS188 cells 
(P = 0.0123). The data points are the averages of 5 independent experiments 
each plated in triplicate. The dose-response curves were fitted by linear 
regression analysis, the mean ± SEM is presented *P < 0.05. The survival 
fraction for all cells was decreased in a dose-dependent manner. The survival 
fractions at 4 Gy were 40.0%, 25.6%, 3.1%, and 0.98% for Balb/c MSCs, 
C3H10 MSCs, FS120 cells, and FS188 cells respectively.Figure 3.2 Radiation 
effects on survival of FS 120 cells, FS 188 cells, C3H10 MSCs, and Balb/c MSCs 
cells. 
 
Figure 3.6 Radiation effects on survival of FS 120 cells, FS 188 cells, C3H10 MSCs, 
and Balb/c MSCs cells.   
Representative images of colonies from FS 120 cells (A), and FS 188 cells (B). Cells 
were seeded after irradiation with 0, 0.5, 1, 2 and 4 Gy (0 represent control un-
irradiated cells). Colonies were fixed, stained and counted 12 days after radiation. 50 
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3.2.2 Effects of TGF-β1 on the growth, morphology and differentiation of MSCs 
 
TGF-β1, a pro-fibrotic cytokine, plays a key role in post-radiation injury (Martin et al., 
2000) and in the growth of MSCs (Ng et al., 2008). It has been shown that TGF-β1 
induced morphological changes in MSCs into cells with a CAF-like morphology and 
leads to an increase in collagen and fibronectin production (Desai et al., 2014). First, to 
establish whether TGF-β1 is playing a role in the growth of C3H10 and Balb/c MSCs, 
in vitro growth curve assays were done. MSCs were cultured in triplicate in the 
presence of TGF-β1 (10 ng/ml) and left for 24 hours in the incubator to allow cells to 
adhere to the plate. Untreated cells acted as controls. 
Counting cells was done on a daily basis (days 1, 2, 3 and 4) as explained in section 
2.2.3. The results show that there was no significant effect of TGF-β on the growth of 
either C3H10 or Balb/c MSCs (Figure 3.2). However, altered cell morphology 
displaying elongated spindle-shaped and compacted cells in contrast to control cells 
that were flat, polygonal, and less spindle-shaped was observed. These results 
suggested that TGF-β induced differentiation of both MSCs into CAF-like cells (Figure 
3.2 A-D). These morphological changes were associated with changes in the expression 
of α-SMA (see later in this chapter), which support that MSCs differentiated into CAF-
like cells in the presence of TGF-β1. Presence of CAF cells in the TME is strongly 
associated with excessive ECM deposition and later fibrosis (De Wever et al., 2008).  
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Figure 3.5 Effects of TGF-β on the growth and morphology of Balb/c and C3H10 MSCs.           
Growth curve for Balb/c MSCs                                      Growth curve for C3H10 MSCs  
 
Figure 3.6 Effects of TGF-β on the growth and morphology of Balb/c and C3H10 
MSCs.  
 
Figure 3.7 Effects of TGF-β on the growth and morphology of Balb/c and C3H10 MSCs.           
Growth curve for Balb/c MSCs                                      Growth curve for C3H10 MSCs  
 
Figure 3.8 Effects of TGF-β on the growth and morphology of Balb/c and C3H10 MSCs.           
Growth curve for Balb/c MSCs                                      Growth curve for C3H10 MSCs  
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Figure 3.2 Effects of TGF-β on the growth and morphology of Balb/c and 
C3H10 MSCs.  
MSCs were plated in 6-well-plates, and either treated with TGF-β (10 ng/ml), or 
control cells (no TGF-β). MSCs grown under normal conditions without TGF-β 
displayed a flattened fibroblastic morphology (A & C), while MSCs grown in the 
presence of TGF-β displayed distinct spindle morphology (B & D). (E) Starting at 
24 hours after plating, and then at daily intervals (for total of 4 days) cells were 
trypsinised and counted. The result revealed that TGF-β had no effects on the 
growth of Balb/c or C3H10 MSCs. Results are expressed as mean cell counts ± 
SEM of three individual experiments (each done in triplicate). N0= the number of 
the cells that were seeded (3 x 104 cells/well). N= number of the cells counted on a 
daily basis whether controls or after treatment with TGF-β.  
 
 
Figure 3.2 Effects of TGF-β on the growth and morphology of Balb/c and 
C3H10 MSCs.  
MSCs were plated in 6-well-plates, and either treated with TGF-β (10 ng/ml), or 
control cells (no TGF-β). MSCs grown under normal conditions without TGF-β 
displayed a flattened fibroblastic morphology (A & C), while MSCs grown in the 
presence of TGF-β displayed distinct spindle morphology (B & D). (E) Starting at 
24 hours after plating, and then at daily intervals (for total of 4 days) cells were 
trypsinised and counted. The result revealed that TGF-β had no effects on the 
growth of Balb/c or C3H10 MSCs. Results are expressed as mean cell counts ± 
SEM of three individual experiments (each done in triplicate). N0= the number of 
the cells that were seeded (3 x 104 cells/well). N= number of the cells counted on a 
daily basis whether controls or after treatment with TGF-β.  
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Figure 3.9 Effects of TGF-β on the growth and morphology of Balb/c and 
C3H10 MSCs.  
 
Figure 3.10 Effects of TGF-β on the growth and morphology of Balb/c and 
C3H10 MSCs.  
 
Figure 3.11 Effects of TGF-β on the growth and morphology of Balb/c and 
C3H10 MSCs.  
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3.2.3 Radiation effects on C3H10 and Balb/c MSC morphology and expression of 
CAF-like cells differentiation markers  
 
MSCs can differentiate into activated fibroblasts or CAFs (as discussed earlier) 
(Sugimoto et al., 2006, Mishra et al., 2008). CAFs are large spindle-shaped cells, which 
express -SMA and, PDGFR-β (Sugimoto et al., 2006, Anderberg et al., 2009). 
Moreover, CAFs secrete collagen, fibronectin and other ECM proteins which 
contribute to tissue fibrosis (Miles and Sikes, 2014). With respect to radiation effects 
on the MSCs’ differentiation ability, western blotting was done on the cell lysates that 
were extracted from both C3H10, and Balb/c MSCs. As shown in section 3.2.2, TGF-
β1 altered the morphology of both MSCs into CAF-like cells. These changes suggested 
that TGF-β1 induced differentiation of both MSCs into CAF-like cells. So, TGF-β1 
was used as a positive control of MSCs differentiation in subsequent experiments. 
3.2.3.1 Effects of direct irradiation on the expression of CAF markers by mouse 
MSCs 
 
Both C3H10 MSCs and Balb/c MSCs were seeded in 6-well plates individually until 
they became ~80% confluent. Then, they were X-ray irradiated directly with 0-4 Gy 
(section 2.2.1.6). One well was treated with 10 ng/ml TGF-β1 alone without radiation 
used as a positive control for differentiation. Another well was left un-irradiated as a 
control. A further well was irradiated with 4 Gy and also treated with TGF-β1 (10 
ng/ml). Plates were incubated for 3 days before extraction of proteins using cell 
extraction buffer (section 2.2.4.2). 20 μg (30 μl/lane) of proteins was loaded in the 
western blotting. Normalisation was done through calculating the ratio of target protein 
to internal control (i.e., dividing or “normalizing” by the loading control).  
As seen in Figure 3.3, only TGF-β1 had a significant effect in the expression of 
collagen-I, fibronectin, PDGFR-β and -SMA in C3H10 MSCs. However, in Balb/c 
cells 0.5 Gy also increased the expression of collagen-I (one-way ANOVA, Dunnett’s 
multiple comparisons test, P = 0.037) (Figure 3.4). Some of the markers showed a 
tendency to increase after low doses of radiation and decrease after high dose radiation 
(2-4 Gy), although these effects were not significant. 
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  Direct irradiation of C3H10 MSCs 
 
Figure 3.12 Effects of direct radiation on the 
expression of CAF markers by C3H10 
MSCs.Direct irradiation of C3H10 MSCs 
 
Figure 3.13 Effects of direct radiation on 
the expression of CAF markers by 
C3H10 MSCs.  
 
Figure 3.14 Effects of direct radiation on the 
expression of CAF markers by C3H10 
MSCs.Direct irradiation of C3H10 MSCs 
 
Figure 3.15 Effects of direct radiation on the 
expression of CAF markers by C3H10 
MSCs.Direct irradiation of C3H10 MSCs 
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Figure 3.3 Effects of direct radiation on the expression of CAF markers by 
C3H10 MSCs.  
Cells were irradiated and/or treated with TGF-β (10 ng/ml). Protein extracts were 
prepared three days’ post-irradiation and analysed for expression of various markers 
expressed by CAFs (collagen-I, fibronectin, PDGFR-β and α-SMA). 20 μg (30 
μl/lane) of proteins were loaded. Radiation had no effect on the expression of all 
markers tested although collagen-I, fibronectin and PDGFR-β tended to increase 
after low radiation doses (0.2, and 0.5 Gy) (A, B, C, and D). There was also a 
tendency of the expression markers to decrease after higher radiation doses (1, 2, 
and 4 Gy). TGF-β1 caused a significant increase in the expression of collagen-I, 
fibronectin, PDGFR-β and α-SMA in un-irradiated cells, with similar effects when 
administered in combination with radiation (A, B, C, and D). One-way ANOVA test 
followed by a Dunnett's multiple comparisons test was used to analyse data. Results 
expressed as means ± SEM and were considered statistically significant when P ≤ 
0.05 (* P<0.05, ** P<0.01). Each graph represents 4 independent experiments 
(N=4). 
 
 
  
 
Figure 3.3 Effects of direct radiation on the expression of CAF markers by 
C3H10 MSCs.  
Cells were irradiated and/or treated with TGF-β (10 ng/ml). Protein extracts were 
prepared three days’ post-irradiation and analysed for expression of various markers 
expressed by CAFs (collagen-I, fibronectin, PDGFR-β and α-SMA). 20 μg (30 
μl/lane) of proteins were loaded. Radiation had no effect on the expression of all 
 
Figure 3.16 Effects of direct radiation on the expression of CAF markers by 
C3H10 MSCs.  
 
Figure 3.17 Effects of direct radiation on the expression of CAF markers by 
C3H10 MSCs.  
 
Figure 3.18 Effects of direct radiation on the expression of CAF markers by 
C3H10 MSCs.  
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Direct irradiation of Balb/c MSCs 
 
Figure 3.19 Effects of direct 
radiation on the expression CAF 
markers by Balb/c MSCs.Direct 
irradiation of Balb/c MSCs 
 
Figure 3.20 Effects of direct 
radiation on the expression CAF 
markers by Balb/c MSCs. 
 
Figure 3.21 Effects of direct 
radiation on the expression CAF 
markers by Balb/c MSCs.Direct 
irradiation of Balb/c MSCs 
 
Figure 3.22 Effects of direct 
radiation on the expression CAF 
markers by Balb/c MSCs.Direct 
irradiation of Balb/c MSCs 
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Figure 3.4 Effects of direct radiation on the expression CAF markers by Balb/c 
MSCs. 
Cells were irradiated and/or treated with TGF-β (10 ng/ml). Protein extracts were 
prepared three days post-irradiation and analysed for expression of various markers 
expressed by CAFs (collagen-I, fibronectin, PDGFR-β and α-SMA). 20 μg (30 
μl/lane) of proteins were loaded. Low radiation dose (0.5 Gy) caused a significant 
increase in the collagen-I expression significantly 3-4 days after radiation (A). 
Collagen-I, fibronectin, PDGFR-β and α-SMA were also increased significantly 
after treatment of the MSCs with TGF-β (A, B, C, and D). 4 Gy tended to decreased 
the expression of differentiation markers, while TGF-β1 caused a significant 
increase in the expression of collagen-I, fibronectin, PDGFR-β and α-SMA in un-
irradiated cells, with similar effects when administered in combination with 
radiation (A, B, C, and D). One-way ANOVA test followed by a Dunnett's multiple 
comparisons test was used to analyse data. Results expressed as means ± SEM and 
were considered statistically significant when P ≤ 0.05 (* P<0.05, ** P<0.01). Each 
graph represents four independent experiments (N=4). 
 
 
 
  
 
Figure 3.4 Effects of direct radiation on the expression CAF markers by Balb/c 
MSCs. 
Cells were irradiated and/or treated with TGF-β (10 ng/ml). Protein extracts were 
prepared three days post-irradiation and analysed for expression of various markers 
 
Figure 3.23 Effects of direct radiation on the expression CAF markers by Balb/c 
MSCs. 
 
Figure 3.24 Effects of direct radiation on the expression CAF markers by Balb/c 
MSCs. 
 
Figure 3.25 Effects of direct radiation on the expression CAF markers by Balb/c 
MSCs. 
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3.2.3.2 Effects of irradiated tumour cells on the expression of CAF markers by 
mouse MSC  
 
In the previous experiments, the direct irradiation of the MSCs caused only very modest 
effect on the expression of CAF markers. For a further understanding of the 
development of the radiation fibrosis within a tumour, it is essential to understand the 
interaction of individual components of the TME with the MSCs, as the development 
and progression of the tumours are determined by the interaction between the cells 
within the TME (Bissell and Hines, 2011). The aim of this experiment was to see 
whether irradiated tumour cells (FS120 cells & FS188 cells) secreted growth factors or 
cytokines that could affect both C3H10 and Balb/c MSCs differentiation marker 
expression. Therefore, FS188 cells, as well as FS120 cells, were cultured in 24-well 
plates and when they became 80% confluent, their media were changed and then 
irradiated with 0, 0.5 and 4 Gy.  
24 hours later, C3H10 MSCs and Balb/c MSCs were seeded separately (3 x 104 in 200 
μl medium) in filter inserts (Falcon® 1.0 μm pore size) and were co-cultured with the 
tumour cells for 3-4 days before cell lysates were prepared. 20 μg of sample protein (30 
μl/lane) was loaded for each lane of the gel in the western blotting. Normalisation done 
by calculating the ratio of target protein to internal control. 
As can be seen from Figure 3.5, the irradiated tumour cells had no significant effects 
on the expression of the various differentiation markers in C3H10 cells (Figure 3.5). 
However, when Balb/c MSCs were co-cultured with irradiated FS188 cells (0.5 Gy), 
there were significant increase in the expression of collagen-I, PDGFR-β and α-SMA 
(but not fibronectin) (Figure 3.6) (One-way ANOVA, Tukey’s multiple comparisons 
test, P = 0.021, 0.036, and 0.022 respectively). Additionally, irradiation of FS188 by 4 
Gy caused an increase in the expression of collagen-I (P = 0.016) and PDGFR-β (P = 
0.026) in co-cultured Balb/c MSCs. On the other hand, co-culture with FS120 cells did 
not cause a significant increase in Balb/c MSC differentiation markers, although there 
was a tendency towards such an increase (Figure 3.6).  
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C3H10 MSCs + tumour cells  
 
Figure 3.26 Effects of 
irradiated tumour cells (FS120 
cells, and FS 188 cells) on the 
expression of CAF markers by 
C3H10 MSCs.C3H10 MSCs + 
tumour cells  
 
Figure 3.27 Effects of 
irradiated tumour cells 
(FS120 cells, and FS 188 
cells) on the expression of 
CAF markers by C3H10 
MSCs. 
 
Figure 3.28 Effects of 
irradiated tumour cells (FS120 
cells, and FS 188 cells) on the 
expression of CAF markers by 
C3H10 MSCs.C3H10 MSCs + 
tumour cells  
 
Figure 3.29 Effects of 
irradiated tumour cells (FS120 
cells, and FS 188 cells) on the 
expression of CAF markers by 
C3H10 MSCs.C3H10 MSCs + 
tumour cells  
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Figure 3.5 Effects of irradiated tumour cells (FS120 cells, and FS 188 cells) on 
the expression of CAF markers by C3H10 MSCs.  
Tumour cells were cultured in 24-well plates and when they became 80% confluent, 
their media were changed and then irradiated with 0, 0.5, and 4 Gy. 24 hours later, 
the C3H10 MSCs were seeded (3 x 104 in 200 μl medium) in filter inserts (Falcon® 
1.0 μm pore size) and were co-cultured with the tumour cells for 4 days before 
extraction of their cell lysates. 20 μg of sample protein (30 μl/lane) was loaded for 
each lane of the gel. Normalisation was done by calculating the ratio of target 
protein to internal control. Presence of irradiated tumour cells (FS120 cells, and 
FS188 cells) with the C3H10 MSCs did not cause any changes in the MSCs 
differentiation markers. One-way ANOVA test followed by a Tukey's multiple 
comparisons test was used to analyse data. Results expressed as means ± SEM. Each 
graph represents three independent experiments (N=3). 
 
 
 
Figure 3.5 Effects of irradiated tumour cells (FS120 cells, and FS 188 cells) on 
the expression of CAF markers by C3H10 MSCs.  
Tumour cells were cultured in 24-well plates and when they became 80% confluent, 
their media were changed and then irradiated with 0, 0.5, and 4 Gy. 24 hours later, 
the C3H10 MSCs were seeded (3 x 104 in 200 μl medium) in filter inserts (Falcon® 
1.0 μm pore size) and were co-cultured with the tumour cells for 4 days before 
extraction of their cell lysates. 20 μg of sample protein (30 μl/lane) was loaded for 
each lane of the gel. Presence of irradiated tumour cells (FS120 cells, and FS188 
i  .    i i   ll   ll ,    ll   
 i       .
 
Figure 3.30 Effects of irradiated tumour cells (FS120 cells, and FS 188 cells) on 
the expression of CAF markers by C3H10 MSCs. 
 
Figure 3.31 Eff cts of irradiated tumour cells (FS120 cells, and FS 188 cells) on
the xpression of CAF mark rs by C3H10 MSCs. 
 
Figure 3.32 Effects of irradiated tumour cells (FS120 cells, and FS 188 cells) on 
the expression of CAF markers by C3H10 MSCs. 
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Balb/c MSCs + tumour cells  
 
Figure 3.33 Effects of irradiated 
tumour cells (FS120 cells, and 
FS 188 cells) on the expression 
of CAF markers by Balb/c 
MSCs.Balb/c MSCs + tumour 
cells  
 
Figure 3.34 Effects of 
irradiated tumour cells 
(FS120 cells, and FS 188 cells) 
on the expression of CAF 
markers by Balb/c MSCs. 
 
Figure 3.35 Effects of irradiated 
tumour cells (FS120 cells, and 
FS 188 cells) on the expression 
of CAF markers by Balb/c 
MSCs.Balb/c MSCs + tumour 
cells  
 
Figure 3.36 Effects of irradiated 
tumour cells (FS120 cells, and 
FS 188 cells) on the expression 
of CAF markers by Balb/c 
MSCs.Balb/c MSCs + tumour 
cells  
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Figure 3.6 Effects of irradiated tumour cells (FS120 cells, and FS 188 cells) on 
the expression of CAF markers by Balb/c MSCs.  
Tumour cells were cultured in 24-well plates and when they became 80% confluent, 
their media were changed and then irradiated with 0, 0.5, and 4 Gy. 24 hours later, 
the MSCs were seeded (3 x 104 in 200-μl medium) in filter inserts (Falcon® 1.0 μm 
pore size) and were co-cultured with the tumour cells for 4 days before extraction 
of their cell lysates. 20 μg of sample protein (30 μl/lane) was loaded for each lane 
of the gel. Normalisation was done through calculating the ratio of target protein to 
internal control (tubulin). From the results, the presence of irradiated FS188 cells 
significantly increased the expression of collagen-I, and PDGFR-β after 0.5 Gy, and 
4 Gy (A and C), and α-SMA after 0.5 Gy (D), while it has no effects on fibronectin 
expression (B). There were no significant effects of FS120 cells on MSCs 
differentiation markers. One-way ANOVA test followed by a Tukey's multiple 
comparisons test was used to analyse data. Results expressed as means ± SEM, and 
were considered statistically significant when P ≤ 0.05 (* P<0.05, ** P<0.01). All 
experiments were accomplished in triplicate and repeated three times and analysed 
using GraphPad Prism 7.0 software. 
 
 
Figure 3.6 Effects of irradiated tumour cells (FS120 cells, and FS 188 cells) on 
the expression of CAF markers by Balb/c MSCs.  
Tumour cells were cultured in 24-well plates and when they became 80% confluent, 
their media were changed and then irradiated with 0, 0.5, and 4 Gy. 24 hours later, 
the MSCs were seeded (3 x 104 in 200 μl medium) in filter inserts (Falcon® 1.0 μm 
pore size) and were co-cultured with the tumour cells for 4 days before extraction 
of their cell lysates. 20 μg of sample protein (30 μl/lane) was loaded for each lane 
of the gel. From the results, the presence of irradiated FS188 cells significantly 
increased the expression of collagen-I, and PDGFR-β after 0.5 Gy, and 4 Gy (A and 
C), and α-SMA after 0.5 Gy (D), while it has no effects on fibronectin expression 
Figure 3.6 ffects f i i    cells) on 
the expression of F arkers by Balb/c S s. 
 
Figure 3.37 Effects of irradiated tumour cells (FS120 cells, and FS 188 cells) on 
the expression of CAF markers by Balb/c MSCs. 
 
Figure 3.38 Effects of irradiated tum r cells (FS120 c lls, and FS 188 cells) on 
the expression of CAF markers by Balb/c MSCs. 
 
Figure 3.39 Effects of irradiated tumour cells (FS120 cells, and FS 188 cells) on 
the expression of CAF markers by Balb/c MSCs. 
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3.2.3.3 Effects of secreted factor(s) produced by irradiated tumour cells on the 
expression of CAF markers by MSCs 
 
In the previous experiment (section 3.2.3.2), the presence of irradiated FS cells 
(especially FS188 cells) was shown to cause an increase in the expression of Balb/c 
MSCs differentiation markers, which implies that secreted factors produced by 
irradiated tumour cells might be responsible. It was important to confirm that, by testing 
conditioned media (both neat and concentrated) from irradiated tumour cells. In the 
light of that, serum-free conditioned media were collected from control and irradiated 
FS cells and concentrated using Amicon Ultra-4 centrifugal filters as described in 
section 2.2.1.7. In the lower chamber of the 24-well plate, either neat or concentrated 
CM was placed, and in the upper chamber filters C3H10 MSCs or Balb/c MSCs (3 x 
104 / 200 μl medium) were seeded in their corresponding media. Incubation was for 3 
days before extraction of the cell lysate. 20 μg of sample protein (30 μl/lane) was loaded 
for each lane of the gel in the western blot. Normalisation was done through calculating 
the ratio of target protein to internal control (tubulin). 
As the neat medium had no effect of the expressions of CAF markers by MSCs, I 
focused on the concentrated CM data. Data from three experiments is shown in Figure 
3.7 and 3.8. There was no effect of the CM (neat or concentrated) extracted from 
irradiated tumour cells on the C3H10 expression markers (Figure 3.7). Concentrated 
CM from irradiated FS120 and FS188 cells had no significant effect on -SMA 
expression in Balb/c MSCs, However, concentrated CM from irradiated (0.5 and 4 Gy) 
FS188 cells, caused a significant increase in the expression of collagen-I (P = 0.0014, 
and 0.0067) and fibronectin (P = 0.038, and 0.031). A similar increase in the expression 
of collagen-I (P = 0.047) and PDGFR-β (P =0.033) was observed using concentrated 
CM from irradiated FS120 cell with 4 Gy (Figure 3.8 A and C). In this experiment, I 
missed to use a non-irradiated medium alone to see whether presence of tumour cells 
was the cause of the increase in the CAFs expression markers expressed by MSCs.   
This work will be done in the future.  
One-way ANOVA followed by Tukey’s multiple comparisons test was used.  
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 C3H10 MSCs + concentrated CM from irradiated tumour cells 
 
Figure 3.40 Effects of factors (s) produced from irradiated tumour 
cells on the expression of CAF markers by C3H10 MSCs.C3H10 
MSCs + concentrated CM from irradiated tumour cells 
 
Figure 3.41 Effects of factors (s) produced from irradiated 
tumour cells on the expression of CAF markers by C3H10 MSCs.  
 
 
Figure 3.42 Effects of factors (s) produced from irradiated tumour 
cells on the expression of CAF markers by C3H10 MSCs.C3H10 
MSCs + concentrated CM from irradiated tumour cells 
 
Figure 3.43 Effects of factors (s) produced from irradiated tumour 
cells on the expression of CAF markers by C3H10 MSCs.C3H10 
MSCs + concentrated CM from irradiated tumour cells 
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Figure 3.7 Effects of factors (s) produced from irradiated tumour cells on the 
expression of CAF markers by C3H10 MSCs.  
C3H10 MSCs were exposed to concentrated CM from irradiated FS120 cells and 
FS188 cells for 3 days. Normalisation was done through calculating the ratio of 
target protein to internal control (i.e., dividing or “normalizing” by the loading 
control). No effects of the concentrated CM extracted from irradiated tumour cells 
were seen on the expression of collagen-I, PDGFR-β, fibronectin or α-SMA. One-
way ANOVA test followed by a Tukey's multiple comparisons test was used to 
analyse data. Results expressed as means ± SEM of 3 experiments, each done in 
triplicate and were considered statistically significant when P ≤ 0.05. 
 
Figure 3.7 Effects of factors (s) produced from irradiated tumour cells on the 
expression of CAF markers by C3H10 MSCs.  
C3H10 MSCs were exposed to concentrated CM from irradiated FS120 cells and 
FS188 cells for 3 days. No effects of the concentrated CM extracted from irradiated 
tumour cells were seen on the expression of collagen-I, PDGFR-β, fibronectin or α-
SMA. One-way ANOVA test followed by a Tukey's multiple comparisons test was 
used to analyse data. Results expressed as means ± SEM of 3 experiments, each 
done in triplicate and were considered statistically significant when P ≤ 0.05. 
 
Figure 3.7 Effects of factors (s) produced from irradiated tumour cells on the 
expression of CAF markers by C3H10 MSCs.  
C3H10 MSCs were exposed to concentrated CM from irradiated FS120 cells and 
Figure 3.7 ff ts  ll   the 
expression of F arkers by 3 10 S s. 
 
 
Figure 3.44 Effects f factors (s) pro uced from irradiated tumour cells on the 
exp ession of CAF markers by C3H10 MSCs.  
 
 
Figure 3.45 Effects of factors (s) produced from irradiated tumour cells on the 
expression of CAF markers by C3H10 MSCs.  
 
 
Figure 3.46 Effects of factors (s) produced from irradiated tumour cells on the 
expression of CAF markers by C3H10 MSCs.  
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Balb/c MSCs + concentrated CM from irradiated tumour cells 
 
Figure 3.47 Effects of factors (s) produced from irradiated tumour 
cells on expression of CAF markers by Balb/c MSCs.Balb/c MSCs + 
concentrated CM from irradiated tumour cells 
 
Figure 3.48 Effects of factors (s) produced from irradiated 
tumour cells on expression of CAF markers by Balb/c MSCs. 
 
Figure 3.49 Effects of factors (s) produced from irradiated tumour 
cells on expression of CAF markers by Balb/c MSCs.Balb/c MSCs + 
concentrated CM from irradiated tumour cells 
 
Figure 3.50 Effects of factors (s) produced from irradiated tumour 
cells on expression of CAF markers by Balb/c MSCs.Balb/c MSCs + 
concentrated CM from irradiated tumour cells 
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Figure 3.8 Effects of factors (s) produced from irradiated tumour cells on 
expression of CAF markers by Balb/c MSCs.  
Balb/c MSCs were incubated with concentrated CM extracted from irradiated 
FS120 cells, and FS188 cells for 3 days. The results showed an increase in the 
expression of collagen-I, and fibronectin in cells treated with concentrated CM from 
0.5 Gy and 4 Gy- treated FS188 cells. Likewise, a significant increase in collagen-I 
and PDGFR-β for MSCs treated with concentrated CM from irradiated FS120 cells 
with 4 Gy. One-way ANOVA test followed by a Tukey's multiple comparisons test 
was used to analyse data. Results expressed as means ± SEM of 3 experiments, each 
done in triplicate and were considered statistically significant when P ≤ 0.05 (* 
P<0.05, ** P<0.01). 
 
Figure 3.54 Effects of irradiated HDMEC on the expression of CAF markers 
by Balb/c MSCs.Figure 3.8 Effects of factors (s) produced from irradiated 
tumour cells on expression of CAF markers by Balb/c MSCs.  
Balb/c MSCs were incubated with concentrated CM extracted from irradiated 
FS120 cells, and FS188 cells for 3 days. The results showed an increase in the 
expression of collagen-I, and fibronectin in cells treated with concentrated CM from 
0.5 Gy and 4 Gy- treated FS188 cells. Likewise, a significant increase in collagen-I 
and PDGFR-β for MSCs treated with concentrated CM from irradiated FS120 cells 
with 4 Gy. One-way ANOVA test followed by a Tukey's multiple comparisons test 
was used to analyse data. Results expressed as means ± SEM of 3 experiments, each 
done in triplicate and were considered statistically significant when P ≤ 0.05 (* 
P<0.05, ** P<0.01). 
 
i re .  ff ts f f t s (s)  f  i i t  t o r cells on 
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Figure 3.51 Effects of factors (s) produced from irradiated tumour cells on 
expression of CAF markers by Balb/c MSCs. 
 
Figure 3.52 Effects of factors (s) produced from irradiated tu ou  cells on 
expre sion of CAF marker  by Balb/c MSCs. 
 
Figure 3.53 Effects of factors (s) produced from irradiated tumour cells on 
expression of CAF markers by Balb/c MSCs. 
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3.2.3.4 Effects of irradiated HDMEC on the expression of differentiation markers 
by Balb/c MSCs  
 
Endothelial cells are important tumour-stromal cells (Hanahan and Weinberg, 2011). It 
has been shown that pro-inflammatory mediators (chemokines and cytokines) were 
increased in the supernatant of irradiated HDMEC (Haubner et al., 2013b). Moreover, 
the presence of endothelial cells co-cultured with MSCs significantly affected their 
differentiation and proliferation (Saleh et al., 2011). Firstly, HDMEC were cultured in 
their standard medium in 24 well plates. Then, when they became 80% confluent, their 
medium was changed to Balb/c medium and incubated for 2 hours and then irradiated. 
24 hours after radiation, Balb/c MSCs were seeded at 3 x 104 / 200 μl medium in the 
1.0 μm pore size filter inserts (upper chamber). Inserts containing the Balb/c MSCs 
were incubated with HDMEC for 3 days and then the cell lysates were extracted. For 
the western blotting, the amount of sample protein loaded in each lane was 20 μg (30 
μl/lane). To normalise the samples, the ratio of target protein was divided by internal 
control (i.e., dividing or “normalizing” by the loading control). 
Fibronectin and PDGFR-β were significantly increased after radiation (0.5 Gy and 4 
Gy) whilst, neither collagen-I nor α-SMA showed any significant changes after 0.5 Gy 
and 4 Gy (although they showed the tendency to increase) (Figure 3.9). 
Because the results from C3H10 MSCs were not robust and not promising (as shown 
in previous experiments), I stopped working with them and continue with Balb/c MSCs 
as a model of stem cells. 
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Figure 3.9 Effects of irradiated HDMEC on the expression of CAF 
markers by Balb/c MSCs.  
Balb/c MSCs co-cultured with irradiated HDMEC (0.5 Gy & 4 Gy) for 3 days 
showed increased expression of fibronectin and PDGFR-β (B & C). There 
were no significant changes in the expression of collagen-I & α-SMA (A & 
D). One-way ANOVA test (Tukey's multiple comparisons test) was used to 
analyse data. Quantitative data represent mean value ± SEM of 3 experiments, 
each done in triplicate and were considered statistically significant when P ≤ 
0.05.  
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Figure 3.58 Effects of irradiated HDMEC on the expression of CAF 
markers by Balb/c MSCs. 
 
Figure 3.59 Effects of irradiated HDMEC on the expression of CAF 
markers by Balb/c MSCs. 
 
Figure 3.60 Effects of irradiated HDMEC on the expression of CAF 
markers by Balb/c MSCs. 
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3.2.3.5 Effects of irradiated HDMEC co-cultured with the irradiated tumour cells 
on the MSCs differentiation markers 
 
To model the TME further, FS120 & FS188 cells were co-cultured with HDMECs. As 
described previously, FS tumour cells were established from transgenic mouse embryos 
by immortalisation with SV40 and H-ras transformation. The cells are routinely 
cultured in medium containing G418, and pyromycin to maintain transgene selection. 
When the cells became 80% confluent, they were trypsinised, centrifuged and re-
suspended with HDMEC medium (without G418 and pyromycin in which HDMEC do 
not survive). At the same time, HDMEC were trypsinised and re-suspended with their 
media. Since endothelial cells were growing slower than FS cells, they were mixed 
together at a ratio of 1:4 (12 x 103 FS + 48 x 103 HDMEC) (Figure 3.10).  
The cell mixture was placed in the lower chamber of 24 well plates and incubated for 
2 days. Then, the media were changed to Balb/c media and incubated for 2 hours before 
they were irradiated with (0.5 Gy or 4 Gy). The cells were incubated for 24 hours, then 
Balb/c MSCs were seeded at 3 x 104 / 200 μl medium into 1.0 μm pore size filter and 
co-cultured with the fibrosarcoma/endothelial cultures for 3 days. For the western 
blotting, the amount of sample protein loaded in each lane was 20 μg (30 μl/lane). 
Normalisation was done by dividing the ratio of target protein to internal control (i.e., 
dividing or “normalizing” by the loading control). Western blot analyses showed that 
collagen-I, fibronectin, and PDGFR-β but not -SMA were significantly increased after 
incubation of MSCs with HDMEC + FS188 cells irradiated with 0.5 Gy and 4 Gy 
(Figure 3.11). In contrast, only collagen-I and PDGFR-β were significantly 
upregulated in Balb/c MSCs that were incubated with HDMEC + irradiated FS120 cells 
(Figure 3.11 A and C). 
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A) 
 
Figure 3.61 Co-culture of HDMEC with tumour cells.A) 
 
Figure 3.62 Co-culture of HDMEC with tumour cells. 
 
Figure 3.63 Co-culture of HDMEC with tumour cells.A) 
 
Figure 3.64 Co-culture of HDMEC with tumour cells.A) 
B) 
 
B) 
 
B) 
 
B) 
Figure 3.10 Co-culture of HDMEC with tumour cells.  
Both tumour cells (FS120 cells & FS188 cells) and early passage HDMEC 
were co-cultured together at ratio of 1:4 respectively using HDMEC 
medium. A) FS 120 cells co-cultured with HDMEC. B) FS 188 cells co-
cultured with HDMEC.  
             Represent FS cells and               represent HDMEC 
 
Figure 3.65 Co-culture of Balb/c MSCs with both irradiated HDMEC 
plus tumour cells.Figure 3.10 Co-culture of HDMEC with tumour cells.  
Both tumour cells (FS120 cells & FS188 cells) and early passage HDMEC 
were co-cultured together at ratio of 1:4 respectively using HDMEC 
medium. A) FS 120 cells co-cultured with HDMEC. B) FS 188 cells co-
igure 3.10 o-culture of  ith tu our cel s. 
                                                                                              
 
118 
 
 
 
                                                                                              
 
119 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Co-culture of Balb/c MSCs with both irradiated HDMEC plus 
tumour cells.  
Balb/c MSCs that were incubated with irradiated HDMEC + FS188 cells showed a 
significant increase in the expression of collagen-I, fibronectin, and PDGFR-β 
(except α-SMA) compared to cells co-cultured with non-irradiated HDMEC and 
FS188 cells (A, B, and C). In contrast, there were no changes in fibronectin and α-
SMA expression in Balb/c MSCs that were incubated with irradiated HDMEC + 
FS120 cells, only significantly increased in collagen-I after 0.5 Gy and 4 Gy and for 
PDGFR-β after 0.5 Gy (A and C). One-way ANOVA test (Tukey's multiple 
comparisons test) was used to analyse data. Quantitative data represent mean value 
± SEM and were considered statistically significant when P ≤ 0.05. 
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Figure 3.11 Co-culture of Balb/c MSCs with both irradiated HDMEC plus 
 
Figure 3.69 Co-culture of Balb/c MSCs with both irradiated HDMEC plus 
tumour cells.  
 
Figure 3.70 Co-culture of Balb/c MSCs with both irradiated HDMEC plus 
tumour cells.  
 
Figure 3.71 Co-culture of Balb/c MSCs with both irradiated HDMEC plus 
tumour cells.  
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3.2.3.6 Effects of chemokines and cytokines on the differentiation markers 
expressed by Balb/c MSCs 
 
It was reported by Klopp et al, that irradiation of tumour cells caused an increase in the 
secretion of cytokines like VEGF, TGF-β1, and PDGF. Moreover, exposure of MSCs 
to irradiated tumour cells caused up-regulation of CCR2, a receptor for MCP-1) (Klopp 
et al., 2007). Some studies have demonstrated that tumour cells secrete stromal cell-
derived factor 1α (SDF-1α) that enhance MSCs migration (Kitaori et al., 2009, Abbott 
et al., 2004). Moreover, I showed that both irradiated tumour cells and their 
concentrated CM increased the expression of differentiation markers by MSCs (see 
section 3.2.3.2, and 3.2.3.3). Therefore, the effects of MCP-1 and SDF-1 on the 
differentiation markers expressed by Balb/c MSCs were important to determine.  
For this experiment, 1 x 105 /ml Balb/c MSCs were seeded in 6-well plates, and when 
the cells reached 80% confluently, cells were treated with either TGF-β1 (10 ng/ml), 
MCP-1 (10 ng/ml), or SDF-1 (100 ng/ml) or left untreated as controls. Cells were 
incubated for 3 days prior to protein extraction. 20 μg of cell lysates were analysed by 
western blotting as described previously. The value of the target protein was divided 
by the loading control to get a relative intensity (target/loading).  
From the western blot analysis, TGF-β1 was the only cytokine that significantly up-
regulated all differentiation markers (Figure 3.12). The morphological changes which 
were seen in both MSCs (C3H10, and Balb/c) (towards CAFs-like cells) after treatment 
with TGF-β1 (see section 3.2.2) in addition to increasing in the expression of α-SMA, 
together indicated that MSCs were acquiring characteristics of CAF cells but only after 
TGF-β1 treatment.  
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Figure 3.12 Effects of TGF-β, MCP-1, and SDF-1 on the differentiation 
markers expressed by Balb/c MSCs.  
Balb/c MSCs were seeded in 6-well plates, each well was treated with either TGF-
β (10 ng/ml), or MCP-1 (10 ng/ml), or SDF-1 (100 ng/ml) and incubated for 3 
days. Cell lysates were extracted and run for western blot. Analyses using one-way 
ANOVA test followed by a Tukey's multiple comparisons test showed that TGF-
β was the only cytokine that significantly up-regulated all differentiation markers 
(A, B, C, and D). Results expressed as means ± SEM of 3 experiments, each done 
in triplicate and were considered statistically significant when P ≤ 0.05 (* P<0.05, 
** P<0.01). 
 
 
Figure 3.72 Effects of TGF-β, MCP-1, and SDF-1 on the differentiation 
markers expressed by Balb/c MSCs.Figure 3.12 Effects of TGF-β, MCP-1, 
i  .    , ,     i i i  
   l /  . 
 
Figure 3.77 Direct irradiation does not increase MSCs migration in 
vitro.Figure 3.78 Effects of TGF-β, MCP-1, and SDF-1 on the differentiation 
markers expressed by Balb/c MSCs. 
 
Figure 3.79 Direct irradiation does not increase MSCs migration in vitro. 
 
Figure 3.80 Direct irradiation does not increase MSCs migration in 
vitro.Figure 3.81 Effects of TGF-β, MCP-1, and SDF-1 on the differentiation 
markers expressed by Balb/c MSCs. 
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3.2.4 In vitro radiation effects on Balb/c MSCs migration (transwell migration 
assay) 
 
Migration in biology usually describes the movement of the cells directly through 
substrates like ECM fibers or basal membranes (Kramer et al., 2013). Recently, there 
has been increased relevance into the migration and homing ability of MSCs into 
tumours (De Becker and Van Riet, 2016). The interaction between MSC and the TME 
play an important role in the development and progression of tumours. It has been 
shown that recruitment of the MSC to the injury sites is important to support tissue 
repair, angiogenesis, immune modulation and stem cell homeostasis (Karnoub et al., 
2007, Mandel et al., 2013). Moreover, migration of MSC to the site of injury or 
inflammation causes either direct or indirect interaction between MSC and tumour cells 
(Melzer et al., 2016). The direct interaction occurs via membrane receptors and gap 
junctions while the indirect interaction is through secretion of cytokines, chemokines 
and growth factors (Mandel et al., 2013, Yang et al., 2015b) (see chapter one).  
MSCs can stimulate neighbouring cells with pro-tumorigenic and/or anti-tumorigenic 
behaviours by releasing these cytokines, chemokines and growth factors. Furthermore, 
tumour cells in the TME have the abilities to stimulate MSCs to develop a tumour-
associated phenotype (Hass and Otte, 2012).  It has been shown that MSCs have the 
ability to migrate to sites of tissue injuries like kidney, skin, and heart as a result of 
inflammatory mediators that are produced locally due to tissue damage (Morigi et al., 
2004, Li et al., 2006). Moreover, Mouiseddine et al showed that the migration of MSCs 
to the radiation-injured tissues was enhanced by local irradiation of the mouse abdomen 
(Mouiseddine et al., 2007). One of the potential methods to induce inflammation and 
tissue injury is local irradiation. Therefore, I tested the effect of irradiation (directly and 
indirectly) on the recruitment of the MSCs using an in vitro transwell migration assay 
model. In addition, I tested the role of the inflammatory cytokines and chemokines in 
radiation-induced MSC migration. 
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3.2.4.1 Effects of direct irradiation on the migration of MSCs in vitro 
 
To investigate the ability of direct radiation to induce migration of MSCs, the in vitro 
transwell migration model was used. C3H10 and Balb/c MSCs were seeded 
individually as 3 x 104 cells / 200-μl medium in transwell dishes (Falcon® 8.0 μm pore 
filters). Next, the cells were irradiated with 0.5 Gy and 4 Gy, with the un-irradiated 
group as control. Migration was observed 8 hours’ post-irradiation as explained in 
section 2.2.5.1. As shown in Figure 3.13, direct radiation of the C3H10 MSCs and 
Balb/c MSCs did not show a significant increase in the migration of these cells. 
3.2.4.2 Irradiated tumour cells increase the migration of Balb/c MSCs in vitro 
 
Our aim was to detect paracrine factor(s) secreted by tumour cells that influence the 
migration of C3H10 and Balb/c MSCs in vitro. So, the in vitro co-culture assay was 
carried out using tumour cells (FS120 cells, and FS188 cells) seeded at the lower 
chamber of the 24-well plate with 2 wells left with medium alone (no tumour cells) 
serving as a negative control. When the cells became 80% confluent, they were 
irradiated with 0.5 and 4 Gy, with the non-irradiated group as a positive control. After 
24 hours, the upper chamber (8.0 μm filter) was seeded with either C3H10 MSCs or 
Balb/c MSCs (3 x 104 cells / 200μl medium) and incubated for 8 hours. Migrated cells 
were then fixed, stained and counted.  Results of this experiment are shown in Figure 
3.14. Regarding the migration of the C3H10 MSCs, there were no effects of irradiated 
tumour cells on the recruitment of the C3H10 MSCs. Also, the presence of un-irradiated 
tumour cells in the lower transwell section did not show any effects on the migration 
of the C3H10 MSCs (Figure 3.14 A).   On the other hand, the presence of un-irradiated 
FS120 cells or FS188 cells in the lower transwell compartment increased the migration 
of Balb/c MSCs compared to medium alone. In addition, irradiation of a tumour cells 
with low-dose (0.5 Gy), and high dose (4 Gy) enhanced the migratory capacity of 
Balb/c MSCs (Figure 3.14 B). These results suggest that tumour cells secreted growth 
factors in their media that positively enhanced Balb/c MSCs migration. This means that 
the growth factors produced by tumour cells were potentially upregulated and secreted 
as a consequence of irradiation. Therefore, studying the effects of these growth factors 
within the conditioned medium from irradiated FS cells on the migration of MSCs was 
the next step. 
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Figure 3.13 Direct irradiation does not increase MSCs migration in vitro. 
C3H10 MSCs and Balb/c MSCs were seeded separately in the 8.0-μm pore 
filters, before they were irradiated with 0, 0.5, and 4 Gy. Migrated cells were 
fixed, stained and counted 8 hours after irradiation. The average number of 
migrated cells per 10 fields of view (40 X objective) were counted. Analyses 
using one-way ANOVA test followed by a Tukey's multiple comparisons test 
showed that there was no significant increase in the migrated cells after direct 
radiation. Results expressed as means ± SEM of 3 experiments. 
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Figure 3.14 Migration capacity of C3H10 and Balb/c MSCs exposed to 
irradiated tumour cells. 
In vitro migration assay for C3H10, and Balb/c MSCs was measured through 
transwells. Co-culture of C3H10 MSCs with FS120 cells and FS188 cells for 8 
hours had no effect on the migration of these cells (compared to cells that migrated 
in the absence of tumour cells) (A). Balb/c MSCs co-cultured with tumour cells for 
8 hours increased their migration compared to medium alone. Irradiation of FS 120, 
and FS 188 cells with 0.5 Gy, and 4 Gy significantly increased the migration of 
Balb/c cells further. Statistical analysis was done using one-way ANOVA test 
followed by Tukey`s multiple comparisons test. Results expressed as means ± SEM, 
of 6 experiments, each done in triplicate and were considered statistically significant 
when P ≤ 0.05 (* P<0.05, ** P<0.01). 
 
 
Figure 3.14 Migration capacity of C3H10 and Balb/c MSCs exposed to 
irradiated tumour cells. 
In vitro migration assay for C3H10, and Balb/c MSCs was measured through 
transwells. Co-culture of C3H10 MSCs with FS120 cells and FS188 cells for 8 
i re .         e sed to 
irr i te  t r cells. 
 
Figure 3.88 Migration capacity of C3H10 and Balb/c MSCs exposed to 
irradiated tumour cells. 
 
Figure 3.89 Migra ion capacity of C3H10 and Balb/c MSCs exposed to 
irradiated tumour cells. 
 
Figure 3.90 Migration capacity of C3H10 and Balb/c MSCs exposed to 
irradiated tumour cells. 
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3.2.4.3 Fibrosarcoma cell-conditioned media enhance Balb/c MSCs migration 
 
Presence of irradiated tumour cells caused an increase in migration of Balb/c MSCs as 
shown in section 3.2.4.2. Therefore, CM (neat and concentrated) from irradiated 
tumour cells were used to see whether growth factor(s) secreted from irradiated 
fibrosarcoma cells accelerated MSCs chemotaxis. Conditioned media from irradiated 
FS120 cells and FS188 cells were extracted and concentrated as described in section 
2.2.1.7. For this experiment, 3 x 104 C3H10 MSCs or Balb/c MSCs were plated onto 
transwell filters (8.0 μm filter) with CM (neat or concentrated) at the lower chamber 
and incubated for 16 hours. In the previous experiments, the incubation time after 
irradiation was 8 hours and so, in this experiment, the MSCs were initially incubated 
with the CM for 8 hours. However, at this time, not enough cells had migrated and so 
it was decided to double the time to 16 hours.  
Neither neat nor concentrated CM had significant effects on the migration of C3H10 
MSCs (Figure 3.15 A). While both neat and concentrated CM from irradiated tumour 
cells caused significant migration of the Balb/c MSCs (Figure 3.15 B). There were 
significant differences between the groups for neat CM (comparing FS120 cells and FS 
188 cells), i.e. more MSCs were migrated when they were treated with CM from FS188 
cells (control and irradiated) than treated with CM from FS120 cells. Moreover, there 
was a significant increase in migrated MSCs treated with CM from FS188 cells 
compared to MSCs treated with their medium alone or with concentrated DMEM alone 
(Figure 3.15 A). Likewise, concentrated CM from irradiated tumour cells enhanced the 
migration of Balb/c MSCs, although effects were similar for FS120 and FS188 cells. 
The presence of concentrated CM caused a significant increase in the migrations of 
MSCs compared to using media alone. All experiments were done using duplicate 
filters and were repeated three times.  
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3.2.4.4 Effects of irradiated endothelial cells on the migration of Balb/c MSCs 
 
Figure 3.15 Effects of CM (neat and concentrated) on the migration of C3H10 
MSCs (A), and Balb/c MSCs (B).  
In vitro migration of both C3H10 MSCs and Balb/c MSCs was measured through 
transwells. Both MSCs were treated individually with CM (neat & concentrated) from 
irradiated FS120 cells and FS188 cells for 16 hours. CM (neat or concentrated) had 
no effect on the migration of C3H10 MSCs (A). However, the presence of CM (neat 
or concentrated) increased the migration of Balb/c MSCs compared to medium or 
DMEM alone (B). Moreover, concentrated CM from control and irradiated with 0.5 
Gy, and 4 Gy tumour cells significantly increased migration of Balb/c MSCs 
compared to non-concentrated CM. One-way ANOVA test followed by Tukey`s 
multiple comparisons test was done using GraphPad Prism 7 software. Results 
expressed as means ± SEM, of 3 experiments, each done in duplicates and were 
considered statistically significant when P ≤ 0.05 (* P<0.05, ** P<0.01). 
 
 
Figure 3.91 Effects of CM (neat and concentrated) on the migration of C3H10 
MSCs (A), and Balb/c MSCs (B).Figure 3.15 Effects of CM (neat and 
ig re 3.15 Ef ects of CM (neat and concentrated) on the migration of C3H10 
s ( ),  al /c s ( ). 
 
Figure 3.95 Effects of CM (neat and concentrated) on the migration of C3H10 
MSCs (A), and Balb/c MSCs (B). 
 
Figure 3.96 Effects of CM (neat and concentrated) on the migration of C3H10 
MSCs (A), and Balb/c MSCs (B). 
 
Figure 3.97 Effects of CM (neat and concentrated) on the migration of C3H10 
MSCs (A), and Balb/c MSCs (B). 
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3.2.4.4 Effects of irradiated endothelial cells on the migration of Balb/c MSCs 
 
It has been shown that endothelial cells increased the migration of MSCs cells (Yuan 
et al., 2015, Kamprom et al., 2016). Additionally, co-culture of MSCs with endothelial 
cells affect their proliferation and differentiation (Saleh et al., 2011).  The effect of two 
types of irradiated endothelial cells (H5V, and HDMEC) on the migration of Balb/c 
MSCs was determined by transwell assays. H5V cells and HDMEC were seeded 
separately in 24 well plates with their media and incubated to become confluent. Then, 
2 hours before irradiation, their media were changed to Balb/c medium and irradiated 
with 0.5 and 4 Gy. Two wells were left without irradiation as a positive control, and 
another two wells left with only Balb/c medium (no cells) as a negative control. 24 
hours after irradiation, Balb/c MSCs were cultured into the insert and incubated for 16 
hours as before.  
The result revealed that there were no effects of the irradiated H5V endothelial cell on 
the migration of Balb/c MSCs (Figure 3.16 A). However, exposure of Balb/c MSCs to 
HDMEC for 8 hours caused significantly increased in the migration of MSCs compared 
to Balb/c medium alone (Figure 3.16 B). Additionally, irradiation of the endothelial 
cells with 0.5 Gy and 4 Gy caused more MSCs migration compared to control non-
irradiated cells. These results indicated that the presence of the HDMEC enhanced the 
migration of the Balb/c MSCs, while irradiation increased this migration ability of these 
cells.  
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Figure 3.16 Migration ability of Balb/c MSCs increased when co-cultured 
with irradiated A) H5V cells, and B) HDMEC.  
Transwell migration assay was done for Balb/c MSCs co-cultured with control 
(no irradiation), and irradiated H5V (for 16 hours) or HDMEC (for 8 hours). There 
were no effects of the irradiated H5V on the balb/c MSCs migration (A). While, 
enhancement of MSCs migration by HDMEC was shown, compared to MSCs 
incubated with medium alone (no HDMEC). Besides, low and high dose radiation 
(0.5, and 4 Gy) significantly increased the migration of MSCs (B). The results 
were statistically analysed using one-way ANOVA test (Tukey`s multiple 
comparisons test) with GraphPad Prism 7. All data are presented as mean ± SEM, 
of 3 experiments, each done in duplicates and were considered statistically 
significant when P ≤ 0.05 (* P<0.05, ** P<0.01). 
 
 
Figure 3.98 Migration ability of Balb/c MSCs increased when co-cultured 
with irradiated A) H5V cells, and B) HDMEC.Figure 3.16 Migration ability 
of Balb/c MSCs increased when co-cultured with irradiated A) H5V cells, and 
B) HDMEC.  
Figure 3.16 Migration ability of Balb/c MSCs increas d when co-cultured 
with irradiated A) H5V cel s, and B) HD EC. 
 
Figure 3.102 Migration ability of Balb/c MSCs increased when co-cultured 
with irradiated A) H5V cells, and B) HDMEC. 
 
Figure 3.103 Migration ability of Balb/c MSCs increased when co-cultured 
with irradiated A) H5V cells, and B) HDMEC. 
 
Figure 3.104 Migration ability of Balb/c MSCs increased when co-cultured 
with irradiated A) H5V cells, and B) HDMEC. 
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3.2.4.5 Co-cultured tumour cells and endothelial cells stimulate migration of 
Balb/c MSCs in vitro 
 
In the tumour microenvironment, cross-talk between tumour cells and endothelial cells 
is essential for angiogenesis (Folkman, 1995, Zeng et al., 2005). Angiogenesis is 
mediated by soluble factors secreted from tumour cells which enhance migration and 
proliferation of endothelial cells (Lutsenko et al., 2003). As the interactions between 
endothelial cells and tumour cells are complicated, and to better understand the 
intercellular interactions between tumour cells and endothelial cells, and whether 
irradiation modifies it, I modelled an in vitro co-culture assay consisting of tumour cells 
(FS120 cells and FS188 cells) and HDMEC. By this assay, I studied if tumour cells 
cultured with HDMEC produce factor(s) that increase recruitment of the Balb/c MSCs 
and whether irradiation modified this factor(s). 
To further evaluate the synergistic effect of both tumour cells and HDMEC on the 
migration of the MSCs (as they have shown significant effects on the migration of the 
MSCs as discussed in section 3.2.4.2, and 3.2.4.4), both cells were co-cultured together 
(as described in section 3.2.3.5). The mixture of cells (FS120 cells + HDMEC) or 
(FS188 cells + HDMEC) were seeded at the lower chamber of 24 well plates and 
incubated till the cells became confluent. Next, their media were changed to MSCs 
medium and incubated for 2 hours before irradiated with 0.5, and 4 Gy with non-
irradiated cells used as controls. The cells were incubated for 24 hours after irradiation, 
and then Balb/c MSCs were seeded at 3 x 104/ 200 μl medium on the filter (8.0 μm 
pores) and incubated for 8 hours. A group of MSCs were seeded with their medium 
only (no tumour cells or HDMEC) to see whether the migration occurs due to the 
presence of cells of via factors present in the medium itself. After 8 hours’ incubation, 
the migrated cells were fixed, stained and counted.  
As shown in Figure 3.17, presence of both endothelial cells and tumour cells together, 
caused significantly more Balb/c MSC to migrate through the transwell filter compared 
to cells were exposed to medium alone (Figure 3.17). Furthermore, irradiation of the 
co-cultures resulted in further significant increases in migration (Figure 3.17). The 
table below (Table 3.1) compares the results from MSCs exposed to irradiated tumour 
cells alone (Figure 3.15), to irradiated HDMEC alone (Figure 3.16) with the results 
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shown in Figure 3.17. It can be seen that the number of migrated Balb/c MSCs were 
further increased after co-culture tumour cells with HDMEC than alone. This 
observation suggests that the presence of both tumour cells + endothelial cells enhanced 
the migratory ability of the Balb/c MSCs. 
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Figure 3.17 Effects of tumour cells co-cultured with endothelial cells on the 
migration ability of Balb/c MSCs.  
Tumour cells (FS120 cells, and FS188 cells) were co-cultured with HDMEC at 
a ratio of 1:4. Then, the co-culture mixture was irradiated by 0, 0.5, and 4 Gy. 
After 24 hours, Balb/c MSCs were seeded on the filter and incubated for 8 hours 
with the control and irradiated co-cultures. Enhancement of MSCs migration by 
both endothelial cells and tumour cells was shown, compared to MSCs 
incubated with medium alone. Low and high dose radiation (0.5 and 4 Gy) also 
significantly increased the migration of MSCs. The results were statistically 
analysed using one-way ANOVA test (Tukey`s multiple comparisons test) with 
GraphPad Prism 7. All data are presented as mean ± SEM, of 3 experiments, 
each done in duplicates and were considered statistically significant when P ≤ 
0.05 (* P<0.05, ** P<0.01, ***P<0.001, ****P<0.0001). 
 
 
Figure 3.105 Effects of tumour cells co-cultured with endothelial cells on 
the migration ability of Balb/c MSCs.Figure 3.17 Effects of tumour cells co-
igure 3.17 ffects of tu our cells co-cultured ith endothelial cells on the 
igration ability of alb/c S s. 
 
Figure 3.109 Effects of tumour cells co-cultured with endothelial cells on 
the migration ability of Balb/c MSCs. 
 
Fig re 3.110 Eff cts of tumour cells co-cultured with endothelial cells on 
the m gra ion ability of Balb/c MSCs. 
 
Figure 3.111 Effects of tumour cells co-cultured with endothelial cells on 
the migration ability of Balb/c MSCs. 
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3.2.4.6 Role of cytokines and chemokines enhanced MSCs migration 
 
In the previous experiments, it was successfully shown that MSCs exposed to irradiated 
endothelial cells co-cultured with irradiated tumour cells resulted in increased numbers 
of migrated MSCs. These results imply that factors secreted from tumour cells and/or 
endothelial cells facilitate MSCs migration. It was reported by Abbott et al and Kitaori 
et al that tumour cells secreted SDF-1α, which enhance MSCs migration, and the 
migration of MSCs was decreased when SDF-1α was blocked by the relevant antibody 
(Abbott et al., 2004, Kitaori et al., 2009). Also, Dwyer et al revealed that primary breast 
cancer cells secreted MCP-1 that caused migration of the MSCs (Dwyer et al., 2007). 
Furthermore, Baek et al and Klopp et al determined that the tumour cells secreted 
cytokines that enhanced the migration of MSCs, like TGF-β1, PDGF, and VEGF, 
which were increased after irradiation (Baek et al., 2011, Klopp et al., 2007).   
In this study, an in vitro migration assay was used (as described previously) using 
transwell filters. In the lower chamber of the transwells, there was Balb/c medium 
 FS120 cells FS188 cells HDMEC HDMEC + 
FS120 cells 
HDMEC + 
FS188 cells 
Control 5.25 6.6 12.48 30 33.7 
0.5 Gy 10 13 18.8 41 44.3 
4 Gy 9 12.58 20.8 45.5 51.6 
one-way ANOVA test (Tukey`s multiple comparisons test) 
FS120 vs. 
HDMEC 
FS188 vs. 
HDMEC 
FS120 vs. 
HDMEC+F
S120 
FS188 vs. 
HDMEC+F
S188 
HDMEC vs. 
HDMEC + 
FS120 
HDMEC vs. 
HDMEC + 
FS188 
P=0.0373 
* 
P=0.0486 
* 
P<0.0001 
**** 
P<0.0001 
**** 
P<0.0002 
*** 
P<0.0001 
**** 
Table 3.1 Average numbers of migrated Balb/c MSCs after exposed to 
different cells types with their statistical significance. 
 
 
Table 3.1 Average numbers of migrated Balb/c MSCs after exposed to 
different cells types. 
 
 
Table 3 2 Average numbers of migrated Balb/c SCs after exposed to 
different cells types. 
 
 
Table 3.3 Average numbers of migrated Balb/c MSCs after exposed to 
different cells types. 
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treated with TGF-β1 (20 ng/ml), MCP-1 (20 ng/ml), or SDF-1α (100 ng/ml, or 200 
ng/ml). The non-treated cells were used as controls. MSCs were incubated with growth 
factor for 16 hours (the time was optimized) before the cells were fixed, stained, and 
counted. The results (Figure 3.18) showed that all these factors enhanced stem cell 
migration significantly. The next step was to test for these growth factors in the CM 
from irradiated tumour cells and establish their involvement in the recruitment of MSCs 
towards them (see chapter 4). 
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Figure 3.18 Cytokines and chemokines in enhanced MSCs migration.  
Balb/c MSCs were treated for 16 hours with 20 ng/ml TGF-β1, 20 ng/ml MCP-1 
(A), or 100 ng/ml, or 200 ng/ml SDF-1α (B). Enhancement of MSCs migration by 
these cytokines or chemokines was shown compared to MSCs with medium alone 
(no treatment). One-way ANOVA test (Tukey`s multiple comparisons test) for (A), 
while unpaired t-test (two-tailed) for (B), were used with GraphPad Prism 7.0. All 
data are presented as mean ± SEM, of 3 experiments, each done in duplicates and 
were considered statistically significant when P ≤ 0.05. 
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3.3 Summary of results 
 
In this chapter, the radiation sensitivity of tumour cells and MSCs were tested using a 
clonogenic assay. Then, the effect of TGF-β1 on the growth and differentiation of 
tumour cells and MSCs was done using a growth curve assay. The western blotting 
technique was used for both C3H10 and Balb/c MSCs to study the expression of the 
MSC differentiation markers collagen-I, fibronectin, PDGFR-β and α-SMA. Different 
techniques were used to determine direct and indirect effects of irradiation on MSCs: 
i) direct irradiation, ii) incubation with CM (neat or concentrated) from irradiated 
tumour cells, iii) co-culture with irradiated tumour cells, iv) co-culture with irradiated 
endothelial cells or v) co-culture with both irradiated tumour cells + irradiated 
endothelial cells. While both C3H10 and Balb/c MSCs expressed high basal levels of 
CAFs-like cell expression markers, still the results from C3H10 MSCs were not robust. 
Therefore, Balb/c MSCs used instead for subsequent experiments. The direct 
irradiation of both C3H10 MSCs and Balb/c MSCs caused minimal changes in the 
expression of various proteins associated with differentiated CAFs. The response of 
Balb/c MSCs to irradiated tumour cells and/or their CM was clearer. The results showed 
that direct irradiation had no significant effects on the differentiation markers of MSCs, 
except for collagen I (significant increase after 0.5 Gy). However, irradiation of tumour 
cells and/or endothelial cells did increase the expression of some differentiation 
markers in MSCs, under certain conditions. This encouraged further study into the roles 
of specific cytokines and chemokines on the differentiation and migration of MSCs. 
TGF-β1, MCP-1, and SDF-1α were studied. The results showed that only TGF-β1 
significantly increased all differentiation markers (collagen-I, fibronectin, PDGFR-, 
and -SMA). However, TGF-β1, MCP-1, and SDF-1α all significantly enhanced the 
migration of MSCs through trans-well plates in vitro. Although there were no effects 
of the direct irradiation on the MSC migration, indirect radiation showed significant 
effects on the migration ability of the MSCs in vitro. Presence of tumour cells or 
endothelial cells (non-irradiated or irradiated) increased the migration of the MSCs 
compared to incubation of MSCs with medium alone. 
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3.4 Discussion 
 
The main objectives of this chapter were to study the in vitro effects of radiation 
(directly or indirectly) on the expression of CAF differentiation markers by MSCs, and, 
to investigate radiation effects on the homing and migration of MSCs. 
First, models of mesenchymal stem cells and tumour cells were developed. 
Fibrosarcoma cells that expressed a single isoform of VEGF were used as models of 
soft tissue sarcoma. Pathologist has checked these mouse tumours and she agreed that 
they are similar to human fibrosarcoma but she did not classified them into grades like 
in humans. In vivo, FS188 cells express only VEGF 188 and produce tumours with 
more CAF-like cells and perivascular pericytes than those produced by FS120 cells 
(Tozer et al., 2008). Collagen I levels are also higher in FS188 tumours versus FS120 
tumours and this correlates with the higher abundance of CAFs in the FS188 tumours 
(English et al, 2017). The differences between these tumour cells make them a good 
model to study the indirect response of MSCs to radiation, by potentially providing 
different growth factors to drive the differentiation of MSCs to CAFs. As discussed in 
chapter two, FS188 cells are more apoptotic and proliferate slower than FS120 cells 
that proliferate rapidly and apoptose less (Kanthou et al., 2014). Furthermore, FS188 
cells showed spindle-shape features with extended processes and ruffles (typical 
mesenchymal features) compared to FS120 cells which area rounded to elongated cells 
with less extended processes (Kanthou et al., 2014). A recent study by English et al has 
shown that FS120 cells have the ability to metastasise in mice to lung and these cells 
form micrometastases in lung more readily than the FS188 cells These metastasised 
FS120 tumours colonies were more sensitive to anti-VEGFA therapy than colonies of 
FS188 (English et al., 2017).  
At the beginning of this research project, C3H10 MSCs were used, which are a cell line 
established in 1973 and were used by many researchers as a stem cell model of MSCs 
that can differentiate into CAF-like cells (Reznikof.Ca et al., 1973). Although both 
C3H10 and Balb/c MSCs expressed high basal levels of CAFs-like cell expression 
markers, still the results from C3H10 MSCs were not as expected. Therefore, Balb/c 
MSCs were used instead. Balb/c MSCs were used by Klopp et al. and have shown a 
good response to radiation as seen by an increase in expression of CCR2, a receptor for 
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MCP-1, and enhancement of Balb/c MSCs migration by cytokines secreted by 
irradiated tumour cells (Klopp et al., 2007). Although direct irradiation of both C3H10 
MSCs, and Balb/c MSCs caused minimal changes in the expression of various proteins 
associated with differentiated CAFs (see section 3.2.3.1), the response of Balb/c MSCs 
to irradiated tumour cells and/or their CM was more robust. Neither irradiated tumour 
cells, nor their CM had any effects on the differentiation markers of the C3H10 MSCs 
(Figure 3.5 & 3.7). On the other hand, Balb/c MSCs showed promising results after 
exposure to irradiated tumour cells (especially irradiated FS188) or their CM such as 
an increase in collagen-I, fibronectin, PDGFR-β, and α-SMA expression as shown in 
Figures 3.6 & 3.8. Compared with the above study, a study by Barcellose-de-Souza 
showed that treatment of MSC with CM from human prostatic cancer cells caused 
enhancement the expression of α-SMA (CAF marker) (Barcellos-de-Souza et al., 2016). 
Furthermore, C3H10 MSCs, unlike Balb/c MSCs, did not respond to either direct 
irradiation, or to treatment with irradiated tumour cells and/or their CM in terms of 
migration (Figure 3.13, 3.14, and 3.15). Since C3H10 cells were rather unresponsive, 
subsequent experiments were performed using only the Balb/c MSC model. 
An in vitro clonogenic cell survival assay was chosen to assess viability and to enable 
a selection of appropriate radiation doses to expose the cells to. In this study, the 
radiation sensitivity of mouse fibrosarcoma cells (FS120 cells, and FS188 cells), 
C3H10 MSCs, and Balb/c MSCs were tested. The results showed no differences in 
radiation sensitivity between FS120 cells and FS188 cells, except at 4 Gy, where FS188 
cells were more radiosensitive than FS120 cells (Figure 3.1). Many studies showed 
that normal fibroblasts and CAFs could tolerate high radiation doses (radioresistant 
cells) (Hawsawi et al., 2008, Papadopoulou and Kletsas, 2011, Tachiiri et al., 2006). 
Similarly, both C3H10 MSCs and Balb/c MSCs were more radio-resistant than the 
tumour cells (Figure 3.1). These results support a study by Islam et al in which adult 
human MSCs were more radioresistant than embryonic stem cells (Islam et al., 2015). 
Furthermore, it has been shown that fractionated or hyperfractionated radiotherapy of 
0.5-2 Gy causes radioresistance in MSCs (Tomuleasa et al., 2010, Clavin et al., 2008). 
Data from clonogenic assays might suggest that most cells die at higher radiation doses. 
However, irradiated endothelial cells and fibrosarcoma cells still produce growth 
factors and cytokines that enhanced MSCs migration and differentiation. The 
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explanation of this could be because irradiation caused senescence of the tumour cells 
and endothelial cells. Senescent cells exhibit increased inflammatory cytokines and 
ROS, decreased nitric oxide production and increased ECM protein production through 
stimulation of TGF-β1 (Wang et al., 2016, Davalos et al., 2010). Several studies showed 
that senescent cells play an important role in radiation fibrosis. Schafer et al showed, in 
lung tissue, that fibrogenesis was enhanced via senescent fibroblasts (Schafer et al., 
2017). Moreover, Beach et al showed that radiotherapy of the lungs caused cellular 
senescence via DNA damage and an inflammatory response which later caused 
pulmonary fibrosis (Beach et al., 2017). Radiation can also cause senescence of the 
endothelial cells (Korpela and Liu, 2014). On the other hand, a study by Krizhanovsky 
et al showed the reverse, in which senescent hepatic stellate cells limit fibrotic processes 
in acute liver damage (Krizhanovsky et al., 2008). It is well known that senescent cells 
secrete growth factors and chemokines such as TGF-β1 and MCP-1 as a part of 
senescence-associated secretory phenotype (SASP) (Acosta et al., 2013). Radiation 
also induces senescence of MSCs (Wang et al., 2010, Wang et al., 2011). 
In the current study, doses between 0.2 and 4 Gy were chosen for either irradiating 
MSCs directly or irradiating tumour and endothelial cells to stimulate MSCs. Although 
4 Gy was a lethal/sublethal dose on tumour cells (SF was 3.1%, and 0.98% for FS120 
cells, and FS188 cells respectively) and a moderate dose for MSCs (SF was 40.0%, and 
25.6% for Balb/c MSCs, and C3H10 MSCs respectively) it was selected to mimic 
radiation doses used in clinical treatment.  
In vitro clonogenic assays may not reflect the actual in vivo radiosensitivity of the cells 
within the TME, for instance because the TME is more hypoxic. It has been shown that 
hypoxia increased radioresistance of MSCs, both in vitro and in vivo, by increasing 
their proliferation, DNA damage repair, and maintained their proliferation and 
differentiation abilities after irradiation (Sugrue et al., 2014, Singh et al., 2012). 
In this chapter, TGF-β1 growth factor was tested for both growth and differentiation of 
MSCs. TGF-β1 has been shown to be an important pro-fibrotic cytokine (Yarnold and 
Brotons, 2010) involved in organ growth and development, differentiation and 
proliferation of the cells, and immune modulation (Lewis et al., 2004).  While TGF-β1 
growth factor has been shown to have a significant effect on MSCs growth (Ng et al., 
2008) in this study, an in vitro growth curve showed no significant effect of TGF-β1 on 
                                                                                              
 
139 
 
the proliferation of C3H10 and Balb/c MSCs. A possible explanation of this may be 
because in the previous study, human MSCs were used while in this study mouse MSCs 
were used.  
Also, in both previous studies and this study 10 ng/ml of recombinant TGF-β1 were 
used, however, the technique, MSCs seeding densities, passage number, and the time 
limit were different (Ng et al., 2008). Moreover, while TGF-β1 is an important cytokine 
for the growth of MSCs it can also act as a negative growth regulator in some cell types 
(Datto et al., 1995, Hannon and Beach, 1994). Kulterer et al and Ng et al showed that 
TGF-β1 is important growth factors in the differentiation of the MSCs (Kulterer et al., 
2007, Ng et al., 2008). In this study, it was demonstrated that TGF-β1 induced 
morphological differentiation of both C3H10 and Balb/c MSCs so that the cells became 
more spindle shaped, which is a characteristic of CAFs. This observation was further 
supported by a western blot study through up-regulation of extracellular matrix proteins 
such as collagen-I, fibronectin, and -SMA (Figure 3.12), and was also supported by 
a trans-well migration assay, where TGF-β enhanced the migration of the MSCs 
significantly (Figure 3.18). Similarly, a recent study by Barcellose-de-Souza has 
shown that MSCs were recruited to the tumour site and differentiated into CAF-like 
cells through TGF-β1 (Barcellos-de-Souza et al., 2016). In this study, higher expression 
of collagen-I, fibronectin, PDGFR-β and -SMA was evident after treatment of MSCs 
with 10 ng/ml TGF-β for 4 days.  
Despite a substantial amount of research in this area, still the role MSCs in cancer 
growth and metastasis is not fully understood. It has been shown that MSCs enhance 
cancer growth and metastasis, while other studies showed the reverse (Karnoub et al., 
2007, Secchiero et al., 2010, Clarke et al., 2015, Shinagawa et al., 2010). Moreover, 
MSCs also play a key role in the TME via their special cellular interactions to cause 
either promotion or inhibition of tumour growth (Klopp et al., 2011). As tumour 
inhibitors, MSCs block AKT and Wnt signalling, suppress angiogenesis, and apoptosis 
through cell cycle arrest (Hass and Otte, 2012, Rhee et al., 2015). As tumour promoters, 
MSCs can be recruited to a tumour and activated by TGF-β1 to form CAFs that play a 
key role in tumour growth, as described above (Barcellos-de-Souza et al., 2016). It has 
been shown that MSCs enhanced angiogenesis and tumour growth through their 
abilities to differentiate into pericyte-like and endothelial-like cells (Oswald et al., 2004, 
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Ball et al., 2004, Suzuki et al., 2011). Moreover, co-culture of adipose-derived MSCs 
with prostate cancer was shown to cause differentiation of MSC into endothelial-like 
cells and increased tumour vascularity and enhancement of the tumour growth (Lin et 
al., 2010, Prantl et al., 2010).  
So, in order to further understand the relation between individual cells of the TME with 
the MSCs, and because the development of tumours determined by the interaction and 
cross talk between the cells within TME, MSCs were co-cultured with irradiated 
tumour cells and/or endothelial cells. Our study demonstrated that co-culture of Balb/c 
MSCs with tumour cells (especially FS188 cells) irradiated by 0.5 Gy, and 4 Gy caused 
a significant increase in the ECM protein (collagen-I, PDGFR-β and -SMA), which 
suggested that the tumour cells are induced to secrete factors in response to irradiation 
that work in a paracrine manner to cause differentiation of MSCs into CAF-like cells.  
Our results were supported by a transwell migration assay with either, tumour cells, or 
with their concentrated CM, where more MSCs were migrated in the presence of the 
tumour cells (controls or irradiated) compared to medium alone suggesting that 
irradiated tumour cells produce factors that stimulate MSCs to home towards the 
tumour. Paracrine factors were also established to cause migration of MSCs into 
parenchyma of irradiated tumours in previous studies (Klopp et al., 2007). Moreover, I 
have found that FS188 cells caused MSCs to express higher levels of differentiation 
markers and they recruited more MSCs than FS120 cells. These results might explain 
the ability of FS188 cells to produce more α-SMA positive cells (CAFs) in vivo as 
shown by Tozer et al, 2008 (Tozer et al., 2008), by potentially producing and secreted 
more cytokines or chemokines in response to radiation. 
In this chapter, the effect of irradiated endothelial cells on the MSC expression markers 
was also studied. Endothelial cells display a high sensitivity to irradiation but also 
cross-talk with MSCs therefore studying the cellular events due to endothelial radiation 
injury is crucial (Barker et al., 2015). It has been shown that co-culture of endothelial 
cells (HUVEC) with MSCs significantly affected their differentiation and proliferation, 
suggesting presence of cross-talk between endothelial cells and MSCs, which regulate 
MSCs in the TME (Saleh et al., 2011). Moreover, Saleh et al showed that HUVECs 
secreted paracrine factors in their CM that induced enhancement of the MSCs 
proliferation when MSCs treated by this CM. Furthermore, an in vitro study showed 
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that low dose radiation (<5 Gy) increases VEGF secretion and enhances tumour growth 
(Heissig et al., 2005, Vala et al., 2010). In this study, Balb/c MSCs co-cultured with 
irradiated HDMEC (0.5, and 4 Gy) displayed an upregulated expression of fibronectin 
and PDGFR-.  
The effects of radiation on the C3H10 MSCs and Balb/c MSCs migration were assessed 
using an in vitro transwell migration assay. C3H10 MSCs did not show significant 
migration after direct radiation, or co-cultured with irradiated tumour cells or with their 
CM, whereas using irradiated tumour cells or their CM strongly enhanced MSCs 
migration at 0.5 and 4 Gy after 8-16 hours. These results are in agreement with Klopp 
et al (2007). In our results, Balb/c MSCs migrated more if they were treated with CM 
extracted from irradiated FS188 cells (see Figure 3.15 B). 
Two models of endothelial cells were used to study recruitment of MSCs, H5V mouse 
endothelial cells, and HDMEC. Both control and irradiated HDMEC recruited Balb/c 
MSCs, while H5V did not. This is might be because H5V cells are endothelial cells that 
were immortalised using Polyoma virus (Garlanda et al., 1994), while HDMEC were 
primary cells taken from the human adult skin. This study was able to show that co-
culture of both; irradiated HDMEC with irradiated tumour cells caused a significant 
increase in the migration of MSCs in a dose-dependent manner as shown in Table 3.1. 
It has been shown that MSC can be recruited to inflammatory sites by crossing the 
endothelium via a multistep process (Henschler et al., 2008, Aldridge et al., 2012). 
Moreover, Luu et al showed that the cross-talk between endothelial cells and MSCs 
caused a decrease in the cytokine-induced leukocyte recruitment (Luu et al., 2013). 
The effects of cytokines and chemokines (TGF-β1, MCP-1, and SDF-1α) on the 
migration of MSCs were reported by (Baek et al., 2011, Wang et al., 2002, Kitaori et 
al., 2009) respectively. Several studies demonstrated MCP-1 as pro-fibrotic mediator 
(Carulli et al., 2005, Distler et al., 2009, Ong et al., 2003). Moreover, studies have 
shown that the MCP-1 chemokine enhance the migration of MSCs, both in vitro and in 
vivo (Boomsma and Geenen, 2012, Dwyer et al., 2007, Belema-Bedada et al., 2008). 
Klopp et al showed that TGF-β1 that secreted from tumour cells and enhanced MSCs 
migration was increased post irradiation (Klopp et al., 2007, Baek et al., 2011). In 
addition, studies demonstrated that MSCs were recruited by SDF-1α in vitro (Schmidt 
et al., 2006, Sordi et al., 2005). Furthermore, Gao et al showed that tumour cells 
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secreted soluble factors that cause MSCs to secrete SDF-1α that, in turn, activates their 
migration (Gao et al., 2009). Similar results were observed in this study, where TGF-
β1, MCP-1, and SDF-1α enhanced the migration of MSCs after 16 hours. 
In summary, the results presented here suggest that radiation caused a significant 
increase in the expression of MSC differentiation markers and enhanced the migration 
of MSCs through secreted factors from tumour cells and endothelial cells.  
In the next chapter, factors produced by irradiated tumour and endothelial cells were 
investigated further for their potential contribution towards MSC recruitment. 
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CHAPTER FOUR: 
Analysis of factor(s) responsible for MSC 
differentiation/migration within the tumour 
microenvironment 
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4.1 Introduction and Aims 
 
In the previous chapter, it was shown that radiation significantly increased the 
expression of several differentiation markers in Balb/c MSCs. Specifically, co-culture 
of Balb/c MSCs with irradiated fibrosarcoma cells or incubation with fibrosarcoma CM 
significantly increased the expression of proteins such as collagen-I, fibronectin, 
PDGFR-β, and α-SMA suggesting that MSCs were induced to acquire CAF-like 
characteristics. In addition, co-culture of Balb/c MSCs with irradiated endothelial cells 
or a mixed culture of irradiated tumour cells and endothelial cells, significantly 
increased the expression of collagen-I, fibronectin and PDGFR-β proteins. In chapter 
three, Balb/c MSC migration was shown to be enhanced by co-culture with 
fibrosarcoma cells or by incubation with fibrosarcoma cell CM. Migration was further 
enhanced by prior fibrosarcoma irradiation. Moreover, incubation of Balb/c MSCs 
either with endothelial cells alone, or with both endothelial cells and tumour cells 
increased their migration. Recombinant growth factors like MCP-1, TGF-β1, and SDF-
1α that might be secreted from tumour cells were tested and found to significantly 
increase migration of Balb/c MSCs in vitro (Figure 3.18).  
In this chapter, the expression of cytokines including MCP-1, TGF- and SDF-1α by 
fibrosarcoma cells and their potential involvement in MSC recruitment and 
differentiation were studied in more detail. Multiple studies have shown that the MCP-
1 receptor CCR2 is expressed on MSC (Ringe et al., 2007, Ponte et al., 2007, Shen et 
al., 2016, Klopp et al., 2007). Moreover, it has been shown that radiation can up-
regulate the expression of CCR2 in MSCs (Klopp et al., 2007, Connolly et al., 2016). 
Therefore, the CCR2 expression by MSC was studied in order to investigate whether 
its expression is altered after radiation.  
Because of potential differences in the ability of FS120 and FS188 cell to enhance the 
migration of MSCs, data obtained from a previous study involving RNA sequencing of 
FS 120 and FS188 solid tumours was analysed further.  RNA sequencing using NGS is 
a technique used to analyse and quantify millions of RNA transcripts in cells and tissues. 
The RNA sequencing data from un-irradiated FS120 and FS188 tumours was checked 
for differences in the expressions of specific genes that might be involved in MSC 
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recruitment and differentiation, which might clarify the development of more CAF-like 
cells in FS188 compared with FS120 tumours (Tozer et al, 2008). 
Subsequently, quantification of MCP-1 chemokine was done using an ELISA assay in 
order to quantify the amount of MCP-1 secreted from tumour cells in response to 
irradiation. Finally, to confirm that MCP-1 chemokine is an important factor that 
mediates MSCs migration to TME, blocking of MCP-1 activity by neutralizing anti-
MCP-1 antibody was performed.  
Thus, the aims of this chapter were: 
- Establish whether radiation modifies the expression of chemokines & cytokines 
involved in chemotaxis of MSCs toward irradiated tumour cells. 
- Study the effect of radiation (direct and indirect) on the expression of 
chemokine receptor CCR2 by Balb/c MSCs. 
- Identify any differences between FS120 and FS 188 tumours that could cause 
differential recruitment of the MSCs 
- Study whether MCP-1 chemokine that is secreted by tumour cells (control, and 
irradiated) plays a key role in the recruitment of MSCs to TME. 
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4.2 Results 
4.2.1 Radiation enhanced the expression/secretion of cytokines and chemokines by 
irradiated tumour cells. 
In the previous chapter, cytokines including TGF-β1, MCP-1 and SDF-1α were shown 
to enhance the migration of MSCs in vitro (see section 3.2.4.6). The aim of this 
experiment was to study the role of cytokines and chemokines involved in radiation-
enhanced MSC migration and whether they were up-regulated in the conditioned media 
from irradiated tumour cells.  To do that, two methods were used, western blot 
technique and an ELISA assay. For analysis of secreted TGF-β1, MCP-1, and SDF-1α 
by western blotting, I tested both neat and concentrated CM. The CM samples (whether 
neat or concentrated) were mixed with reducing Laemmli buffer and heated at 70°C for 
10 minutes. The amount of CM was adjusted according to cell numbers (see 2.2.1.7), 
so that 30 μl of each sample was analysed per lane (30 μl /0.5 x 106 cells). As shown in 
Figure 4.1, FS120 and FS188 cells produced MCP-1, TGF-β1, and SDF-1α, and 
furthermore, radiation significantly increased their expression/secretion.  
This increase was radiation dose-dependent. There was a tendency for higher levels of 
growth factors within concentrated CM from FS188 cells (Figure 4.1). These results 
agreed with previous array work that showed MCP-1 from FS188 cells was more than 
from FS120 cells (unpublished data from our group) and were confirmed by us using 
an ELISA assay (see later). Within the neat CM, these factors could not be detected, so 
only results from concentrated CM are shown. One-way ANOVA test followed by 
Tukey’s multiple comparisons test was used to analyse data, and were considered 
statistically significant when P ≤ 0.05 (* P<0.05, ** P<0.01). 
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Figure 4.1 Radiation up-regulated the expression of cytokines and chemokines 
in the serum-free concentrated CM from fibrosarcoma cells.  
Serum-free CM collected from control and irradiated tumour cells (4 days after 
irradiation) was concentrated and mixed with reducing Laemmli sample buffer. 30 
μl (corresponding to /0.5 x 106 cells) was analysed by western blotting to detect 
MCP-1, TGF-β, and SDF-1α. A significant increase in the expression of the 
cytokines and chemokines was revealed for both CM extracted from irradiated 
FS120 cells or from irradiated FS188 cells. One-way ANOVA test followed by a 
Tukey's multiple comparisons test was used to analyse data. Results expressed as 
means ± SEM of 3 experiments, each done in triplicate and were considered 
statistically significant when P ≤ 0.05 (* P<0.05, ** P<0.01).  
 
                                                                                              
 
149 
 
4.2.2 Radiation increased levels of MCP-1 secreted from tumour cells in a dose-
dependent manner  
 
As established in the previous work (see chapter 3), MCP-1 plays a key role in the 
migration and differentiation of the Balb/c MSCs. In order to quantify the amount of 
MCP-1 chemokine (chemotactic cytokine) that was secreted from irradiated tumour 
cells, an ELISA was performed as described in chapter two (section 2.2.6). Serum-free 
CM from irradiated FS120 and FS188 tumour cells 4 days’ post-irradiation was 
analysed to detect mouse MCP-1 protein. At the beginning, both concentrated and neat 
serum-free CM were tested, but as the results from concentrated CM were too high 
(above the range of the standards), so only neat CM were analysed. Different dilutions 
were tested for CM samples with the reagent diluent (1:10, 1:50, 1:100, 1:150, and 
1:200) as described in section 2.2.6. Dilutions of the neat CM were performed until the 
values were within the linear range of the standard curve. Results from two dilutions 
(1:150 and 1:200) were found to be within the range of the assay and were used to 
calculate the amount of MCP-1 (pg/ml) in CM using GraphPad Prism software (Linear 
regression test). The values obtained were multiplied by the dilution factor (150 or 200) 
and divided by the number of the cells from which the CM was extracted (in millions). 
As shown in Figure 4.2, FS188 tumour cells secreted significantly more MCP-1 than 
FS120 tumour cells as established by analysing the values obtained from both dilutions. 
MCP-1 secreted from irradiated FS188 cells significantly increased after 4 days of 
irradiation compared to control un-irradiated FS188 cells in a dose-dependent manner. 
There was no significant induction of MCP-1 production by irradiation in FS120 cells 
although there was a trend for an increase (Figure 4.2).  
One-way ANOVA test followed by Tukey’s multiple comparisons test was used to 
analyse data, and were considered statistically significant when P ≤ 0.05 (* P<0.05, ** 
P<0.01). To compare between two controls groups, unpaired t-test (two-tailed) was 
used. 
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Figure 4.2 MCP-1 proteins production from tumour cells under normal (un-
irradiated) and irradiated conditions.  
The R&D ELISA assay kit for MCP-1 was used to analyse CM from FS120 and 
FS188 cells. The results were obtained from two dilution sets, 1:150 (A) and 1:200 
(B). MCP-1 produced from irradiated FS188 tumour cells increased in a radiation 
dose-dependent manner 4 days after irradiation. Furthermore, FS188 tumour cells 
secreted significantly more MCP-1 than FS120 tumour cells as established using 
both dilutions. One-way ANOVA test followed by Tukey’s multiple comparisons 
test was used to analyse data and unpaired t-test (two-tailed) was used to compare 
between control FS188 cells and control FS120 cells. All data are presented as mean 
± SEM of 3 experiments, each done in duplicate and were considered statistically 
significant when P ≤ 0.05 (* P< 0.05, ** P< 0.01). 
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4.2.3 MCP-1 secreted from tumour cells plays a role in enhancing MSC migration 
toward TME  
 
I hypothesized that the chemokine MCP-1 secreted from tumour cells is a potential 
mediator of MSC migration. In Chapter 3, it was shown that the fibrosis and 
differentiation markers (collagen-I, PDGFR-β, and α-SMA) expressed by MSCs were 
increased after co-culture of MSCs with irradiated tumour cells (especially FS188 cells) 
(Figure 3.5). Additionally, presence of tumour cells (control & irradiated) or their CM 
significantly increased MSC migration (Figure 3.14, & 3.15). Also, I showed that 
migration was significantly enhanced by 20 ng/ml recombinant MCP-1 protein (section 
3.2.4.6). In this chapter, ELISA revealed that radiation significantly increased the 
amount of MCP-1 secreted from irradiated FS188 tumour cells. In the light of that, and 
to determine whether MCP-1 is a potential mediator of Balb/c MSCs migration, MCP-
1 activity was blocked using a neutralizing antibody.  
Serum-free concentrated CM from irradiated tumour cells (FS188 cells & FS 120 cells) 
was used. Before starting the assay, the concentrated CM was tested using western 
blotting to make sure that MCP-1 is present. As the results from ELISA assay showed 
that FS188 tumour cells produce more MCP-1 protein than FS120 tumour cells, 
concentrated CM extracted from FS188 cells were tested only. Using the 24-well plate, 
the following samples were used: 
 Concentrated CM from control Fs188 cells (un-irradiated). 
 Concentrated CM from irradiated Fs188 cells (4 Gy). 
 Concentrated CM from control FS188 cells + non-immune IgG (10 μg/ml). 
 Concentrated CM from irradiated FS188 cells (4 Gy) + non-immune IgG (10 
μg/ml). 
 Concentrated CM from control FS188 cells + anti-MCP-1 antibody (10 μg/ml). 
 Concentrated CM from irradiated FS188 cells (4 Gy) + anti-MCP-1 antibody 
(10 μg/ml). 
 Recombinant MCP-1 in serum-free medium (20 ng/ml). 
 Recombinant MCP-1 in serum-free medium (20 ng/ml) + non-immune IgG (10 
μg/ml). 
 Recombinant MCP-1 in serum-free medium (20 ng/ml) + anti-MCP-1 antibody 
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(10 μg/ml). 
 Control (just serum-free medium). 
Non-immune IgG was used to ensure that the results are specific and not caused by 
non-specific effects on the cells by any immunoglobulin. Neutralizing antibody to 
MCP-1 was used to show that this protein is involved in driving the migration of the 
cells after incubation with CM. The trans-well migration assay was done as previously 
explained (see section 2.2.5.2).  
As shown before (Figure 3.15) there was a significant increase in the Balb/c MSCs 
migration after treatment with concentrated CM from FS188 cells irradiated with 4 Gy 
whether alone or with non-immune IgG compared to CM from un-irradiated tumour 
cells (Figure 4.3). However, blocking the activity of MCP-1 using anti-MCP-1 
antibody (ab203128) prevented the radiation-induced increase in the migration of the 
Balb/c MSCs (Figure 4.3). Likewise, recombinant MCP-1 protein either alone or 
combined with non-immune IgG significantly enhanced the migration of Balb/c MSCs. 
As a control for recombinant MCP-1, its activity was blocked with an anti-MCP-1 
antibody, which resulted in suppression in the migration of MSCs. 
MSCs exposed to concentrated CM from un-irradiated tumour cells significantly 
increased their migration compared with MSCs treated with serum-free medium alone. 
These results agreed with our previous results in which presence of tumour cells or their 
concentrated CM enhanced the migratory ability of Balb/c MSCs (see 3.2.4.2, and 
3.2.4.3). Blocking the activity of MCP-1 had no effect on MSC migration, where cells 
were exposed to CM from un-irradiated tumour cells. These results strongly suggest 
that MCP-1 chemokine secreted from FS188 tumour cells is an important mediator of 
radiation-induced Balb/c MSCs migration toward TME. For statistical analysis, One-
way ANOVA test followed by Tukey’s multiple comparisons test was used to analyse 
data and were considered statistically significant when P ≤ 0.05 (* P<0.05, ** P<0.01, 
*** P< 0.001). 
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Figure 4.3 MCP-1 produced by FS188 cells enhanced Balb/c MSCs migration. 
 A significant increase in the MSCs migration was seen after treatment with 
concentrated CM from FS188 cells irradiated with 4 Gy whether alone or with non-
immune IgG compared to CM from unirradiated tumour cells. However, blocking 
the activity of MCP-1 by anti-MCP-1 antibody produced no increase in the 
migration of the MSCs. Likewise, recombinant MCP-1 protein either alone or 
combined with non-immune IgG significantly enhanced the migration of MSCs. As 
a control for recombinant MCP-1, its activity was blocked with anti-MCP-1 
antibody, which resulted in suppression in the migration of MSCs. Interestingly, 
MSCs exposed to concentrated CM (no radiation) significantly showed migration 
ability more than those treated with free-serum alone.  These results strongly suggest 
that MCP-1 chemokine secreted from FS188 tumour cells is an important mediator 
of Balb/c MSCs migration toward TME and it is significantly increased after 
irradiation. The statistical test was done using One-way ANOVA test followed by 
Tukey’s multiple comparisons test. Unpaired t-test (two-tailed) was used to compare 
the results from concentrated CM from control FS188 cells with serum-free medium 
only. Quantitative data represent mean value ± SEM of 3 experiments, each done in 
duplicates and were considered statistically significant when P ≤ 0.05 (* P< 0.05, 
** P< 0.01, *** P< 0.001, **** P< 0.0001). 
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4.2.4 Radiation effects on the expression of the chemokine receptor CCR2 by 
Balb/c MSCs. 
 
There are many chemokines associated with cancer progression and fibrosis. Among 
them, MCP-1 and its receptor (CCR2) signalling has been recognised as a key player 
in stimulating tumour formation and metastasis (Zhang et al., 2010, Borsig et al., 2014). 
So far, this project has shown that MCP-1 plays an essential role in the increased 
migration of the Balb/c MSCs when exposed to CM from irradiated tumour cells. Here, 
I investigate the effects of radiation (direct & indirect) on the expression of the 
chemokine receptor CCR2 by Balb/c MSCs. Cell lysates from Balb/c MSCs were 
collected from different experimental conditions, 3-4 days after: 
 Direct irradiation of the Balb/c MSCs. 
 Co-culture of Balb/c MSCs with irradiated tumour cells. 
 Incubation of Balb/c MSCs with concentrated CM from irradiated tumour cells. 
Anti-CCR2 antibody (1:1000 concentration) was used. MSCs treated with Balb/c 
medium alone or with no radiation, were regarded as control cells. 
Normalisation was done by dividing the ratio of target protein to internal control (i.e., 
dividing or “normalizing” by the loading control). Western blotting analysis revealed a 
main band present in all samples at ~ 45 kDa, which is the predicted molecular size of 
CCR2. There was no significant increase in the expression of CCR2 in Balb/c MSCs 
exposed to direct irradiation (Figure 4.4, A). In contrast, MSCs co-cultured with FS188 
tumour cells irradiated with 0.5 Gy or their concentrated CM showed a significant 
increase in the expression of CCR2 (Figure 4.4, B & C). On the contrary, there was no 
effect of the irradiated FS120 tumour cells or their concentrated CM on the expression 
of CCR2 by MSCs. One-way ANOVA test followed by Tukey’s multiple comparisons 
test was used to analyse data and were considered statistically significant when P ≤ 
0.05. 
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Figure 4.4 Effects of (A) direct radiation, (B) co-culture with concentrated CM 
from irradiated tumour cells, and (C) co-culture of MSCs with irradiated 
tumour cells on the chemokine receptor CCR2 expressed by Balb/c MSCs.   
Cell lysates from different experiments (A, B and C) were tested for CCR2 using 
western blot technique. Direct irradiation of the Balb/c MSCs did not show an 
increase in the expression of the chemokine receptor CCR2 (A). In contrast, Balb/c 
MSCs co-cultured with FS188 tumour cells irradiated with 0.5 Gy or their 
concentrated CM showed a significant increase in the expression of CCR2 (B & 
C). There was no effect of the FS120 tumour cells or their concentrated CM on the 
expression of CCR2 by Balb/c MSCs. Statistical analysis was done using one-way 
ANOVA test followed by Tukey’s multiple comparisons test. Results expressed as 
means ± SEM of 3 experiments, each done in triplicate and were considered 
statistically significant when P≤ 0.05 (* P<0.05). 
Tubulin 
CCR2 
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4.2.5 Searching for genes that might explain the variations between FS120 and 
FS188 tumours using NGS information. 
 
Tumour samples from an experiment carried out by a post-doctoral scientist, Dr 
Debayan Mukherjee, were used. He injected FS120 and FS188 cells tumour cells 
subcutaneously into separate groups of CD1 nude mice. When the tumours reached 
~1000-1200 mm3, they were excised and frozen. Dr Will English extracted the RNA 
from the un-irradiated tumour sections for sequencing by the NGS service at the 
Sheffield Children's Hospital. Dr James Bradford, carried out the bioinformatics 
analysis.  
Through literature searching, a list of all factors (chemokine receptors & ligands) that 
might be involved in recruitment or differentiation of MSCs to tumours was prepared 
(see chapter one, Table 1.1). Using this list, the NGS database was explored in order 
to find whether gene expression levels of any of these factors was significantly different 
between FS120 and FS188 tumours. The highlighted genes that showed significant 
differences between the two groups are shown in Figure 4.4. The results considered 
statistically significant when P ≤ 0.05. 
Although this project is interested in growth factors MCP-1, TGF-β1, and SDF-1α and 
have shown that they were significantly increased the migration of the MSCs in vitro, 
the NGS results did not show significant differences between FS120 and FS188 
tumours in regard to those factors. 
From the data shown in Figure 4.4, CTGF and TGF-β2 were chosen for further study, 
as both of them play an important role in radiation fibrosis (Hill et al., 2001, Westbury 
et al., 2014, Bonniaud et al., 2004). Thus, CTGF and TGF-β2 were tested in both 
concentrated CM and cell lysates from irradiated tumour cells. The CM was 
concentrated as described in section 2.2.1.7. For western blotting, a 15% SDS-PAGE 
gel was prepared as explained in section 2.2.4.4. Recombinant Human TGF-beta2 
protein was used as a positive control and run at 2 μg/lane and resolved with the gel 
under reducing conditions. Each membrane was blocked by either anti-CTGF antibody 
(ab 6992) or anti-TGF-β2 antibody. Western blotting results from cell lysates were 
normalised by calculating the ratio of target protein to internal control (i.e., dividing or 
“normalizing” by the loading control). 
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The western blot analysis for CTGF showed a significant increase in the expression of 
CTGF for cell lysate samples from FS120 cells versus FS188 cells (unpaired t-test, P = 
0.041) (Figure 4.5, A). This means that FS120 cells produce more CTGF than FS188 
cells. Moreover, irradiation of FS120 cells with 0.5 Gy caused an increase in the 
expression of CTGF in both cell lysates and concentrated CM (One-way ANOVA, 
Tukey’s multiple comparisons test, P = 0.027) (Figure 4.5, A & B). In contrast, there 
was no increase in the expression of CTGF for both concentrated CM and cell lysates 
extracted from irradiated FS188 tumour cells.  
Regarding TGF-β2 expression, as noticed in Figure 4.5 C, TGF-β2 protein is expressed 
at its expected molecular weight size (~50 kDa) for the cell lysate samples. There was 
also a large band running at ~37 kDa, and a very faint lower molecular weight bands at 
~25 kDa. No TGF-β2 was detected in the CM (neat & concentrated) extracted from 
irradiated tumour cells (FS120 and FS188 cells) as shown in Figure 4.5.D whereas the 
positive control (Recombinant Human TGF-beta 2) protein was expressed at its 
molecular size, 13 kDa for the monomer, and 25 kDa for the dimer (Figure 4.5 D).  
Western blot analysis for TGF-β2 was done for the band at ~50 kDa, which is the 
expected molecular size of the target protein. There was no difference in the expression 
of TGF-β2 between FS120 and FS188 cells. In addition, there was no expression of 
TGF-β2 in the concentrated CM extracted from irradiated tumour cells (positive control 
expressed only) (Figure 4.5, D). 
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Figure 4.5 NGS database results for chemokine receptors and ligands 
expressed by control (non-irradiated) mouse fibrosarcoma tumours (FS120 
tumours & FS188 tumours).  
A) Quadruplicate data from NGS analysis of murine fibrosarcoma control sections. 
The genes that showed significant differences between the two tumour types are 
highlighted. The results considered statistically significant when P≤ 0.05. B) CTGF 
and TGF-β2 were examples of two genes that were significantly different between 
FS188 and FS120 tumours values from the RNAseq analysis are plotted for 
comparison (B). 
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Figure 4.6 Expressions of CTGF, and TGF-β2 proteins in the concentrated CM 
and cell lysates obtained from irradiated tumour cells.  
The expression of the CTGF protein is significantly increased in the cell lysates 
from FS120 cells versus from FS188 cells (un-paired t-test, P = 0.041) (A). 
Moreover, the expression of the CTGF protein (cell lysates & concentrated CM) is 
significantly increased after irradiation of the FS120 cells with 0.5 Gy (One-way 
ANOVA, Tukey’s multiple comparisons test, P = 0.027) (A & B). On the other 
hand, TGF-β2 was expressed in the cell lysates extracted from FS188 cells and 
FS120 cells (no differences between the two groups) (C). No expression of the TGF-
β2 in the concentrated CM extracted from irradiated tumour cells (positive control 
expressed only) (D). TGF-β2 antibody detected in the cell lysate samples showed a 
big band at ~37 kDa, in cell lysates as well as very faint lower molecular weight 
bands at ~25 kDa. Western blot analysis was done for TGF-β2 band at ~50 kDa (real 
molecular weight). One-way ANOVA test followed by Tukey’s multiple 
comparisons test was done to analyse data from each group individually. While 
unpaired, two-tailed t-test was used to analyse two control groups (control FS12, 
and control FS188). Results expressed as means ± SEM of 3 experiments, each done 
in triplicate and were considered statistically significant when P ≤0.05. 
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4.3 Summary of results 
 
Radiation up-regulated the expression and secretion of cytokines and chemokines 
(TGF-β1, MCP-1, and SDF-1α) by fibrosarcoma cells. This up-regulation of MCP-1 
and its ability to enhance the migration of MSCs (as previously shown) was followed 
by a study of the expression of its receptor (CCR2) by MSCs. CCR2 expression by 
Balb/c MSCs was increased significantly after exposure to FS188 tumour cells 
irradiated by 0.5 Gy or their concentrated CM. While exposure of MSCs to FS120 
tumour cells or their concentrated CM did not show any significant changes in the 
CCR2 expression.  
Because of potential differences in the ability of FS120 and FS188 cell to enhance the 
migration of MSCs, data obtained from a previous study involving RNA sequencing of 
FS 120 and FS188 solid tumours was analysed further.  NGS analysis was done using 
control unirradiated tumours from in vivo experiment. The NGS analysis showed 
significant differences in the expressions of certain genes (chemokine receptors & 
ligands) between FS120 and FS188 tumour sections. The expression of CTGF and 
TGF-β2 were studied in cell lysates and concentrated CM from irradiated tumour cells. 
CTGF protein levels were higher in the extracts and CM from FS120 cells versus FS188 
cells. These results are in the agreement with the NGS database results for gene 
expression in un-irradiated solid tumours. On the other hand, the TGF-β2 protein was 
expressed in cell lysates of both FS188 and FS120 tumour cells at similar levels, with 
no expression in their CM, as assessed by western blotting. In order to quantify the 
amount of the MCP-1 protein secreted from tumour cells in their CM, an ELISA assay 
was used. The results showed that FS188 tumour cells secreted significantly more 
MCP-1 protein than FS120 cells. Likewise, irradiation of the FS188 tumour cells 
increased the secretion of MCP-1 in a dose-dependent manner. Finally, the migration 
assay using blocking antibodies suggested that MCP-1 chemokine secreted from 
tumour cells (especially FS188 cells) is an important factor that facilitates radiation-
induced MSC migration toward TME. 
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4.4 Discussion 
 
In the previous chapter, it was successfully shown on the basis of western blotting 
analysis, that irradiation modifies the secreted factor(s) produced from tumour cells that 
caused an increase in the expression of CAF-like differentiation factors expressed by 
Balb/c MSCs. It was also seen, in vitro, that Balb/c MSCs display a particular tendency 
to migrate after exposure to irradiated tumour cells or their concentrated CM (Figure 
3.14, and 3.15). Moreover, this Balb/c MSCs migration mediated by paracrine factors 
secreted by irradiated tumour cells.  
It has long been thought that radiation causes tissue injury and subsequent local 
inflammation. As a consequence of radiation-responding inflammation, a number of 
paracrine mediators including inflammatory cytokines secreted from fibroblasts, 
macrophages, and epithelial cells are up-regulated (Chen et al., 2002). It has been 
shown that the level of serum cytokines and their receptors (TNF-, IL-6, IL-8, VEGF, 
M-CSF and bFGF) were elevated in STS patients compared to healthy controls 
(Rutkowski et al., 2002). The next step was to study whether irradiation of fibrosarcoma 
cells could modify the expression/secretion of paracrine factors such as MCP-1, TGF-
β1, and SDF-1α in their CM. To investigate that, these cytokines were first analysed in 
the CM from control and irradiated tumour cells using a western blotting technique. 
The results showed that the expression of MCP-1, TGF-β1, and SDF-1α was increased 
significantly in the concentrated CM of irradiated tumour cells in a radiation dose-
dependent manner (Figure 4.1). However, the amount of these factors was undetected 
in the neat CM possibly due to their low levels.  
In the previous chapter (see section 3.2.4.6), it was demonstrated that after 16 hours 
treatment of Balb/c MSCs either with MCP-1, or TGF-β1 or SDF-1α their migration 
abilities significantly increased compared to control (Figure 3.18). Because many 
studies have already been performed on TGF-β1 and its role in recruitment/ 
differentiation of MSC, MCP-1 cytokine was chosen to study further here. MCP-1 
protein is expressed and upregulated in CAFs (Li et al., 2014). Furthermore, studies 
showed that MCP-1 expressed by human ovarian cancer cells (Furukawa et al., 2013) 
and by human endometrial cancer cells and affect their treatment with chemotherapy 
(Wang et al., 2006). Recently, it has been shown that MCP-1 is upregulated in triple-
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negative breast cancer cells with enhanced its metastasis and invasiveness (Dutta et al., 
2018). Moreover, the role of MCP-1 in fibrosis and recruitment of MSC to the site of 
injury is still controversy; some studies support its role in recruitment of MSCs while 
others not (Tokuda et al., 2000, Anders et al., 2002, Moore et al., 2001, Ringe et al., 
2007, Takano et al., 2014). 
Many methods are available to detect and quantify the amount of the MCP-1 chemokine 
secreted from tumour cells in response to radiation such as ELISA (sandwich), cytokine 
bead arrays and microarrays, antibody array and flow-cytometry. ELISA (sandwich) 
was chosen because it is a reliable, less expensive, colorimetric method that requires 
less time to set up and optimize than some other methods. ELISA results showed that 
the secretion of MCP-1 chemokine by tumour cells increased significantly after 4 days 
of irradiation. Moreover, ELISA assays revealed that the increase in the secretion of 
MCP-1 chemokine was in a radiation dose-dependent manner (Figure 4.2). This dose-
dependent increase in the amount of MCP-1 chemokine was only with the CM from 
irradiated FS188 tumour cells and not FS120 tumour cells (although there was a 
tendency to increase in the amount of MCP-1).  
These results are different from the data obtained from the western blotting analysis in 
which both tumour cell types were shown to produce MCP-1 cytokine to similar levels 
and increased in a radiation dose-dependent manner (Figure 4.1). Proteins in the 
western blot methods are denatured using SDS-PAGE, while in ELISA, the proteins in 
its native form. This big difference in the amount of MCP-1 measured by the above two 
methods could be due to the sensitivity of ELISA assays in quantification of proteins 
compared to the western blot. Also, for ELISA, a neat non-concentrated CM was used 
while in the western blot, a concentrated CM was used, so it is possible that proteins 
were lost or degraded during the concentration of the CM.  Our previous results showed 
an enhancement of MSC migration in a radiation-dependent manner after treatment 
with cell lysates or CM from control and irradiated tumour cells (Figure 3.14, and 3.15). 
This dose-dependent increase in MCP-1 levels in the CM from FS188 cells might 
explain the ability of these cells to recruite more α-SMA positive cells (CAFs) than 
FS120 cells (Tozer et al., 2008). Moreover, the differences between the two-
fibrosarcoma isoforms, FS188 and FS120, might explain this, independent of radiation.  
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CAFs are responsible for the synthesis of ECM components like collagen (Bentzen, 
2006) and MCP-1 was shown to be expressed and upregulated in CAFs (Li et al., 2014). 
ELISA confirmed that tumour cells secrete MCP-1 in response to irradiation. As shown 
in chapter three, MCP-1 caused migration of MSCs in vitro (see section 3.2.4.6). 
Moreover, it has been shown that inhibition of MCP-1 caused a decrease in the 
migration of MSCs (Ren et al., 2012, De Becker and Van Riet, 2016). To address this 
issue, migration assays were done using a blocking MCP-1 antibody in order to 
establish whether it is the potential mediator of Balb/c MSCs migration or not. The 
same time scale that was used before (see section 3.2.4.6) were used for incubation (16 
hours). As ELISA assays showed that FS188 produce more MCP-1 than FS120 tumour 
cells, concentrated CM from FS188 was tested. The results showed that the anti-MCP-
1 antibody significantly suppressed Balb/c MSCs migration and suggest that MCP-1 is 
potentially a major chemokine that caused the migration of MSCs in the co-culture 
systems that were used in this study. These results (Figure 4.3) supported the results 
obtained from the migration assay that was done before (see section 3.2.4.2, and 3.2.4.3) 
in which presence of the tumour cells or their CM cause a significant increase in the 
migration of MSCs compared with using serum-free medium alone. To establish the 
differences between FS188 and FS120 tumour cells, blocking the activity of MCP-1 
using concentrated CM from FS120 needs to be done in the future. Moreover, it has 
been shown, in chapter three, that TGF- and SDF-1 also enhanced the migration of 
MSCs significantly. Therefore, the next step was to test both TGF- and SDF-1 
using the migration assay with blocking antibody and if they show significant effects, 
ELISA assays would be the next step. This work will be done in the future to establish 
the differences between the two fibrosarcoma tumour cells in vitro and whether MCP-
1, TGF- or SDF-1play a role in the migration/recruitment of MSCs. 
Because chemotaxis involves the release of signals or chemokines recognised by 
receptors expressed on the migrating cells, and as it was established in this chapter that 
tumour cells up-regulated MCP-1 chemokine signalling in their concentrated CM in 
response to radiation, it was important to establish whether MCP-1 receptor (CCR2) 
was also expressed by the MSCs cells. It has been shown that CCL2-CCR2 signalling 
plays an important role in cancer progression, fibrosis and metastasis (Zhang et al., 
2010, Borsig et al., 2014). In this chapter, it established that treatment of Balb/c MSCs 
with either irradiated FS188 tumour cells (0.5 Gy) or their concentrated CM cause a 
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significant increase in the expression of the CCR2 by Balb/c MSCs. These results are 
in agreement with Klopp et al and Connolly et al, who showed that chemokine receptor 
CCR2 was expressed by MSCs and its levels of expression increased after irradiation 
(Klopp et al., 2007, Connolly et al., 2016). These finding could indicate that after 
irradiation, the tumour cells secrete MCP-1 cytokine that leads to up-regulation of its 
receptor (CCR2) on MSC, and eventually cause recruitment of the MSC to the MCP-1 
ligand-bearing tumour. To prove that, migration assay using anti-CCR2 antibody needs 
to be done to see whether that blocking of CCR2 will suppress MSCs migration after 
irradiation in vitro. Inflammatory cytokines like TNF-, and other growth factors 
secreted by tumour cells can also up-regulate CCR2 (Ringe et al., 2007, Ponte et al., 
2007). 
NGS analysis was done using control unirradiated tumours from in vivo experiment 
done by Dr Mukherjee (as discussed in chapter 2). The NGS analysis showed 
significant differences in the expressions of certain genes (chemokine receptors & 
ligands) between FS120 and FS188 tumour sections. Multiple studies have shown that 
CTGF and TGF-β2 play an important role in radiation fibrosis (Hill et al., 2001, 
Westbury et al., 2014, Bonniaud et al., 2004, Ihn, 2002). Moreover, the fibrotic activity 
of TGF-β depends on the CTGF activities (Mori et al., 1999, Liu et al., 2013, Parada et 
al., 2013). Recently, it has been shown that blockage of the CTGF activities can reverse 
the fibrotic process in the lungs (Bickelhaupt et al., 2017). In the light of that, I decided 
to study the expression of CTGF and TGF-β2 in cell lysates and concentrated CM from 
irradiated tumour cells. Although the results were against what expected (FS188 cells 
produce more CTGF), it was in agreement with the NGS data analysis, in which the 
expression of CTGF was greater in FS120 cells than FS188 cells.  
Comparing our results with previous results, Tozer et al showed that FS188 tumours 
produce more α-SMA positive cells (more fibrotic) than FS120 tumours in vivo (Tozer 
et al., 2008). However, in vitro results in this work were controversial. This project 
showed, using ELISA, that FS188 produce more MCP-1 than FS120 tumour cells. 
However, in contrast, it is shown in this work that FS120 secreted more CTGF than 
FS188 cells. Furthermore, NGS data showed complex differences between FS188 and 
FS120 tumours, and the ability of fibrosarcoma tumours to recruit CAF-like cells and 
pericytes depends not only on one factor, but it is a combination of many factors such 
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as TGF- and SDF-1. Many studies showed that tumour cells growth, migration and 
metastasis depends mainly on cross-talk between tumour cells and local TME which is 
more complex in vivo than in in vitro models (Chambers et al., 2002, Fidler, 2003, 
Steeg, 2006, Wirtz et al., 2011).  
On the other hand, TGF-β2 was expressed in the cell lysates from both tumour cells, 
with no radiation modification of its expression (Figure 4.5). There was no expression 
of TGF-β2 in the CM (neat or concentrated), although the positive control (recombinant 
human TGF-β2 protein) was detected at its correct molecular size, 13 kDa for the 
monomer, and 25 kDa for dimer (Figure 4.5 D). This might be either because the TGF-
β2 isoform is secreted as a latent precursor large molecule (Roberts, 1998) or it was 
cleaved by ionising radiation. 
In summary, this work found that MCP-1 chemokine and its receptor CCR2 play a key 
role in the recruitment of Balb/c MSCs toward the irradiated tumour environment, with 
a dose-dependent manner, as the MCP-1 amount was increased. Moreover, this work 
also demonstrated that CTGF secretion from FS120 tumour cells was more than FS188 
tumour cells in vitro. In the next chapter, staining and analysing of the fibrosarcoma 
tumour sections from an in vivo experiment for fibrosis markers was done and analysed. 
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CHAPTER FIVE: 
In vivo fibrosarcoma model 
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5.1 Introduction & aims 
 
In the previous work, it was shown that radiation significantly increased the expression 
of differentiation markers in Balb/c MSCs in vitro such as collagen-I, fibronectin, 
PDGFR-β, and α-SMA suggesting that the cells were induced to acquire CAF-like 
characteristics. ELISA assay showed that FS188 tumour cells secreted more MCP-1 
protein than FS120 cells. Likewise, irradiation of the FS188 tumour cells increased the 
secretion of MCP-1 in a dose-dependent manner. It was also shown that MCP-1 induced 
migration of MSCs toward tumour cells in vitro.  As detailed in chapter one, CAFs are 
the primary source of ECM proteins such as collagen and fibronectin in TME. So, it 
was important to investigate levels of CAFs within FS188 and FS120 tumours in vivo 
and the response to irradiation. 
Paraffin-embedded and frozen tumour sections (control and irradiated) from an 
experiment done by a post-doctoral scientist, Dr Debayan Mukherjee were used. 
Immunohistochemical staining for α-SMA, as a marker for CAF-like cells, was carried 
out in paraffin-embedded tumour sections. Masson’s trichrome staining, originally used 
in smooth muscle tissue (Puchtler and Isler, 1958), was used to detect collagen fibres 
within tumour sections. Masson’s trichrome staining is still used to detect collagen 
fibres in cardiac, renal, and liver fibrosis (de Jong et al., 2012, Zhou et al., 2013, Lo 
and Kim, 2017).  
Analysis of Massson’s staining in images of tumour sections was done using 
Imagescope and HistoQuest software after scanning of the slides with a TissueGnostics 
confocal slide scanner. Many studies have used Imagescope or HistoQuest to quantify 
tissue injury and inflammation (Daunoravicius et al., 2014, Hernandez-Morera et al., 
2016, Vranceanu et al., 2014, Chen et al., 2016). In this chapter, immunofluorescent 
staining with CD31 and α-SMA was used to study radiation effects on the TME. 
Moreover, vascular staining with CD31 enabled us to study vascular differences 
between two tumour types expressing single isoforms of VEGF (FS188 and FS120 
tumours) and to identify whether radiation increased ECM produced from CAF-like 
cells (α-SMA staining).  
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Accordingly, the aims of this chapter were to: 
- Analyse α-SMA expression within control and irradiated paraffin-embedded 
mouse fibrosarcoma tumour sections using immunohistochemistry to see 
whether radiation enhances the CAF-like cells and if there are any differences 
in the α-SMA expression between FS188 and FS120 tumours. 
- Establish whether radiation modifies the expression of collagen in both FS120 
and FS188 tumours using Masson’s trichrome staining on paraffin tumour 
sections. 
- Identify any differences in vasculature and ECM contents post-irradiation 
between FS120 and FS188 tumours in vivo that could explain their abilities to 
recruit MSCs using immunofluorescent staining with CD31 and α-SMA for 
frozen tumour sections. 
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5.2 Results 
5.2.1 Immunohistochemical staining of fibrosarcoma tumour sections 
 
In the previous chapters, the results from in vitro experiments verified that irradiation 
of the tumour cells caused them to secrete factor(s) that enhanced the migration of the 
Balb/c MSCs. Moreover, it was shown that irradiation (indirectly) increased the CAF-
like differentiation markers expressed by Balb/c MSCs. The aim of this experiment was 
to study the radiation effects on the recruitment of CAF-like cells in fibrosarcomas, 
using expression of α-SMA. As discussed in chapter two section 2.2.7, Dr Debayan 
Mukherjee performed the in vivo experiments and Mrs Maggie Glover provided 
formalin-fixed, paraffin-embedded tumour sections, while Mr Matthew Fisher prepared 
frozen tumour sections. 
Mr Matthew Fisher provided the original IHC protocol. Formalin-fixed and paraffin-
embedded fibrosarcoma sections were deparaffinised and rehydrated as discussed in 
chapter two, section 2.2.7.1. Randomly assigned fields were chosen with different 
magnifications (10X and 20X objectives) and captured using a Nikon microscope 
(Nikon Optiphot-2). A positive reaction for α-SMA was observed, but unfortunately, 
there was a lot of background, which made identification of truly α-SMA positive cells 
difficult. In order to decrease the background (Menon and Fisher, 2015), the followings 
were done: 
 Increased the incubation period with IgG blocking from 60 minutes to 90 
minutes at room temperature. 
 Decreased the concentration of primary antibody (α-SMA) from 1:10,000 to 1: 
20,000. 
 Decreased the concentration of secondary antibody (biotinylated anti-mouse 
IgG) from 1:250 to 1:300 and 1:350. 
 Increased washing time with PBS and decreased incubation with DAB staining. 
However, the background staining did not disappear. 
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Figure 5.1 α-SMA distributions within irradiated and un-irradiated 
fibrosarcoma tumour sections.   
FS120 and FS188 tumour cells were implanted subcutaneously into CD1 nude mice. 
Once tumours had grown to ~100 mm3
 
in diameter, they were irradiated in situ with 
20 Gy over 4 days (8 X 2.5 Gy fractions). Tumours were excised when they reached 
~1000-1200 mm3, and were embedded in paraffin, sectioned and stained for α-SMA. 
Random fields were chosen with different magnifications (10X and 20X objectives) 
using a Nikon microscope. A positive reaction for α-SMA was observed. Stromal 
spindle cells, which were positive for α-SMA, were regarded as CAF-like cells 
(yellow arrows). Perivascular cells positively reacted α-SMA were regarded as 
pericytes (white arrow). Unfortunately, there was a lot of background for most of 
the slides, which made identification of α-SMA positive cells difficult.  
 
 
 
Figure 5.2 α-SMA distributions within irradiated and un-irradiated 
fibrosarcoma tumour sections.   
FS120 and FS188 tumour cells were implanted subcutaneously into CD1 nude mice. 
Once tumours had grown to ~100 mm3
 
in diameter, they were irradiated in situ with 
20 Gy over 4 days (8 X 2.5 Gy fractions). Tumours were excised when they reached 
~1000-1200 mm3, and were embedded in paraffin, sectioned and stained for α-SMA. 
Random fields were chosen with different magnifications (10X and 20X objectives) 
using a Nikon microscope. A positive reaction for α-SMA was observed. Stromal 
spindle cells, which were positive for α-SMA, were regarded as CAF-like cells 
(yellow arrows). Perivascular cells positively reacted α-SMA were regarded as 
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5.2.2 Collagen staining (Masson’s trichrome staining) of paraffin-embedded 
fibrosarcoma tumour sections 
 
This technique detects collagen fibres tissues and it consists of three-colour staining, 
dark brown-black for cell nuclei, orange-red for cytoplasm, and green-blue for collagen 
(Puchtler and Isler, 1958). Through this triple staining, Masson’s can provide a clear 
morphology of stroma (normal and reactive). To measure collagen deposition/fibrosis 
within the tissues, FS120 and FS188 paraffin tumour sections were de-waxed, fixed, 
and stained as explained in Chapter two, section 2.2.7.2. The stain worked well after 
optimising the protocol (Figure 5.2). 
The ways of analysis of images from Masson’s trichrome staining was described in 
chapter two (section 2.2.7.2) using both, Aperio Imagescope and HistoQuest software 
analysis system V 4.0. 
The difference in percentage collagen staining areas between viable and necrotic areas 
within the control and irradiated tumour sections is shown in Figure 5.3. The results 
revealed that there was a significant increase in the average collagen positivity areas 
within the viable regions after irradiation of the tumours in vivo (FS188 & FS120 
tumours) (Figure 5.3 A). Moreover, within the necrotic areas, the percentage area 
stained positive for collagen was significantly higher in the irradiated FS188 tumours 
compared to control (un-irradiated) tumours (Figure 5.3 B). There were no significant 
differences in collagen staining between FS188 and FS120 tumours, although there was 
a tendency for it to be higher in FS188 tumours for both unirradiated and irradiated 
tumours.  
To analyse data, one-way ANOVA test followed by Tukey’s multiple comparisons test 
was used. Results expressed as means ± SEM and were considered statistically 
significant when P ≤ 0.05. 
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Figure 5.2 Masson’s trichrome staining for paraffin-embedded fibrosarcoma 
tumour sections (irradiated FS188 tumour) showing collagen deposition 
(magnification A- 10X and B- 20X).  
Note that green-blue fine and coarse fibres represent collagen, which is clearly 
visible. Abundant amount of collagen surrounding blood vessels (arrow). 
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Figure 5.3 Differences in collagen staining (Masson’s trichrome) within viable 
and necrotic regions of control and irradiated fibrosarcoma FS188 and FS120 
the section established using Aperio ImageScope software.  
Eight images were taken from each stained tumour section (16 tumour sections were 
used) using a 10X objective and a Nikon microscope (Nikon Optiphot-2). Collagen 
stained areas were significantly increased within the viable regions of the tumours 
(FS188 & FS120 tumours) after irradiation compared to control areas (non-
irradiated) (A). Likewise, the collagen stained areas were significantly increased 
within the necrotic areas in the irradiated FS188 tumour sections compared to 
control (un-irradiated) areas of the tumour (B). The positivity was calculated by 
summation of all the positive areas (weak positive + positive + strong positive) then 
divided by the total area (all positive areas + negative areas). The percentage of 
positivity was estimated by multiplying positivity by 100. One-way ANOVA test 
followed by Tukey’s multiple comparisons test was used for data analysis. Results 
expressed as means ± SEM, and were considered statistically significant when P ≤ 
0.05. 
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The second method used to analyse Masson’s trichrome staining in paraffin sections 
was by scanning sections with the TissueGnostics Confocal Slide scanner (TISSUE 
FAX 200, Tissue Gnostics Vienna, Austria) (see Chapter two, Figure 2.13 and 2.14) 
and using HistoQuest software analysis system V4.0.  
By HistoQuest software, 38 stained tumour-sections were analyzed (10 sections for 
control FS188, 10 sections for control FS120, 9 sections for irradiated FS188, and 9 
sections for irradiated FS120 tumours). Radiation significantly increased the collagen 
content of the FS188 tumours and FS120 tumours (Figure 5.4). Furthermore, there was 
more collagen within the control (non-irradiated) FS188 tumours than within control 
FS120 tumours (A, B & C).  Irradiated FS188 tumours showed more collagen 
percentage than irradiated FS120 tumours in both, viable and necrotic areas (Figure 
5.4, A, B and C). One-way ANOVA test followed by Tukey’s multiple comparisons test 
was used to analyse the data.   
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Figure 5.4 Percentage of collagen staining (Masson’s trichrome) within the 
viable and necrotic regions of the paraffin embedded fibrosarcoma tumour 
sections using HistoQuest software analysis system.  
Thirty-eight stained tumours sections (10 sections for control FS188, 10 sections for 
control FS120, 9 sections for irradiated FS188, and 9 sections for irradiated FS120 
tumours) were analyzed using HistoQuest software. The graphs showed the 
percentage of green stained (collagen) areas within viable regions of the tumour (A), 
within necrotic regions (B) and as a fraction of the total tumour area (C). Radiation 
caused a significant increase in collagen for both FS188 tumours and FS120 
tumours. Furthermore, the percentage of collagen content within the control (non-
irradiated) FS188 tumours was more than within control FS120 tumours (A, B & 
C). There was a significant difference between irradiated FS188 and irradiated 
FS120 (more collagen content within irradiated FS188). One-way ANOVA test 
followed by Tukey’s multiple comparisons test was used to analyse data.  Results 
expressed as means ± SEM and were significant when P≤0.05 (* P≤0.05, ** P≤0.01, 
*** P≤0.001). 
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5.2.3 Immunofluorescence staining of frozen fibrosarcoma tumour sections using 
CD31 & α-SMA  
 
Frozen tumour sections (see section 2.2.7) were provided by Mr Matthew Fisher. The 
tumour sections were dried at room temperature, fixed and stained for 
immunofluorescence as discussed previously (see section 2.2.7.3). Slides were 
visualised using an Olympus BX61 microscope that has an Olympus laser-based 
autofocus unit (Figure 5.5). First, areas with high cell density were identified under 
bright field. Then, sections were observed using microscope filters of different 
excitation and emission wavelengths to detect DAPI stained nuclei (excitation 350/50 
and emission 460/50 nm), FITC for CD31 (excitation 470/40 and emission 620/60 nm), 
and TX-RED filter for α-SMA (excitation 545/30 and emission 525/50 nm). Fourteen 
tumour sections were stained (3 FS188 control, 2 FS120 control, 4 FS188 irradiated, 
and 5 FS120 irradiated), and eight images were taken per each tumour section. CD31-
positive cells represent endothelial cells. The red colour α-SMA-positive cells either 
represent CAF-like cells if they were within the stroma or pericytes if surrounding the 
blood vessels. Images from each tumour are shown in Figure 5.6. Because of time 
issues and problems with scanning the slides, quantification of staining was not possible. 
Instead, subjective visual assessment of α-SMA and CD31 positivity was performed.  
Images were processed and merged using Adobe Photoshop CS6 software.  
 
 
 
 
 
 
 
 
Figure 5.5 Olympus BX61 microscope used to visualise IF slides 
 
ig re 5.5 ly s 61 icrosco e se  to vis alise I  sli es 
 
                                                                                              
 
182 
 
On observation, it appeared that irradiated FS188 and FS120 tumours had an abundance 
of pericytes and CAFs. In some tumour sections, numerous CAFs were located around 
the tumour edges (tumours 4, 6, and 10). CD31 staining in all tumour sections shows 
that all tumours were well vascularised (especially FS188 tumours). Because of the 
small number of tumours that were included in this analysis it is not possible to say 
whether irradiation caused any changes in α-SMA-stained cells or blood vessels, 
although in irradiated tumours perivascular α-SMA stained cells (pericytes) appeared 
particularly abundant (see tumour 4, 5, 6, 10, and 13). 
More tumour sections need to be stained and analysed with specific quantification of 
blood vessels and α-SMA stained cells to establish if radiation recruited CAFs and 
pericytes to these tumours. 
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Figure 5.6 Immunofluorescence staining for mouse fibrosarcoma frozen 
tumour sections (control and irradiated) using CD31, and α-SMA stain.  
Blood vessels were stained for CD31 (green), CAFs or pericytes were stained for α-
SMA (red), and nuclei stained with DAPI (blue). In some but not all tumour sections 
we can see that irradiated FS188 tumors expressed more α-SMA than irradiated 
FS120 tumor sections, some of which were associated with CD31-positive blood 
vessels (see tumour sections 4, 5, and 6). Moreover, irradiation of FS188 and FS120 
tumours appeared to increase the number of pericytes and CAF-like cells in the 
tumours. Radiation seems to enhance the perivascular pericytes cells especially in 
FS188 tumours compared to FS120 tumours (see tumour sections 4, 5, 6, 10, and 
13). 
               Represent pericytes, and                 represent CAF-like cells. 
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5.3 Summary of the results 
 
After showing in vitro that radiation enhanced MSC migration and their differentiation 
into CAF-like cells, it was important to study these radiation effects in vivo. Paraffin 
tumour sections were stained for Masson’s trichrome staining while frozen tumour 
sections were stained for immunofluorescence with CD31 and α-SMA. Results from 
analysis of the stained images showed that radiation enhanced collagen content within 
viable and necrotic areas of the tumours. In addition, collagen content within irradiated 
FS188 was more than within FS120 tumours. Unfortunately, results from 
immunofluorescence staining were inconclusive, although they were suggestive of an 
increase in CAF-like and pericyte-like cells post-irradiation in both tumour types.  
5.4 Discussion 
 
It has been observed in previous chapters that radiation caused differentiation of MSCs 
into CAF-like cells in vitro in response to growth factors secreted by tumour cells. 
Furthermore, FS188 tumour cells secreted more MCP-1 than FS120 cells which were 
responsible for migration of MSCs toward TME in vitro.  MCP-1 has been shown to 
cause expression of collagen through enhancing TGF-β1 or IL-4 endogenous signalling 
(Distler et al., 2006). 
In order to confirm that radiation could modify TME and increase ECM protein 
deposition within the tumour-stromal tissue, paraffin and frozen tumour sections from 
an in vivo experiment were stained and analysed for ECM protein. Since the most 
common marker used to detect CAFs is α-SMA (Park et al., 1999, Sugimoto et al., 2006, 
Kim et al., 2015), IHC staining for α-SMA was performed for paraffin tumour sections. 
Unfortunately, although some slides showed a positive reaction to staining, there was a 
lot of background for most of the slides. Efforts were made to decrease the background 
but failed (see section 5.2.1). One explanation for this background could be because 
the tumours were excised from mice that have been treated with lectin and 
pimonidazole (as a marker for hypoxia).  
As a suggestion from Dr William English, a research fellow, I asked Mr Matthew Fisher, 
our technician, to optimise the protocol for future use by pre-adsorbing the secondary 
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antibody with mouse serum. Although other members of the team tested this, again the 
problem was not resolved and the background remained.  
As previously reported, many types of collagen are present in fibrotic conditions that 
make their quantifications difficult by immunohistochemical staining (Katsuda et al., 
1992, Mostaco-Guidolin et al., 2013). Therefore, staining that works for different 
collagen types, namely Masson’s trichrome were used. Masson’s trichrome staining 
was used to stain perivascular and interstitial collagen within fibrosarcoma tumours. 
The protocol was optimised until clear staining was achieved (see Figure 5.2). The key 
steps were, firstly, to use Weigert’s iron haematoxylin staining instead of Mayer’s 
haematoxylin (advice from colleagues on the ResearchGate website), in which 
Weigert’s has iron that is mordant and resistant to acid. Secondly, to decrease the 
incubation time with phosphomolybdic acid-phosphotungstic acid to 2 minutes insteade 
of 5 minutes. Many studies have used this staining technique to detect collagen fibres 
in fibrotic conditions such as liver, renal or cardiac fibrosis (Lo and Kim, 2017, Zhou 
et al., 2013, de Jong et al., 2012).  
The difficulty in analysing or quantification tissues stained with Masson’s trichrome 
stain is due to three colours of the stain that co-localise or overlap to the same areas 
(Miot and Brianezi, 2010). An Aperio Imagescope and HistoQuest software were used 
to analyse images of tumour sections stained with Masson’s trichrome. The results are 
in the agreement with our previous results in vitro in which radiation significantly 
increased the expression of ECM proteins such as collagen and fibronectin by MSCs 
(see chapter 3). The high collagen contents of FS188 tumours compared to FS120 
reflect the ECM differences between the two tumours in vivo, which could be due to 
the ability of this tumour to recruit more CAF-like cells than FS120 tumours (Tozer et 
al., 2008, Kalluri and Zeisberg, 2006). This result, also supports a recent study by 
English et al showed that FS188 tumour expressed more collagen-I compared to FS120 
tumours, both in vitro and in vivo while it was the reverse for laminin (English et al., 
2017). 
Failure to quantify α-SMA staining due to background staining led to testing an 
immunofluorescence method on frozen sections. To examine FS188 and FS120 
tumours for vascularity differences and distribution of CAF-like cells (α-SMA +ve 
cells), immunofluorescent staining with CD31 and α-SMA was done. Dual staining for 
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both CD31 and α-SMA indicated the presence of pericyte-like cells. No cross-reactivity 
with primary antibody occurred; otherwise, the whole tissue would have stained with 
each antibody. Presence of dim red fluorescence in certain tumour sections could be 
due to poor washing after incubation with the secondary antibody. Although the plan 
was to scan the stained slides and quantify images, time constraints and problems with 
some slides breaking during scanning meant that images could only be assessed by eye. 
However, the results were in agreement with the Masson’s trichrome staining results, 
in which radiation increased the deposition of α-SMA positive cells (CAF-like cells) in 
the tumour stroma. IF staining showed, in both tumour types, that α-SMA positive cells 
lining blood vessels (pericytes) was more intense with FS188 tumours than with FS120 
tumours (Figure 5.6, tumours 2, 3, 4, 6, 9,13). This was also in agreement with the 
English et al study, where IF for laminin staining was more intense for FS188 tumours 
than for FS120 tumours regarding α-SMA positive cells lining blood vessels (pericytes) 
(English et al., 2017). For future work, using different markers for ECM protein 
expression like laminin, FSP-1 and FAB-α is mandatory as recently Dr English showed 
that both fibrosarcoma tumours expressed α-SMA (unpublished data). This could be 
also a cause for background staining of α-SMA in IHC for tumour sections done in this 
project. 
In summary, our results represent progress in understanding the role of radiation in 
mouse fibrosarcoma tumours that expressed VEGF 120, and VEGF 188. This study 
was able to show that FS188 tumours expressed more CAF-like cells than FS120 
tumours in vivo using different laboratory techniques. Furthermore, our results suggest 
that radiation increased the ECM content of fibrosarcoma tumours significantly. This 
result has an important impact on the future treatment outcome of sarcoma with anti-
VEGF drugs as presence of CAF-like cells lead to fibrosis and make vessels 
impermeable to macromolecules and resistant to further treatment with drugs and 
chemotherapy. Furthermore, these results suggest that blocking CCR2, a receptor for 
MCP-1 expressed on the MSCs could decrease the recruitment and/ or differentiation 
of MSCs into CAF-like cells that cause fibrosis and make the tumour more aggressive. 
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CHAPTER SIX: 
General discussion, future work and conclusion 
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Table 6.1 Outline of the approach used in this PhD. study with the limitations 
and future work. 
 
 
Laboratory 
techniques 
Aim cells Limitation and future 
work 
Clonogenic 
assay 
-To select an 
appropriate 
radiation doses for 
the cells. 
-Tumour cells  
-MSCs 
- To do it for endothelial 
cells (HDMEC) 
-Do it in hypoxic 
condition. 
Western 
blotting 
-To study CAFs 
differentiation 
markers expressed 
by MSCs 3-4 days 
after irradiation. 
-Tumour cells 
-MSCs 
-Endothelial 
cells 
- Tumour cells + 
endothelial cells 
-To increase the time 
post irradiation. 
-Culture same numbers 
of tumour cells and 
endothelial cells for co-
culture assay to exactly 
study their cytokines and 
chemokines secretion in 
response to radiation. 
-To repeate experiment 
in hypoxic condition. 
Transwell 
migration 
assay 
-To study whether 
direct or indirect 
radiation cause 
recruitment of the 
MSCs. 
-Tumour cells 
-MSCs 
-Endothelial 
cells 
- Tumour cells + 
endothelial cells 
- To study why C3H10 
did not cause migration 
as Balb/c did. 
ELISA -To detect and 
quantify mouse 
MCP-1 chemokine 
in the serum-free 
- Serum-free CM 
from both, 
control (un-
irradiated) and 
-To test other cytokines 
and chemokines such as, 
SDF-1α and TGF-β1 in 
the serum-free CM from 
irradiated tumour cells.  
In vitro 
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CM from irradiated 
tumour cells. 
irradiated FS188 
and FS120 cells. 
Transwell 
migration 
assay with 
blocking 
antibody 
-To determine 
whether MCP-1 is a 
potential mediator 
of Balb/c MSCs 
migration. 
-Serum-free CM 
from un-
irradiated and 
irradiated (4 Gy) 
FS 188 cells. 
-To test serum-free CM 
from FS120 cells (un-
irradiated and 
irradiated). 
-To test other cytokines 
and chemokines such as, 
SDF-1α and TGF-β1 in 
the serum-free CM from 
tumour cells. 
 
 
Laboratory 
techniques 
Aim Tumour Limitation and future 
work 
IHC -To Study whether 
α-SMA content of 
the tumours 
increased in 
response to 
irradiation that 
reflect more CAFs 
cells. 
-Control (un-
irradiated) and 
irradiated FS 
188 and FS120 
tumours. 
-Need to repeat the in 
vivo experiment to get 
fresh tumour sections 
that can stained easily 
with better expectation. 
Mason’s 
trichrome 
staining 
-To detect collagen 
fibres in tissues. 
- Control (un-
irradiated) and 
irradiated FS 
188 and FS120 
tumours. 
-As above. 
IF -To study whether 
α-SMA content of 
the tumours 
increased in 
response to 
irradiation that 
reflect more CAFs 
cells. 
-Control (un-
irradiated) and 
irradiated FS 
188 and FS120 
tumours. 
-As above 
-Needs more sections to 
stain and analyse. 
-Analysing staining 
using proper slide 
scanning with proper 
image analysis.  
 
In vivo 
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6.1 General discussion 
Radiotherapy is one of the standard treatments for patients with intermediate and high-
grade soft tissue sarcoma. One of the major complications from radiation therapy in the 
treatment of STS is fibrosis (Delanian and Lefaix, 2004, Martin et al., 2000). Radiation-
induced fibrosis is life-threatening and a very complicated process that involves many 
growth factors, inflammatory cytokines, differentiation of fibroblasts and remodelling 
of ECM (Wynn, 2008). Fibrosis is represented by the presence of CAFs (activated 
myofibroblasts), which are responsible for secretion of extracellular matrix proteins 
such as collagen and fibronectin. The origin of CAFs in irradiated tumours has not been 
clearly established.  Some studies showed that MSCs were recruited to irradiated 
tumours (Klopp et al., 2007, Fenton and Paoni, 2007). MSCs can differentiate into 
pericytes and CAF-like cells but the effects of radiation on their recruitment or 
differentiation remain unclear. CAFs can be derived from circulating BM-derived 
MSCs according to animal models and human breast cancer studies (Ishii et al., 2003, 
Direkze et al., 2004, Direkze et al., 2006, Allinen et al., 2004, Chauhan et al., 2003). 
Moreover, a study by LaRue et al, using mice that had been transplanted with cells 
derived from a single enhanced green fluorescent protein (EGFP)-positive 
hematopoietic stem cells, supports that theory that CAFs can originate from circulating 
BM-derived MSCs (LaRue et al., 2006). The focus of this project was to investigate 
whether radiation influences MSCs and triggers their differentiation into CAF-like cells 
either directly or indirectly via effects on other cell types present within the TME. 
Moreover, the radiation effects on recruitment/ migration of MSC towards the TME 
were also investigated. These alterations of MSCs in response to radiation have the 
potential to play a significant role in radiation-induced changes within the tumour 
microenvironment linked to CAF-induced tumour progression as well as the 
development of fibrosis.   
Using in vitro models, and on the basis of western blotting analysis, this project showed 
that direct irradiation of MSCs produced some small effects in terms of the induction 
of expression of proteins such as collagen-I, which are associated with differentiated 
CAFs. Similarly, direct irradiation of MSCs had no effect on their migration. However, 
the indirect effects of radiation were prominent suggesting that it is the interactions 
between components of the TME and radiation that are important in recruiting and 
differentiating MSCs in tumours. This project was able to demonstrate that 
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fibrosarcoma cells are induced to secrete factors in response to irradiation, such as 
MCP-1, SDF-1 and TGF-β1, that can work in a paracrine manner to cause the migration 
and differentiation of MSCs into cells with CAF-like characteristics. These factors were 
identified by western blotting analysis of FS188 and FS120 CM. Direct evidence for a 
specific involvement of MCP-1 in MSC recruitment was obtained from migration 
experiments where MCP-1 was neutralised in the CM of fibrosarcoma cells. These 
experiments showed that MSC migration was inhibited by blocking MCP1 activity, 
suggesting that MCP-1 produced by fibrosarcoma cells was responsible, at least in part, 
for triggering MSC migration. These experiments point to potentially a key role for 
tumour-derived MCP-1 in radiation-mediated recruitment of MSCs in vivo. Further 
studies are needed to confirm if MCP1 is involved in the recruitment of MSCs towards 
solid fibrosarcomas following radiotherapy.  
In this project, the MCP-1 receptor CCR2 was upregulated by MSCs exposed to 
irradiated FS188 tumour cells or their concentrated CM. Klopp et al showed that CCR2 
was expressed by MSCs and its levels of expression increased after irradiation (Klopp 
et al., 2007). Many factors, including growth factors produced from tumour cells and 
inflammatory cytokines like TNF-α can up-regulate CCR2 (Ringe et al., 2007, Ponte et 
al., 2007). Klopp et al confirmed the involvement of the CCR2 receptor in the 
recruitment of MSCs towards irradiated tumour cells by using an anti-CCR2 that 
decreased MSC migration markedly. It will be interesting to see if blocking CCR2 
could inhibit migration of MSCs induced by irradiated fibrosarcoma cells and their CM.  
In this project, when MSCs were incubated with irradiated fibrosarcoma tumour cells 
or their CM for 3-4 days, some changes in expression of proteins characteristic of 
differentiated CAFs were noted but these changes were small. Mishra et al showed that 
human MSCs exposed to tumour-conditioned medium for long periods of time (30 
days), enhanced their CAF-like myofibroblast phenotype (Mishra et al., 2008). It is 
possible therefore that if MSCs were incubated for longer with CM from irradiated 
fibrosarcoma cells more prominent effects might have been observed. The biological 
differences between FS188 and FS120 tumours cells and solid tumours (i.e. in vitro and 
in vivo) in response to radiation that could potentially affect migration and 
differentiation of MSCs were studied. Irradiated FS188 cells have a tendency to cause 
MSCs to expressed higher levels of differentiation markers and to recruit more MSCs 
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than irradiated FS120 cells (although not significant). However, the in vivo analysis 
established that radiation enhanced fibrosis in FS188 tumours more than FS120 
tumours, which could potentially derive from more MSCs differentiated into CAF-like 
cells. The behavioural difference between two tumour cells (Kanthou et al., 2014) and 
the ability of FS188 cells to produce more CAF-like cells in vivo (Tozer et al., 2008) 
could be explained on the basis that FS188 cells secreted more cytokines such as MCP-
1 than FS120. This was evident from ELISA quantification of MCP-1 in CM from 
control and irradiated FS188 and FS120 cells. Moreover, some studies showed, both in 
vitro and in vivo, that MCP-1 enhanced the migration of MSCs (Boomsma and Geenen, 
2012, Dwyer et al., 2007, Belema-Bedada et al., 2008). Also MCP-1 has been shown 
to be expressed by human ovarian cancer cells (Furukawa et al., 2013), human 
endometrial cancer cells (Wang et al., 2006) and triple-negative breast cancer cells 
(Dutta et al., 2018).  
Although MCP-1 was identified as a factor capable of inducing MSC migration, other 
cytokines are also likely to be involved. The migration of MSCs in response to other 
cytokines and chemokines was also studied in this project. TGF-β1, and SDF-1α 
significantly enhanced the migration of MSCs in vitro. The RNA sequencing of solid 
tumours by NGS confirmed that several factors that are known to be involved in 
differentiating fibroblasts and CAFs were differentially expressed by the fibrosarcomas. 
FS188 cells were found to express TGF-β2 transcripts more abundantly than FS120 
cells. Similar to TGF-β1, TGF-β2 or TGF-β3 could also be involved in the recruitment 
of MSCs to tumours (Deng et al., 2017). However, FS120 cells produced more CTGF 
than FS188 cells which might suggest that FS120 cells had more capacity to induce 
fibroblast/CAF differentiation. It is likely that in vivo the recruitment of MSCs/CAF-
like cells by fibrosarcoma cells is dependent on a complex array of different growth 
factors and chemokines and not a single factor, thus reflecting the cross-talk between 
cells within the TME. 
Another important and novel finding of this study, was that irradiated endothelial cells 
induced the migration of MSCs in a radiation dose-dependent manner. Most studies in 
the literature refer to effects of MSCs on endothelial cells (Haubner et al., 2013a, Luu 
et al., 2013, Liang et al., 2017, Burlacu et al., 2013, Chen et al., 2015). To my 
knowledge, this is the first work establishing that endothelial cells induced the 
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migration of MSCs in vitro and furthermore radiation enhanced their migration further. 
Many studies showed that irradiation of endothelial cells affected their cytokine 
production (Schroder et al., 2018, Haubner et al., 2013a) that could therefore drive the 
effects on MSC migration seen here. 
To translate this work into the in vivo setting, analysis of solid fibrosarcomas was also 
performed. In this thesis, α-SMA, the most common CAF marker (Park et al., 1999, 
Sugimoto et al., 2006, Kim et al., 2015), was used to stain sections of control and 
irradiated fibrosarcomas. Masson’s trichrome staining was used also to stain 
perivascular and interstitial collagen within fibrosarcoma tumours. Many studies have 
used this staining technique to detect collagen fibres in fibrotic conditions such as liver, 
renal or cardiac fibrosis (Lo and Kim, 2017, Zhou et al., 2013, de Jong et al., 2012). 
This analysis showed more abundant collagen production within the FS188 tumours 
than FS120 tumours, which is in accordance to previous findings showing more 
abundant α-SMA stained cells in FS188 tumours. Furthermore, in irradiated tumours 
the levels of collagen were significantly higher compared to controls (especially in the 
FS188 tumours). Although analysis of α-SMA staining was inconclusive, the data taken 
together imply that radiation resulted in recruitment and/or activation of more CAFs 
producing more collagen within the tumour.  
Together, in vivo data presented in this thesis suggest that radiation enhanced the ECM 
protein deposition within the stroma and perivascular areas of the tumours (especially 
FS188 tumours). Recently, English et al showed, both in vitro and in vivo, that FS188 
tumours expressed more collagen-I than FS 120 tumours while the reverse was so for 
laminin (English et al., 2017). 
The in vitro models in this project were done in two-dimensional (2D) models. This 
means that cells plated and growing directly on a flat , adherent surfaces (glass or plastic) 
with coated substrate to enhance their adhesion and behaviour like differentiation and 
proliferation (Morrison et al., 2011). 2D models are important, especially they are 
reasonably cheap, homogenous culture and reproducible tool to be used in similar with 
animal models. The problems in 2D models are they do not mimic real in vivo 
microenvironment (real microenvironment is more complex, hypoxic and organised), 
limitation in cell-cell interaction (only side-by-side contact), lack of interactions 
between cells and ECM and the oxygen diffusion with waste removal dynamics is 
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lacked (Antoni et al., 2015, Morrison et al., 2011). The limitations of the 2D models 
can affect cell survival, morphology, differentiation and proliferation that make three -
dimensional (3D) models more important. A 3D cell culture models play an important 
role in cell and cancer biology as it offers an effective way to study the dynamics of 
cell in in vivo-mimicking conditions (Centeno et al., 2018). Moreover, 3D models allow 
cells to interact with each other and with ECM, provide better spatial organisation and 
more relevant in vivo environment models (Edmondson et al., 2014, Knight and 
Przyborski, 2015). However, 3D models have some disadvantages such as they are an 
expensive method, need special technique for visualisation/ microscopy, problems in 
homogenous distribution of the oxygen and nutrients (leads to necrosis and cell death); 
and require an expensive equipment (such as bioreactors) and expert optimisation and 
handling (Breslin and O'Driscoll, 2013, Rimann and Graf-Hausner, 2012). 
 
6.2 Future work 
While this thesis has established several effects of radiation on MSC biology and 
behaviour using a fibrosarcoma model, opportunities to extend the scope of this work 
remain.  
6.2.1 In vitro  
It will be important in the future to analyse in detail the factors secreted from endothelial 
cells in response to radiation that enhanced migration of MSCs in vitro. As highlighted 
in this project,  MSCs migrated towards endothelial cells  (Figure 3.16) as well as 
endothelial cells co-cultured with fibrosarcoma cells (Figure 3.17). Furthermore,  
irradiation of endothelial cells further increased migration of MSCs in a dose-dependent 
manner. Some studies showed that endothelial cells produce cytokines such as PDGF, 
TGF-β1, TNF-α, bFGF, and VEGF  (Wachsberger and Burd, 2004, McBride et al., 
2004) which could potentially induce recruitment of MSCs to tumours. It will also be 
important to investigate the role of factors other than MCP-1 in the recruitment of 
MSCs towards the fibrosarcomas. Both TGF-β1 and SDF-1α were found to induce the 
migration of MSCs (as shown in Figure 3.18) and were produced by irrdiated 
fiborasrcomas. It will be interesting to study the role of these cytokines in MSC 
migration in similar experiments to those performed with MCP-1 and using neutralizing 
anti-TGF-β1 or anti-SDF-1α antibodies.   
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As stated above, CCR2 expression was increased after co-culture of MSCs with 
irradiated tumour cells or their concentrated CM (Figure 4.4). To confirm that MCP-1 
and its receptor was responsible for MSCs migration in vitro and not other 
inflammatory cytokines (Ringe et al., 2007, Ponte et al., 2007), blocking of CCR2 using 
anti-CCR2 antibody can also be done (Klopp et al., 2007). 
6.2.2 In vivo  
RNA sequencing of control non-irradiated fibrosarcoma tumours revealed differences 
in the expression of genes that are involved in fibroblast and CAF differentiation. To 
study the differences between FS188 tumours and FS120 tumours in response to 
radiation in vivo, it will be important for similar analyses to be performed using 
irradiated tumours. The information from such a study will be extremely useful in 
identifying factors that might be involved in radiation-mediated fibrosis and radiation 
mediated MSC recruitment into tumours.  
6.3 Conclusion   
The results of this study increased our understanding of the interactions between 
radiation and cells within the TME and their consequences on MSC biology. The results 
represent progress in understanding the role of radiation in a model of fibrosarcoma. 
The project was able to demonstrate that fibrosarcomas are influenced by radiation to 
recruit MSCs that can potentially acquire CAF-like characteristics and increase the 
ECM content of the tumour leading to fibrosis. This result has an important impact on 
the future treatment outcome of sarcoma, as presence of CAF can make tumours more 
aggressive and trigger fibrosis potentially making vessels impermeable to 
macromolecules and resistant to further treatment with drugs and chemotherapy. A 
better understanding of the interaction between MSCs and cells within tumour stroma 
will help to develop strategies to improve tumour therapies taking into account radiation 
effects on TME that influence tumour proliferation and metastasis. Further studies are 
needed to establish the best way to deliver radiation therapy to tumours with fewer 
negative consequences and taking into account patient survival and quality of life. 
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